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Abstract
Macrocyclic ligands based on cyclen form lanthanide complexes with good thermodynamic 
stability and kinetic inertness due to the large degree of preorganization of the ligand. 
Conversely, it is these favourable properties which have impeded their development as 
magnetopharmaceudcals as the functionalization of cyclen remains synthetically challenging. 
This thesis describes the development of new synthetic routes to substituted cyclen ligands, 
which after complexation with Gd(III), could have potential as MRI contrast agents.
At present, cyclen is primarily functionalized by alkylation with halide substrates. In an 
attempt to prepare bifunctional ligands, cyclen was alkylated with derivatised amino acids. 
Elimination of the halide substrate to give the corresponding alkene was found to be a 
significant problem using this approach.
As an alternative route to functionalized macrocycles, the Michael addition of cyclen to 
activated alkenes was investigated. The aza-Michael addition of cyclen to acrylamide was 
found to be regioselective with the tri-amide substituted cyclen (D03PAM) being the major 
product. Hydrolysis of D03PAM  with 12M HCl gave the corresponding tri-acid substituted 
cyclen (D03P) in a yield of 90 %. D 03P  is an analogue of the important cyclen ligand, 
D03A, which has three acetate substituents. Trifluoromethanesulfonic acid was found to 
catalyse the conjugate addition of mono-N-Z-cyclen to methyl-2-acetamidoacrylate under mild 
conditions. This methodology of mono-Z-protecrion followed by acid-catalysed addition and 
deprotection offers a new and versatile route to tri-iV-substituted cyclen derivatives. The 
addition of cyclen to ethyl-rir-jl-cyanoacrylate was regioselective as addition occurred 
exclusively at the carbon (3 to the nitrile group.
The ligands D 03P  and D03PAM  were complexed with gadolinium(III) and the f  spin- 
lattice relaxation times of the complexes were measured. The corresponding T^-relaxivity 
values (r^ ) of Gd(D03P) and Gd(D03PAM) were determined to be 4.0 and 4.6 mM'^ s'^  (60 
MHz, 25 °C), respectively. These complexes provide significantly better relaxivity values than 
that of the best-selling MRI contrast agent, Magnevist (Gd-DPTA), which has an value of 
2.8mM 's-' (60 MHz, 25 °C).
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Chapter 1
Introduction
C h apter 1 Introduction
1.0 Introduction
Magnetic resonance imaging (MRI) is a powerful and non-invasive diagnostic technique 
useful in providing images of the inside of the human body \  It has become widely used in 
hospitals around the world, since it received FDA approval for clinical use in 1985. It is a 
clinical imaging technique, which relies on the detection of NMR signals emitted by 
hydrogen protons in the body when placed in a magnetic field. MRI is based on the 
principles of nuclear magnetic resonance (NMR), a spectroscopic technique used by 
chemists to obtain structural information about molecules. In 2003, Paul C. Lauterbur and 
Sir Peter Mansfield won the Nobel Prize in physiology and medicine for their discoveries 
concerning MRI because it can be widely used for the non-invasive diagnosis and 
monitoring of human diseases, such as heart disease and cancer.
Nowadays, around 40 % of all MRI scans are performed employing a contrast agent, which 
is an exogenous compound able to enhance the relaxation rates of water protons In this 
way, the quality of the MRI images obtained can be greatly improved (Figure 1.1).
I
Figure 1.1 Enhancement of cancer imaging with a gadolinium-based contrast agent 
{Left) MRI before contrast agent is administered
{Right) MRI with contrast agent
3
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Polyaminopolycarboxylic complexes of gadolinium(III) (Gd ), which are administered 
intravenously, are the most widely used contrast agents in MRI (Figure 1.2)
OoC
(GdCO
1.1 1.2
Figure 1.2 Structure of Gd-DOTA (1.1) and Gd-DPTA (1.2).
These first generation contrast agents currently in clinical use are small-molecular, 
extracellular (systemic) agents such as Gd-DTPA and Gd-DOTA" (Figure 1.2). They 
distribute non-specifically throughout plasma and interstitial spaces and are rapidly 
excreted via the kidneys, or in the case of lipophilic hepatobiliary agents, via the liver. The 
next generation of contrast agents are geared towards more specific or directed functional 
imaging. With this in mind, the aim of this project was to synthesise new 
ligands/complexes with improved targeting properties.
In the following sections of this chapter, the theory of MRI is introduced. It is then outlined 
how gadolinium-based contrast agents improve the detail of MRI scans. After the different 
types of contrast agents are reviewed, an account of cyclen chemistry is given. The chapter 
concludes with a section outlining the aims of the thesis.
‘ DTPA refers to diethylenetriaminepentaacetic acid,
DOTA refers to 1,4,7,10-tetra(carboxymethyl)-1,4,7,10-tetraazocyclododecane
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1.1 Basic principles of NMR and MRI
The property of Nuclear Magnetic Resonance (NMR) was first described by Purcell and 
Bloch in 1946 Since then, NMR has become a powerful tool in the analysis of chemical 
composition and structure. In 1973, Lauterbur used the principles of NMR to describe a 
technique (essentially Magnetic Resonance Imaging or MRI) for determining physical 
structure This work led to the development of MRI for applications in biomedical 
imaging. The MRI technique is based upon the interaction of the magnetic moment of 
nuclei with the main magnetic field of an MRI scanner
As a result of its nuclear spin (7 = 1/2) and positive charge (+1), a proton has an intrinsic 
magnetic moment ( |J ) .  The magnetic moments of hydrogen nuclei causes them to behave 
like tiny compass needles. Other nuclei with an odd number of protons also have net 
magnetic moments and are candidates for magnetic resonance (see Table 1.1).
Table 1.1 The frequency of nuclei in a magnetic field
Nucleus Magnetic field 
(Tesla)
Larmor frequency 
(MHz)
'h 0.15 6.4
0.5 21.3
1.0 42.6
1.5 63.9
1.0 10.71
31p 1.0 17.25
Nuclei with no spin include "*°Ca.
When a proton is placed into a strong external magnetic field, it experiences a turning 
force, known as a torque, which makes it precess (rotate) around the direction of the field 
(Figure 1.3).
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Figure 1.3 A spinning nucleus precesses in an applied magnetic field 
at its characteristic Larmor frequency.
The precessional frequency, v, of the proton is found to be directly proportional to the 
external magnetic field, given by the Larmor equation:
V =
r B p  
2  n
(1.1)
where v = 
Bo =
r  =
Larmor frequency (in Hz or MHz)
applied magnetic field (in Tesla)
magnetogyric ratio which is specific for different nuclei
(e.g. the value of y  11% for protons is 42.58 MHz/T).
The spin of a proton is quantized and in the presence of an external magnetic field can 
exist in either one of two states (Figure 1.4) \  The spin-up (or a-state) is aligned parallel to 
the main field while the spin-down (or p-state) aligns anti-parallel to it. The frequency 
required to induce a transition from the a  to the slightly higher energy p-state corresponds 
to the precessional frequency of the nucleus in question; that is, its Larmor frequency;
C h apter 1 Introduction
where AE  
h
AE = hv = h
energy of transition,
/
\ 2n (1.2)
Planck’s constant (6.63 x 10'^“' J s),
For an NMR instrument with a magnetic field strength of 7.0 Tesla, radioffequency 
irradiation of approximately 300 MHz is needed to effect a spin-state transition for a 
proton (Figure 1.4). In MRI, the magnetic field is not as strong and the energy required to 
effect a spin-state transition is consequently lower. For example, a scanner with a magnetic 
field strength of 1.4 Tesla, requires irradiation at 60 MHz to effect a spin-state transition in 
a proton.
No,spin = -1/2
AE =
■ 60 MHz
AE = t  AE => 75 MHz ^  300 MHzEnergy
spin = + 1/2
0 1.4 1.8 7.0
Nr.
Magnetic field strength, Bq (Tesla)
Figure 1.4 Proton energy levels at different magnetic field strengths in H^ NMR.
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When an MRI or NMR spectrum is being recorded, the population difference between the 
a  and p states is being sampled. The population difference at equilibrium between the two 
states is described by the Boltzmann equation:
/ - A ^ \  / - A y
=  exp --------- =  exp   I (1 .3)
\ k T j  \  k T
where N  = number of nuclei in spin state (a  = spin-up, p = spin-down) 
k  = Boltzmann constant (1.3806 x 10'^  ^J K'^)
T = temperature
For both NMR and MRI, the population differences between the two states are only in the 
order of 1 part in 10  ^ even with the strongest available field strengths. As a consequence, 
one of the practical problems of both NMR and MRI is that they are inherently insensitive 
techniques. From eqn 1.3, it can be seen that the only 2 variables influencing the 
population difference is the field strength and temperature. In MRI, body temperature 
cannot be changed so increasing the field strength is the only way to improve net 
magnetization and the strength of the MR signal. High field strengths (> 1.0 T), which 
have better signal to noise (SNR) ratios, are generated with superconducting magnets
Inside the bore of an MRI scanner, the main magnetic field runs straight down the centre of 
the tube in which the patient is placed. This means that if a patient is lying on his or her 
back in the scanner, the hydrogen protons in his or her body will line up in the direction of 
either the feet or the head The vast majority of these protons will cancel out each others 
magnetic effects but a slight excess fraction of the hydrogen nuclei will be aligned with the 
main magnetic field termed Bq. At body temperature (37 °C) and in a 1.5T scanner, the 
population difference works out at about 1.000004, which means that for every million 
protons in the spin-down direction there are a million-and-four protons in the spin-up 
direction. This results in a net magnetisation vector (NMV) as shown in Figure 1.5(a).
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90° RF pulse
w
100 %
Signal
63%
b
At time T], 63 % of the 
signal has returned
Time (ms)
Figure 1.5 The net magnetization vector and its behaviour following a 90° RF pulse
In Figure 1.5(a), the hydrogen nuclei precess around the main magnetic field (B q) in the 
longitudinal plane: for clarity, only the excess protons in spin-up alignment are shown. 
Since the external magnetic field (provided by the static magnet) is much greater than the 
sample's net magnetization, it is not possible to detect the sample's small magnetization in 
this state. The sample magnetization must be separated from the external magnetic field by 
applying a secondary magnetic field perpendicular at a 90° angle to the external field. An 
RF pulse applied along the +X axis instantaneously creates a secondary magnetic field that 
causes the magnetic moments to tip away from the equilibrium state. The combined 
precession of many spins generates a small but detectable excess oscillating magnetic field 
in the X-Y plane perpendicular to the external magnetic field (i.e. the transverse plane). 
These oscillations induce an alternating voltage (the NMR signal) in a detection coil.
- 7 -
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Application of the RF pulse at the same precessional frequency of the nuclei (i.e. their 
resonance frequency) promotes them to an excited state. After the RF pulse is switched off, 
the protons ‘relax’ back to their original aligned state parallel to Bq (Figure 1.5, b-d). This 
longitudinal relaxation along the longitudinal plane (Z-axis) is called Ti-relaxation (spin- 
lattice relaxation). This relaxation process involves transfer of energy from the protons to 
the surroundings (Figure 1.6).
Figure 1.6 Spin-lattice (Fi) relaxation; where spins transfer energy to the 
surrounding lattice.
A second relaxation process in the sample is the de-phasing of the individual precessing 
spins that combine to make the NMV. This relaxation along the transverse plane is called 
T2 relaxation (spin-spin relaxation) and involves changes in precessional frequency due to 
the interaction between spins in close proximity to one another (Figure 1.7).
Bn
B0 + ÔB
Figure 1.7 Spin-spin (Tq) relaxation; One spin in close proximity to another 
experiences a change in magnetic field strength which changes its 
precessional frequency.
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When analyzing the structure of chemical compounds in laboratory NMR instruments, 
samples are placed in a highly uniform static magnetic field so that a single line (or 
multiplet) for each chemically different proton may be obtained for analysis. A different 
resonance fi’equency (or chemical shift) is observed for each chemically different nucleus 
because it is surrounded by different electron densities and as a result experiences a unique 
local magnetic field. In contrast. Magnetic Resonance Imaging (MRI) makes use of linear 
field gradients in order to obtain an image. In 1973, Paul Lauterbur showed that the 
Larmor equation could be used to obtain geometric information if the magnetic field was 
made inhomogeneous in a controlled way Using magnetic field gradients, he showed that 
the frequency of a signal can be used to convey the location of protons within the field.
This effect is demonstrated in Figure 1.8 11
(a)
Be
(b)
Bq
Figure 1.8 (a) A spectrum obtained from 2 tubes of water in a constant magnetic field
will display only one frequency when Fourier-transformed, (b) If the signal 
is acquired in the presence of a magnetic field gradient, the frequency 
spectrum will show 2 frequencies, with a separation that depends on their 
spatial separation.
This basic idea can be elaborated so spatial information can be imparted to NMR signals in 
order to create an MRI image. This is achieved by varying the pattern and timing of the RF 
pulse and the use of three-dimensional magnetic field gradients.
-9
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1.2 Relaxivity in tissues
Differentiation between biological tissues is the primary objective for imaging use in 
clinical diagnosis, and requires that the signal intensities vary depending on tissue type. 
Most human soft tissues contain about the same amount of water and therefore do not 
allow tissue differentiation on the basis of water content alone. However, the T\ 
(longitudinal) and T2 (transverse) relaxation times of water protons vary markedly 
depending on tissue type, and therefore, may be used as the source of contrast in MR 
images (Table 1.2).
Table 1.2 NMR values for tissue at 10 MHz and 37 °C
Tissue Fi
(msec)
Fz
(msec)
Proton content 
(%, relative)
blood 720 175 90
muscle 435 40 84
lung 595 90 72
adipose 170 130 86
water 2500 2500 100
Examination of Table 1.2 shows that protons in biological tissues usually have shorter Ti 
and much shorter T2 than pure water. T\ depends on tissue composition, structure and 
surroundings When the lattice consists of mostly water, it is difficult for the protons to 
dissipate their energy as the small water molecules move too rapidly. Thus, water has a 
long Fi. On the other hand, protons attached to discrete fat or protein molecules tumble 
near the Larmor frequency Consequently, Fi relaxation is much more efficient resulting 
in short Fi times. T\ is also longer in a strong magnetic field as the protons precess faster. 
This results in inefficient energy transfer from the relaxing protons to the lattice with more 
slowly fluctuating magnetic fields.
-10
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1.3 The contrast agent effect
The image contrast in MRI is typically classified according to its sensitivity to the three 
tissue parameters, proton density (p), the longitudinal (or spin-lattice) relaxation times Fi, 
and the transverse (or spin-spin) relaxation times Fz Using different RF pulse sequences, 
image intensity can be weighted with respect to Fi or F2 . In MRI, relaxation times are 
relatively slow (0.1 to 2 sec), increasing the time required to obtain clinically useful images 
and negatively affecting image quality. As the NMR signal is intrinsically weak, the 
observed spectra suffer from a poor signal-to-noise ratio (SNR). This can be mitigated by 
signal averaging, that is, adding the spectra from repeated measurements.
Since paramagnetic ions like Gd^  ^ significantly shorten the Fi of protons in the tissues 
where they accumulate, the use of contrast agents in MRI accelerates the signal averaging 
technique. The Gd^^ ion behaves like any magnetic field inhomogeneity but acts over a 
very small distance. Tissues which take up the agent have an enhanced signal intensity on 
Fi-weighted images. In Figure 1.1, this effect can be clearly seen. Tumours have more 
blood-carrying vessels than normal tissues and appear very bright on Fi-weighted images 
after a contrast agent is injected.
1.4 Properties of gadolinium complexes
The chemical and physical properties of Gd^^ complexes and the parameters affecting 
relaxivity have recently been discussed by Caravan and Aime However, a brief review 
of these parameters is necessary here in order to gain some understanding of the rationale 
behind the design of new gadolinium-based MRI contrast agents.
-11
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1.4.1 Physico-chemical properties of gadolinium
The first requirement for a successful MR imaging contrast agent is to be able to interact 
magnetically with hydrogen nuclei As single unpaired electrons have magnetic dipole 
moments that are 657 times stronger than the magnetic dipole moment of protons, the 
magnetic effects of unpaired electrons dominate the magnetic effects of the atom. Since the 
relaxation properties of hydrogen nuclei vary as the square of the magnetic dipole moment 
(of the atom or molecule used as a contrast agent), it is the number of unpaired electrons in 
the outer shell of an atom that principally determines its effect as a relaxation contrast 
agent. Gd^^has seven unpaired electrons (unlike any other ion) which results in a magnetic 
moment of 7.9 magnetons (Table 1.3).
Table 1.3 Electronic configuration and magnetic moments of metal ions
Atomic
number
Ion 3d 4f Magnetic moment
( Magneton *)
24 Cr'^ Î Î  Î 3.8
25 Î Î Î Î Î 5.9
26 Î Î Î Î Î 5.9
29 i t  i t  i t  i t  t 1.7-2.2
63 i t  t t  t t  t t 6.9
64 t t  t t  t t  t 7.9
66 D y '" i t  i t  t t  t t  t 5.9
Gadolinium is a member of the 14 lanthanides or ‘rare-earth’ elements The most 
common and usually the most stable oxidation state of the lanthanides is the trivalent state. 
Lanthanide cations like Gd^^ are hard acids and tend to bind most effectively to hard bases. 
Like other cations in this category, Gd^  ^ shows a marked preference for oxygen ligands 
and especially chelating ligands.
One magneton is the magnetic dipole moment of a single free electron
- 12
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Hard Acids: Gd'% Na+ Ca^+, Al% Fe^"
Hard Bases: H2O, NH3, OH', ROH, RO', COs^', F , OF
In an aqueous solution of paramagnetic metal chelate, there is a dipolar magnetic 
interaction between the electronic magnetic moment of the paramagnetic atom and the 
much smaller magnetic moments of the protons belonging to nearby water molecules. Gd^  ^
reduces T\ significantly and 7% slightly. The overall effect is highly dependent on the Gd^  ^
concentration and concentrations of approximately 0.5M are required to provide significant 
improvement in tissue contrast.
Gd^^ is a very efficient water relaxation catalyst for nuclear magnetic resonance (NMR) 
due to its high magnetic moment and very labile water coordination Each Gd^^ ion can 
influence the relaxation of the protons of more than 106 water molecules per second. Gd^^ 
is largely insoluble above pH 6, where it hydrates to produce insoluble oxides and 
hydroxides. It also readily precipitates with carbonate and phosphate ions, both ubiquitous 
in blood and tissues. Furthermore, like other heavy metals, it is also capable of competing 
for binding sites normally occupied by endogenous biological cations such as Zn^^ and
1.4.2 The use of cyclen-based ligands In contrast agents
As the naked Gd^^ ion is very toxic, it must be wrapped in a tightly-bound organic ligand 
framework; in other words, it must be chelated Simple monodentate or even bidentate 
ligands will not suffice because they do not remain bound to Gd^^ in solution. Ligands with 
higher coordination numbers are therefore required. The obvious candidate is EDTA"^ *, 
ethylenediaminetetraacetate, which is a commonly employed hexadentate ligand used to
 ^ A chelate is a multidentate ligand which contains more than one donor atom coordinated to a metal ion. 
A complex, in contrast, may be a metal ion with just one water molecule ligand
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complex transition metals. However, gadolinium tends to favour high coordination 
numbers of 8 and 9 in aqueous media due to its large size. Ligands such as DOTA, which 
are prepared from cyclen (1,4,7,10-tetraazacyclododecane), provide a stable framework for 
the coordination of the Gd^^ ion (Figure 1.9).
V
/
-O
1.4
Figure 1.9 X-ray structure^^ of [Gd(DOTA)]‘ (1.3) and schematic representation (1.4).
The DOTA ligand binds to Gd^^ through four oxygen atoms of the carboxylates and four 
nitrogen atoms of the amines. Chelation to DOTA increases the solubility of the Gd^^ at 
the body's neutral pH and still allows for the paramagnetic effect required for an MRI 
contrast agent. DOTA simultaneously binds the Gd^^ ion tenaciously and yet permits one 
water molecule to coordinate to Gd^ .^
Substitution of the nitrogen atoms of cyclen by pendant arms containing donor groups is 
essential in order to ensure a thermodynamically stable and kinetically inert Gd^^ 
complex Several functional groups have been used, such as carboxylates, phosphonates, 
amides and alcohols. Generally, carboxylates are preferred as the resulting complexes are 
thermodynamically more stable. A-functionalized cyclens form exceedingly stable and 
inert lanthanide complexes due to the stable [3.3.3.3]-square conformation adopted by 
cyclen in the complexes Figure 1.9 shows how the DOTA ligand adopts a wrapping
conformation to encapsulate the metal cation.
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1.5 Relaxivity theory
The presence of a ion increases the longitudinal and transverse relaxation rates, l/Ti 
and 1/72, respectively, of water protons. The observed solvent relaxation rate, (l/21)obs is 
the sum of the diamagnetic (l/7î)d and paramagnetic (l/7i)p relaxation rates where the 
subscript i refers to either the longitudinal (1/Ti) or the transverse rate (I/To):
(l/ i^)obs ^ (1-4)
The diamagnetic term (l/7])d corresponds to the relaxation rate of the solvent (water) 
protons in the absence of the paramagnetic solute. The paramagnetic term (l/7])p gives the 
relaxation rate enhancement caused by the paramagnetic substance, which is linearly 
proportional to the concentration of the paramagnetic species, [Gd^^]:
(1 / T; =  (1 / Tj )d + n  [Gd3+] (1.5)
According to Equation 1.5, a plot of the observed relaxation rate versus the gadolinium 
concentration is linear with a slope that defines the relaxivity, n. The unit of relaxivity is 
mM'^ s '\
1.5.1 Paramagnetic relaxation enhancement
The relaxivity of a paramagnetic Gd^^ complex depends on the magnitude of the magnetic 
dipole-dipole interaction between the electron spin on the metal and the proton spin on the 
water molecule coordinated to the metal A fast exchange (on the NMR time scale) 
between the inner-sphere water and the bulk water then results in propagation of the 
paramagnetic influence to the solvent (Figure 1.10).
15-
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Figure 1.10 Three classes of water: inner-sphere (directly coordinated to Gd^^), 
outer-sphere (hydrogen-bonded to the complex) and bulk water.
The total paramagnetic relaxation enhancement due to the paramagnetic agent can be 
divided into two components, inner-sphere and outer-sphere as in Equation (1.6), or 
expressed in relaxivities as in Equation (1.7):
os
os
( 1.6)
(1.7)
where the superscripts TS’ and ‘OS’ refer to the inner and outer sphere, respectively.
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1.5.2 Inner sphere relaxation
Efficient catalysis of relaxation by a dilute metal complex in 55.5 M water requires that a 
water molecule reside at the metal no longer than necessary to be relaxed The change 
observed in Ti of bulk water protons in the presence of a dissolved Gd^^ complex can be 
described by Equation (1.8):
H p ' =  ^  (1.8)
where = Inner-sphere relaxivity
(1/71 jobs = reciprocal of the observed T\
(1/Ti)w = reciprocal of Ti of the bulk water
[M] = molar concentration of paramagnetic complex
q = number of bound water molecules per Gd^^
T^im = longitudinal relaxation time of the bound water protons
Tm = lifetime of the water molecule in coordination site
(which is the reciprocal of the solvent exchange rate, hex)
Tm  for protons on water coordinated to Gd^^are on the order of microseconds. If Xm is long 
relative to Tim, ‘slow exchange’ conditions exist and no communication between the 
lanthanide and bulk water occurs. Examples of such systems include tetra-amide 
gadolinium complexes, in which the overall relaxivity is almost entirely due to the outer- 
sphere contribution ‘Fast exchange’ conditions exist when Xm« Tm-
The term 1/Tim is composed of a dipole-dipole term (DD) and a scalar term (SC) 
(Equation 1.9).
1 1 1
IM
— —  -
'f^DD J'^SC
(1.9)
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As the scalar term becomes negligible at magnetic field strengths above 0.2 T and since 
most clinical experimental MR images are acquired at field strengths higher than 0.2 T, the 
scalar term is not an important factor in proton relaxation Thus, 1/Tim is essentially 
determined by the 1/Ti°° term. The dipole-dipole (through space) and scalar (through 
bonds) interaction between the protons on coordinated water and gadolinium complexes is 
described by the Solomon-Bloembergen-Morgan (SBM) equations SBM theory
predicts a maximum relaxivity of 100 mM'^s'^ for a small-molecular gadolinium complex 
with a hydration number of one The relaxivity of a water molecule by a Gd^^ complex is 
a multi-faceted and complex phenomenon with at least eleven inter-dependent parameters 
describing water relaxation at a given magnetic field strength
1.5.3 Outer sphere relaxation
Contrast agents can display relaxivity even when q = 0 (For example, see Egad in Figure 
1.20 on Page 32). As there is no water in the inner coordination sphere, the relaxivity must 
come from outer sphere contributions. These can take two forms;
(i) second sphere relaxation where water molecules hydrogen bonded to the 
carboxylate oxygen atoms are relaxed via dipolar mechanisms, and
(ii) outer sphere relaxation which arises due to diffusion of water molecules in the 
bulk near to the Gd^^ complex (see Figure 1.10).
For small-sized complexes, it is estimated that the outer-sphere contribution may account 
for up to 50 % of the overall relaxivity However, the outer sphere contribution to 
relaxivity is not very well understood, as it is difficult to quantify the number of second- 
sphere water molecules
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1.6 Enhancement of relaxivity
Figure 1.11 schematically describes the molecular parameters that influence inner- and 
second-sphere relaxivity. In Figure 1.11, the hydrogen nuclei are small magnetic dipoles 
denoted by the small vectors whereas the Gd^^ ion has a much larger vector. There are q 
waters in the inner-sphere with a Gd-H distance r and a residency time Xm, and q ’ waters in 
the second-sphere at a Gd-H distance r ’ and residency time Xm% e^x refers to the water 
exchange rate and is equal to 1/ Xm. % refers to the molecular rotational correlation time.
%  -  — - y H  {  1/î'm ( - ^ e x )  yM
X f  X  wk
2”** sphere 
water
Figure 1.11 Schematic representation of a Gd^^ chelate with one inner-sphere 
water molecule, surrounded by bulk water
Relaxivity arising from the inner-sphere water(s) is given by eqn (1.10), which 
incorporates 2-site exchange where Tim is the T\ of the water hydrogen in the inner-sphere 
and [H2O] is the water concentration in mM In order to increase relaxivity, one can 
increase q or decrease Tim or Xm.
Q [H2 O]
( ^IM
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1.6.1 Hydration number ( q )
For a small monomeric complex, a primary determinant of relaxivity is its hydration
number Clinically-available agents are all nine-coordinate, with the polyamino- 
polycarboxylato ligand providing 8 donors, and a water molecule occupying the ninth 
coordination site (q= 1). Heptadentate ligands allow the coordination of 2 water molecules 
in the inner sphere of the metal and consequently yield higher relaxivity with respect to 
Gd^^ complexes of octadentate ligands. For example, removing an acetate arm from 
[Gd(D0TA)(H20)]2 to give [Gd(D03A)(H20)2] doubles the hydration number but still
results in a stable complex (Figure 1.12) 15
> " n N C f '
1.5
ri = 4.2
T / v
.N \ NH
O
O
1.6
ri  =  6.0
Figure 1.12 Structures of [Gd(D0TA)(H20)] and [Gd(D03A)(H20)2].
Unfortunately, the water molecules in [Gd(D03A)(H20)2] can be displaced by binding 
from anions found in vivo such as phosphate and bicarbonate (Scheme 1.1).
" - o r "  " - 0 - "
lactate
HO Q-
H eptadentate ligand
Hq Q
H ep tadentate  ligand
Scheme 1.1 Schematic diagram of the displacement of inner-sphere water
molecules upon lactate binding
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1.6.2 Rotational correlation time ( T r )
At the magnetic field strengths used in MRI scans (0.5-1.5 T, 20-60 MHz), the longitudinal 
relaxation times of the bound water protons, Tim, is dominated by the molecular 
reorientation (rotational correlation) time, Tr . If the rotation or tumbling rate of a complex
is reduced, the rotational correlation time is longer leading to faster relaxation rates and 
hence higher relaxivities Therefore, slowing the rotational correlation time by 
increasing the molecular weight of a complex or by chelating the metal ion with bulky 
ligands will optimize the rotational correlation time. This method of improving relaxivity 
was substantiated by the work of Tweedle et a l They found that relaxivity per Gd^^ ion 
was found to correlate well with molecular weight up to 5 kDa for a series of monomeric 
and multimeric Gd^^ chelates. Their results are reproduced in Figure 1.13 below.
S  10
T3
1000 2000 3000 4000
Molecular weight
5000 6000
Figure 1.13 Relaxivity per Gd^  ^ion versus molecular weight 
for various multimeric complexes
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1.7 Contrast agent design
1.7.1 Attributes of MRI contrast media
Like other pharmaceutical products, contrast agents (CAs) must satisfy a number of 
requirements including target specificity to minimise dose. They must be excreted within a 
reasonable length of time to minimise toxicity but remain in vivo long enough for images 
to be produced. Other criteria for clinical contrast agents include:
adequate in vivo relaxation enhancement
high water solubility
low osmotic potential (osmolality)
acceptably low toxicity and high thermodynamic stability
in vivo specificity, appropriate lipophilicity and biodistribution
easy to synthesize
1.7.2 Small molecule or macromolecular contrast agents ?
Macromolecular contrast agents may be defined as paramagnetic compounds of sufficient 
molecular weight, generally >20,000 Da, that demonstrate prolonged vascular retention. 
Often based on nanoparticles, dendrimers, antibodies, and proteins, they have a high 
relaxivity relative to traditional contrast agents. The rotational correlation time of Gd^^ in 
small complexes is generally too fast, in the order of 10‘ °^ s, to be optimally effective. 
Slowing the rotational correlation time to approximately 10'  ^ s will tend to improve the 
relaxation effectiveness of each Gd^^ ion. Fortunately, an increased molecular size results 
in a slowing of molecular rotation. Thus, macromolecular contrast agents with molecular 
weights greater than 10,000 daltons will tend to have higher proton Ti relaxivity than small 
molecular Gd^^ complexes. The relaxation effectiveness of each Gd^^ ion can be increased
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three- to fourfold by linking the Gd^^ complex to a bulky macromolecular carrier (Table 
1.4).
Table 1.4 Properties of selected macromolecular contrast media
Gd-DTPA Albumin-Gd-DTPA Dextran-Gd-DTPA
Gd^  ^ions per 
molecule
1 30 15
molecular weight 
(Da)
538 92,000 75,000
ri in H2O 
per Gd^^
3.7 14.4 10.5
ri in H2O 
per molecule
3.7 432 157
Macromolecules demonstrate a wide range of possibilities in molecular imaging. However, 
disadvantages of macromolecular contrast agents include lengthy and expensive 
preparations, limited shelf-life, and potential immunogenicity Their size can also 
prevent effective cellular delivery.
In contrast to the larger macromolecules, smaller molecular contrast agents like Gd-DTPA 
(MW = 547 Da) rapidly equilibriate between the blood and extravascular interstitial space. 
They have promising targeting ability due to their high diffusion rates and ability to 
penetrate tissues. However, the relaxivity of these agents is limited and research is ongoing 
to increase their sensitivity.
23-
C h apter 1 Introduction
1.7.3 Acyclic or macrocyclic contrast agents ?
All gadolinium chelates currently in clinical use are based on either the acyclic DTP A 
ligand or the macrocyclic DOTA ligand (Figure 1.14). DTPA (1.7) is the first and most 
widely used acyclic chelator for the complexation of Gd^ .^ DTPA is an octadentate ligand 
and when it is complexed with Gd^^ accumulates non-specifically and is excreted 
rapidly
r
HOgC N "N ' "COgH
J  L N
HOgC COgH HOgC—/  \  /  \^CO gH
1.7 1.8
Figure 1.14 Structure of the ligands DTPA (1.7) and DOTA (1.8).
The macrocyclic ligand, DOTA (1.8), is one of the most frequently employed chelating 
agents, primarily because of the high stability and kinetic inertness of its metal complexes. 
Both these properties are crucial but kinetic inertness is essential. This stability and 
inertness has been ascribed to the macrocyclic structure of the ligands. The macrocyclic 
effect states that complexes of macrocyclic ligands are more stable than those with 
polydentate ligands of similar binding ability (or similar donor atoms) The stability of 
the majority of macrocyclic gadolinium chelates is higher than that of complexes derived 
from acyclic ligands. Conformationally constrained ligands are preferred because it is 
considered;
(i) a certain degree of preorganisation  ^should favour the complexation process, and
(ii) décomplexation should be disfavoured due to the presence of steric barriers.
 ^ Preorganised means that the donor atoms are held in the correct spatial positions for coordination 
to a metal
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Additionally, DOTA-type complexes are kinetically more stable because the rigid ring 
structure of the macrocycle prevents release of the metal, as at least five coordination sites 
would have to break simultaneously, whereas in Gd-DTPA, it is possible to envisage 
sequential breaking of the coordination sites The gadolinium chelate of DOTA is 
currently used as an MRI contrast agent under the brand name Dotarem (Guerbet, France). 
DOTA is the parent molecule of an ever-growing family of macrocyclic lanthanide (III) 
chelating agents
1.8 Types of contrast agents
There are a number of ways in which contrast agents (CAs) can be classified. For example, 
it may be based on clinical applications, target organ, chemical composition, and so on. 
MRI contrast agents can be classified as positive (appearing bright on MRI) or negative 
(appearing dark on MRI), Ti or T2 , contrast agents. T\ agents containing Gd^^ and Mn^^ are 
usually preferred to T2 contrast agents like SPIO (Supei^aramagnetic iron oxide) particles 
as a positive contrast enhancement is often more easily detected than a negative one. The 
first generation of contrast agents (Figure 1.2) are all non-specific, even if their distribution 
in the body is far from homogenous They reside mainly in the blood stream because of 
their hydrophilic nature. There remains a need for more selective and efficient contrast 
media that would aid radiologists in making more accurate diagnoses These second 
generation agents will be able to selectively visualise for instance, the liver or 
cardiovascular system.
In this section, CAs conjugated to targeting biomolecules will be discussed in Section 1.8.2 
and are referred to as targeted contrast agents. Activatable contrast agents, by comparison.
- 2 5 -
C h apter J Introduction
are switched on by a specific environmental factor and are chemically responsive to 
physiological states within tissues (Section 1.8.3).
1.8.1 Blood-pool contrast agents
Many injuries and diseases such as atherosclerosis manifest themselves through 
abnormalities of the blood vasculature Also, abnormal angiogenesis (blood vessel 
growth) is observed in the development of most tumours. In order to efficiently image 
blood vessels, compounds need to stay in the circulation and should not partition into the 
interstitial space. Filtration by the glomeruli in the kidney defines the molecular weight of 
blood pool agents to be > 20,000 High molecular weight macromolecules have been 
investigated in recent years as potential blood pool imaging agents. Macromolecular 
molecules cannot be eliminated by glomerular filtration and have much longer dwell times
in the body. Furthermore, due to longer rotational correlational times (7>), high molecular
weight agents based on Gd^^ are characterised by higher relaxivities (see Section 1.7.2).
For example, Gd-DTPA covalently bonded to albumin was found to provide excellent 
enhancement of blood in rats However, retention of Gd^^ in vivo for several weeks 
raised concerns of the contrast agent’s long term toxicity. The long residence time of 
macromolecules in the body improves their susceptibility for cell uptake. Additionally, 
large molecules are more likely to be antigenic than small molecules, leading to drug- 
directed antibodies and potentially anaphylaxis Probably as a result of these concerns, no 
macromolecular agents have as yet advanced to human trials. One non-macromolecular 
compound with good potential as a blood pool imaging agent is MS-325 or AngioMARK 
(Figure 1.15).
Anaphylaxis is an acute, systemic (multi-system) and severe Type I hypersensitivity allergic reaction .
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protein-binding moiety
6d>.:' O2C
Figure 1.15 Structure of MS-325 ( AngioMARK )
MS-325 was developed by Lauffer et a l and is currently undergoing human trials. 
Animal and human studies showed that blood vessels were strongly enhanced for over one 
hour. The critical positioning of the hydrophobic, diphenylcyclohexyl group next to the 
hydrophilic phosphodiester is thought to give rise to albumin binding. This 
diphenylcyclohexyl-substituted DTPA non-covalently binds to human serum albumin 
(HSA) and reduces the free concentration available for glomerular filtration (Figure 1.16).
Renal
excretionHuman
serum
albumin
(HSA)
MS-325
MS-325
HSA with bound MS-325
rj = 30-50 mM'^sec'^
Molecular rotation rate ~ lO^sec'^
Free MS-325
r\ = 6.6 mM'^sec'^
Molecular rotation rate ~ lO^^sec'^
Figure 1.16 Mechanism of action for MS-325 The bound agent is in equilibrium with a 
small amount of the free form, which is renally excreted steadily over time. The bound form has 
greatly increased relaxivity by virtue of its slower molecular tumbling rate.
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1.8.2 Targeted contrast agents
A desirable feature of a contrast agent is that it targets a tissue or organ. The basis for 
designing probes for a given application depends on the location of the target molecule 
(vascular, extracellular matrix, cell membrane, intracellular, near or at the cell nucleus). 
Design and synthesis of targeted agents is an active area of research but some compounds 
are already in clinical use These include the manganese-based, metalloporphyrin 
contrast agent (Mn(III)TPPS4) which is used to preferentially enhance contrast of tumours 
that are iso-intense to surrounding areas on Ti-weighted images Superparamagnetic iron 
oxide (SPIO) particles are used clinically to image the lymph nodes Limitations with 
targeted agents include the delivery of sufficient quantities of contrast material to the site 
of the receptor and the biological implications of saturating certain receptors
One challenge that has beset contrast agents for years was their inability to cross cell 
membranes. This barrier hampered the development of the role of MRI contrast agents in 
addressing biological questions. In 2003, Allen and Meade found that conjugating 
Gd(DOTA) to arginine gave a CA (1.9) that crossed cell membranes (Figure 1.17)
arginine
V 1.9NH
Figure 1.17 A membrane-permeable contrast agent (1.9).
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A  similar agent (1.10) was developed by Aime et This conjugate, consisting of 
glutamine and Gd-DOTA, was found to be actively transported through cell membranes 
(Figure 1.18).
glutamine
HO
Figure 1.18 A membrane-permeable and tumour-selective contrast agent (1.10) 44
Proliferation of tumour cells require greater amounts of nutrients like the amino acid 
glutamine and the corresponding membrane-transporters in these cells are up-regulated 
and/or over expressed. This study found that four times more 1.10 was uptaken by tumour 
cells than by healthy cells. Clearly, the possibility of targeting cells with low molecular 
weight, easy to synthesize, gadolinium chelates is highly attractive. The previous examples 
raise the possibility of diagnosing medical conditions before they become untreatable. For 
instance, clinical oncology has a need for contrast agents that can identify tumours 
and métastasés at a size of 100,000 cells rather than 1,000,000,000 cells
Amyloid plaques are a characteristic feature in Alzheimer’s disease (AD) Early 
diagnosis is vital as once the symptoms of the disease become evident, irreversible damage 
has often occurred. Recently, researchers found that conjugation of the peptide, K6Api-30 
(which binds specifically to plaques) to Gd-DPTA enabled earlier detection of the
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plaques As well as detecting symptoms of the disease earlier, this agent may also prove 
useful for following therapeutic approaches targeting the condition.
Monoclonal antibodies (McAb) have been raised against tumours and covalently attached 
to DOTA via the ester intermediate (1.11; Scheme 1.2) Complexation of the resultant 
conjugate with Gd^^ gave the highly-specific, contrast agent (1.13).
. 0  -,
- A
GCJ2O3
\  / ' T A  H
1.13
A
Scheme 1.2 Preparation of a McAb-Gd(DOTA) contrast agent (1.13)
One problem with this approach is that the antibody-DOTA agent (1.13) delivers only one 
Gd^^ ion to the target which is insufficient to image a tumour. For most biological targets 
of interest for imaging, multiple Gd^^ ions are required to provide the necessary change in 
relaxation rate. To this end, Lanza et developed a perfluorocarbon-based nanoparticle 
loaded with several thousand Gd^  ^ ions. This fibrin-targeted agent (1.14) contained 
-50,000 paramagnetic gadolinium chelates per 250 nm particle, and could detect clots as 
small as 500 pm (Figure 1.19).
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1.14
biotin
antibody
avidin
perfluorocarbon
target 
( fibrin )
Figure 1.19 Preparation of a fibrin-targeted, fluorocarbon-based nanoparticle (1.14) 49
To construct this nanoparticle, lipids containing biotin were incorporated into the 
fiuorocarbon micelle. Avidin, which has a strong affinity for biotin, was then derivatized 
with an antibody raised against fibrin (which is found in clots). In this manner, a 
nanoparticular, contrast agent targeted to fibrin was prepared.
The nanoparticle approach may be more sensitive than the small-molecule approach, as 
each particle brings tens of thousands of gadolinium atoms to the target site, as compared 
to a single one. The major drawback of the nanoparticle approach is that not all 
biochemically-interesting sites can be reached. The average size of this type of 
nanoparticle is 250 nm which limits intracellular access. Clinical trials of targeted 
paramagnetic, nanoparticles are expected within a few years
1.8.3 Activatable or “smart” contrast agents
Many new contrast agents are being developed that are capable of reporting on the 
physiological status and metabolic activity of cells or organisms These ‘Procontrasf 
agents have been designed to exploit three fundamental physical properties of 
paramagnetic complexes that function as the switch or trigger to make them detectable by 
MRI. These properties are: first, q, the number of water molecules coordinated to the
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paramagnetic ion; second, Xm, the lifetime of a water molecule bound to the paramagnetic 
ion; and third, t r , the rotational correlation time of the complex. If motion, hydration 
number, or water exchange can be altered by an ion, metabolite, enzyme, or a change in 
pH, then this change may be detected by a change in relaxivity. Since the relaxivity of 
activatable CAs can be modified by different physiological states, they are predicted to 
have a crucial role in the imaging field
The first example of a responsive or smart agent is EGad (1.15), which was developed by 
Meade et a l (Figure 1.20)
>
OHH
HO.
OH
1.15
P-galactosidase 
 ►
-O
Figure 1.20 Activation of EGad (1.15) by the enzyme, P-galactosidase 
(where R is H or Me).
1.15 is an galactosidase-responsive agent and is essentially DOTA with a galactopyranosyl 
moiety attached. In 1.15, all 9 coordination sites of the metal ion are occupied and there is 
no water molecule in the first coordination sphere. When p-galactosidase cleaves the 
galactopyranosyl moiety enzymatically, a free coordination site appears which is quickly 
occupied by a water molecule. Consequently, a 20 % increase in relaxivity is observed in 
the presence of the enzyme. EGad is used as a research tool to determine if gene delivery 
has been successful; the enzyme p-galactosidase is not expressed naturally in all human
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cells 1.15 is a prototype agent which demonstrates the potential of MRI for
determining the level and location of an enzyme within biological tissues. Egad also 
demonstrates that MRI is capable of detecting an enzyme that is present at very low 
(nanomolar) concentrations.
Other research has focused on agents that may enable the observation of cellular processes 
as they turn off and on. To accomplish this, CAs like 1.16 are being developed whose cage 
doors are not removed but instead are being opened and closed in a reversible process 
(Figure 1.21).
o. o
COo-
o
o
W  r ’O
CO, -  'OoC
1.16
Figure 1.21 A contrast agent (1.16) that is sensitive to Ca^^ ions
In 1.16 changes occur in response to the concentration of calcium, an intracellular ion that 
plays an important role in cell signalling, regulation and metabolism The RCOO' groups 
have a higher selectivity for Ca^^ than Gd^\ As the concentration of Ca^^ increases, the
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RCOO' groups preferentially bind to Ca^^ and expose the Gd^^ to water molecules. As a 
result, water can come into contact with gadolinium resulting in a detectable increase in T\ 
relaxivity.
The measurement of pH in vivo is an important goal in the diagnosis of kidney disease and 
cancer Although tissue pH can be measured using microelectrodes, electrodes are 
invasive and cannot provide good resolution beween different tissues. Therefore, MRI 
contrast agents have been investigated as possible non-invasive reporters of extracellular 
pH One promising pH-sensitive contrast agent is GdD0TA-4Amp (1.17) shown in
Figure 1.22 62
<
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O '
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1.17
Figure 1.22 Structure of GdD0TA-4Amp (1.17); a CA that can sense tissue pH.
Between pH 2 and 4, 1.17 displays a 25 % increase in relaxivity whereas between pH 6 
and 9, an 84 % enhancement of relaxivity is obtained. It is thought the phosphonate side- 
chains enable rapid prototropic exchange between the single bound water molecule of the 
complex with the bulk water giving the complex a unique pH-dependent relaxivity.
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1.9 Synthesis of macrocyclic ligands based on cyclen
The macrocyclic ligands, DOTA and D03A, are prepared from cyclen (1,4,7,10- 
tetraazacyclododecane). Cyclen, shown in Figure 1.23, is a tetraazamacrocycle with 12 
atoms and is an aza analogue of crown ether
H. .H
1.18
N n :
:n n '
1.19 J
:n N :[
H" I I^H
Figure 1.23 Structure of cyclen (1.18: [12]aneN4)^ and cyclam (1.19: [14]aneN4)
Cyclen and cyclam are often viewed as models of natural macrocyclic tetra-amine ligands 
such as porphyrins and corrins which are widespread in nature. The development of 
synthetic macrocyclic chemistry has resulted in an increased understanding of these 
important biological macrocycles. Like crown ethers, cyclen derivatives are capable of 
selectively binding cations like Zn^^ as shown in Figure 1.24
Figure 1.24 Zn^^ coordinated to cyclen and an ethanol molecule 65
One of the biggest drawbacks of macrocyclic ligands lies in their synthesis The 
commercial synthesis of cyclen itself is long and tedious (Scheme 1.3) Richman and
This notation indicates the size of the ring, the number and type of donor atoms, and any substituents 
that are present
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Atkins’ protocol involves the condensation of tosylated diethanolamine with the sodium 
salt of tosylated diethylenetriamine under conditions of high dilution. Unless the reactants 
are very dilute, ordinary polymerization and not cyclization will take place. The lack of an 
efficient, commercially-available synthesis of cyclen probably contributes to its high cost 
(5 g of cyclen from Strem Chemicals, USA costs £83, 2008).
I s
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H2 S0 4 .NH HN.
NH HN"
Scheme 1.3 Richman and Atkins synthesis of cyclen 66
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1.9.1 Functionalization of cyclen
Figure 1.25 shows one energy-minimised conformation of cyclen. It can be seen that the 
methylene groups adopt a staggered conformation. Since hydrogen atoms occupy more 
space than lone pairs, the lone pairs tend to point towards the centre of the ring Three 
lone pairs point towards the centre of the ring (endocyclic) and one lone pair points away 
(exocyclic). This preference is consolidated as the size of the A-substituent increases.
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Figure 1.25 3D view of cyclen base in one energy-minimised conformation.
(generated in Chem 3d Ultra 8.0, nitrogen H = white, nitrogen lone pair = pink)
Tertiary (NRR'R") and secondary (NHRR') amines are chiral, the nitrogen atom bears four 
distinct substituents counting the lone pair Most chiral amines cannot be resolved into 
separate enantiomers because the two enantiomeric forms rapidly interconvert by 
pyramidal inversion (Scheme 1.4). The energy barrier for the inversion of the stereocentre 
is relatively low, e.g. -25 kJ/mol for a trialkylamine.
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Scheme 1.4 Pyramidal inversion of amines interconverts the two mirror-image forms
When cyclen is A-substituted, inversion of the remaining nitrogens is less likely as the 
increased angle strain in the macrocycle raises the barrier for inversion. In effect, the 
macrocycle becomes more rigid after each successive substitution. This restriction of 
conformational mobility may cause the remaining lone pairs to point towards the centre of 
the ring making them unavailable for reaction.
Tetraazamacrocycles generally follow the trend that two of the pKa values are high, 
whereas the other two are significantly lower. This is thought to be due to electrostatic 
effects (Scheme 1.5). The second proton can bind to a nitrogen atom trans to the first 
one whereas the third and fourth protons must bind cis to the positively charged 
ammonium group.
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Scheme 1.5 pKa values of cyclen (1.20)
Since the nitrogen atom is nucleophilic, it can be alkylated or acylated. Cyclen has been 
substituted with a wide variety of side chains containing donor groups capable of binding a 
metal atom These include -CH 2COOH, -(CH 2)2NH2 , -CH 2CN, -(CH2)20H and 
-(CH 2)2P0 3 H2 . In general, these side chains are introduced onto preformed cyclen using 
halogenated derivatives Selective substitution of cyclen is more difficult than 
substitution of all the ring nitrogens. This may be due to two factors; the values of the 
cyclen amines and the size of the substituent groups. The pATa of the amine groups on 
cyclen can be divided into 2 sets (Scheme 1.5); those with higher pKa values (10.5, 9.5) 
and those with lower pKa values (0.8, 1.6). These groupings of pATa values make the 
asymmetric substitution of cyclen difficult as the conditions needed to alkylate one amine 
in each pKa pair can also lead to the alkylation of the second amine within the pair. 
Consequently, attempted mono-A-substitution of cyclen can lead to significant amounts of 
the di-A-substituted product. Similarly, attempted tri-A-substitution of cyclen can lead to
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significant amounts of the tetra-jV-substituted product. Strategies to prevent over-alkylation 
include the use of protecting groups and high dilution techniques.
Mono-A^-substituted cyclen has been prepared by a procedure which employs a statistical 
effect This involves the reaction of a large excess of cyclen with the alkylating agent 
(10:1) in order to minimise the formation of polysubstituted products. This method works 
well if a carboxylate side chain is introduced onto the cyclen ring as separation of products 
from starting material is straightforward. A second method as outlined in Scheme 1.6, 
involves the protection of three amino groups leaving one available for further alkylation. 
In Scheme 1.6, cyclen is temporarily tri-protected with Boc. This tri-protected species 
(1.21) is then alkylated with a halogenated substrate (RCl) to give a tetra-substituted 
intermediate (1.22). Deprotection of this intermediate yields the mono-A-substituted cyclen 
(1.23).
/  \  B oc y  \  Boor 0  f I . / ' ]
HN NH UK.HN
B oc
ii. RCl / EtgN
HN NH /  \  / B o c
r  'I iil. HCI/MeOH N("
k  '  J   ------------------  [ 1.22 ^
^ N  NH k. J
R \ ■ /  B oc
Scheme 1.6 Mono-A-substitution of cyclen (1.23) via tri-Boc cyclen (1.21) 61
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1.9.2 Synthesis of Gd(D03MA)
The synthesis of Gd(D03MA) (1.28) illustrates several important aspects of the synthesis 
of a contrast agent (Scheme 1.7)
O---------------------------------- / ---- \  0 .5^ 0 Bn
+
DIPEA y  ^
L J  N \
NH 6 3  %  B n p  I 1.26 I
OSO2 CF3  ^ V
1.24 (3 .5  eq .) 1.25 (1 e q .) /  O
H g/Pd 7 8 %
.0  O ^ O H
/ r \ , ^ -  - y  I .
1 0-—!-— ^d>— r ''   / "  '%  \
r i = 4 . 4 m M s - i  v 7 3 %  HO | 1 2 7  |
(20 MHz. 40 \ , \ ..... k ................ y
7 3  OH
NH
Scheme 1.7 Synthesis of the contrast agent Gd(D03MA), 1.28
As tri-substituted cyclen was required, cyclen was mono-A-protected with a formyl group 
to give 1.25. To avoid the formation of a mixture of diastereomers  ^(which may exhibit 
different coordination chemistry with Gd^^), chiral L-benzyl lactate was used as starting 
material. In order to facilitate the alkylation reaction, the lactate alcohol was converted into 
a triflate leaving group rather than a chloride or bromide. It was thought that the use of a 
better leaving group like triflate would avoid forcing conditions such as high temperature 
which may have resulted in extensive racemization
® Diastereoisomers have opposite configurations at one or more stereogenic (asymmetric) centres, but the 
same configuration at others. For example, 1R,4R,7R D03MA is enantiomeric with 1S,4S,7S D03MA 
and diastereomeric with 1R,4S,7R D03MA
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Treatment of A-formylcyclen (1.25) with 3.5 eq. electrophile (1.24) and 3.5 eq. of the 
hindered base, diwopropylethylamine (DIPEA) in acetonitrile at ambient temperature 
afforded 1.26 in a yield of 63 %. Simultaneous deformylation and débenzylation of 1.26 
were achieved in aqueous methanolic HCl in the presence of a palladium catalyst at 
ambient temperature. The crude product was purification by ion exchange 
chromatography. Treatment of the free acid of D03MA (1.27) with gadolinium oxide 
resulted in pure Gd(D03MA) (1.28) in a 73 % yield. X-ray structure analysis of 
crystallized D03MA revealed that the three asymmetric carbons bearing a-methyl groups 
all had (i?)-configurations. In addition, the chelate was found to be optically active in 
solution. These facts, together with the synthetic methods chosen, suggest that significant 
racemization did not occur during the synthesis of Gd(D03MA).
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1.10 Aims of this project
The current generation of MRI contrast agents are non-targeted, hydrophilic compounds 
with low molecular masses Since their masses are less than 500 Da, they are rapidly 
cleared from the intravascular space through the capillaries into the interstitial space, and 
therefore their biodistribution is non-specific. The search for a new generation of contrast 
agents is strongly orientated towards CAs that display high tissue and/or organ specificity 
36, 73-76 non-invasive nature of MRI, its near-cellular resolution, and the ability to 
acquire images at different time points, all make contrast-enhanced MR imaging a unique 
and powerful tool to study biological processes at the molecular and cellular level. In this 
context, the aim of this project is to synthesise a core, bifunctional ligand (1.29) that can be 
derivatised for use as either a targeted or an activatable contrast agent (Figure 1.26).
HO NH
1.29OH OH
NH
NH
Site of attachment for 
targeting biomolecule 
e.g. biotin, folic acid.
Figure 1.26 Structure of the bifunctional target ligand (1.29).
A bifunctional chelating agent (BFCA) contains a reactive group for coupling to proteins 
or other molecules and a strong metal chelating group such as those in DOTA The 
target ligand (1.29) is bifunctional as it possesses 7 donor groups to complex the Gd^^ ion 
and keep it in place as well as possessing free amino groups for conjugation to targeting 
biomolecules.
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The presence of an amino group in the side chain of 1.29 allows for conversion into 
various functional groups (e.g. aminocarboxylates, aminophosponates, etc) or for amide 
coupling to compounds with free carboxyl groups such as peptides or folic acid. Attaching 
a contrast agent to a targeting biomolecule that accesses a specific catalysed-transport 
mechanism creates a Trojan-Horse like deception that tricks the membrane into welcoming 
the contrast agent through its gates Covalently linking 1.29 to a monoclonal antibody 
(McAb), for example, should impart biological specificity to the metal chelate complex; 
the resultant CA should concentrate at the McAb target site e.g. a tumour
The use of a cyclen-based macrocyclic ligand instead of an acyclic DTP A ligand should 
improve the safety profile of the resultant complex, minimising any dechelation in vivo. 
Substitution of the pendant arms in 1.29 should enhance its stability. For example, 
a-methyl substitution of the arms on D03MA (Scheme 1.8) is believed to contribute to the 
high stability of the corresponding gadolinium complex; Gd(D03MA) has a 
thermodynamic stability constant nearly as high as Gd(DOTA)’ even though it is 
heptadentate
In addition to containing 4 secondary amines, the target ligand (1.29) possesses 3 carboxyl 
groups for coordination to the Gd^^ metal. Since Gd^^ has 3 positive charges, the overall 
complex will be charge-neutral. This is important as neutral, non-ionic complexes are 
better tolerated in vivo and thus allow the administration of higher doses Once 
complexed with Gd^% the resulting complex will be heptadentate. This will allow the eight 
and ninth coordination sites of gadolinium to be occupied by water molecules, that is, the 
complex will have a q value (hydration number) of two. An increase in the hydration state 
should translate into an increase in relaxivity (see Section 1.6.1).
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Currently, targeted contrast agents (1.32) are generally prepared by the the 1+3 route 
(Scheme 1.8).
NH HN R — Br ^ N H  N .
C J —" L , J
‘NH HN NH HN
H O j C ^  ,  y  R C O j f B u ^  y ----\  RV  HCl V  'nC'
r  1.32 J  r  1-31 j
HOgC— ^  \ _____ /  ^  C O 2H B u f O g C - /  \  /  \ - ' C 0 2 f f i u
Scheme 1.8 The commonly-used 1+3 protocol for the preparation of a targeted 
MRI contrast agent (1.32).
One reason for the popularity of the 1+3 route to targeted CAs is its relative simplicity. 
After cyclen is mono-iV-alkylated with a targeting molecule, it can then be reacted with 
^er^-butyl 2-bromoacetate to give the fully-substituted cyclen (1.31). Hydrolysis of the 
^-butoxylcarbonyl ester groups then yields 1.32 A drawback of this method is that 
targeting biomolecules like antibodies may be sensitive to the basic conditions used to 
introduce the acetate groups onto cyclen or the acidic conditions required to remove the 
/-butoxylcarbonyl groups.
Chapters 2 and 3 of this thesis will describe attempts to synthesise the bifunctional, 
core ligand (1.29). The synthesised ligands will then be complexed with the paramagnetic, 
lanthanide metal, gadolinium (Chapter 4). The ability of the complexes to increase the 
relaxation rate of water protons, that is, their -relaxivity will be determined. The values 
obtained should indicate the suitability of the complexes for use as MRI contrast agents.
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Functionalization of cyclen via alkylation
C h apter 2 Alkylation of Cyclen
2.0 Introduction
This chapter consists of two parts; both of which are concerned with the alkylation of 
cyclen using halogenated derivatives. Part A of this chapter describes the alkylation of 
cyclen using amino acid derivatives in pursuit of a generic target ligand. This ligand can be 
potentially coupled to a variety of targeting biomolecules and can be considered to be 
bifunctional (see Section 1.10, Chapter 1). Part B of the chapter deals with the synthesis of 
a cholic acid-cyclen conjugate which, after complexation with gadolinium, could be used 
as a blood-pool imaging agent. It is an example of a targeted contrast agent.
As discussed in Chapter 1 (Section 1.9.1), alkylation is the primary method used to 
functionalize cyclen. For example, the core ligand D03A can be prepared by the alkylation 
of the commercially available unprotected cyclen ( 1,4,7,10-tetraazacyclododecane) with 
chloroacetic acid to give a final yield of 26 % As a result of over-alkylation, DOTA is 
also produced in the reaction but it can be readily separated from D03A by anion 
exchange chromatography (Scheme 2.1).
c , +  3 eq. Cl.N ^  'OH
KOH (6 M)
H O g C -^  /  \  / - C O g H  H O gC -^-/ ---- \  / — COgH HOgC-x y---- - ^ C O g H
.N anion-exchange Yj.
I +  I I chromatography
H O ,C -^ "v_/V co,H  HO,C-/ w "'h "
D 0 3 A
Scheme 2.1 Synthesis of D03 A via alkylation of cyclen
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In an effort to improve the yield of D03A, cyclen was mono-A-protected with a formyl 
group and then reacted with ^eA-butyl-bromoacetate (4 eq.) to give a tetra-substituted 
intermediate Hydrolysis of this intermediate gave D03A in a yield of 69 % (Scheme 
2.2).
o
« ' " w \
+
KOH
4 eq .
C. JN n;
Buf02C-/ \ ----/  '^C02fBu
H2SO4
H02C-\^ y----
. N  NH
s  J
H0 2 C—^  \  /  ^— C0 2 H
D 0 3 A
Scheme 2.2 Synthesis of D03A via alkylation of mono-A-formyl cyclen
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Part A Alkylation of cyclen using amino acid derivatives
2.1 Alkylation of cyclen with derivatised 4-amino-3-hydroxybutyric 
acid
In Scheme 2,3, disconnection of the target molecule 2.1 next to the cyclen ring (2.4) leads 
to 2.3 as the electrophilic synthon. The synthetic equivalent of 2.3 is 4-amino-3- 
mesylbutanoic acid (2.5) which can be conveniently prepared from commercially- 
available, 4-amino-3-hydroxybutyric acid (2.6), In essence, replacement of the hydroxyl 
group in 2.6 allows nucleophilic substitution reactions to be performed at the C-3 atom. 
The nucleophilic synthon cyclen is also commercially available.
COoH
target ligand (2.1)
HN NH
C 2.2 J
HN N -
+
Scheme 2.3
"COzH
HoN'
2.3
Proposed route to the target ligand (2.1).
HN NH
^  2.4 J
HN N
2.5
HO
HoN
CO2 H
2.6
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2.1.1 Derivatisation of 4-amino-3-hydroxybutyric acid
The first substrate investigated as a starting material in the route to the target ligand was 
4-amino-3-hydroxybutyric acid (2.6). Since the amine and carboxyl groups are 
nucleophilic, protection is required. A protecting group (PG) must suppress this 
nucleophilic reactivity by delocalising its electron density into a suitable substituent or by 
shielding its reactivity behind a sterically-hindered group After these protection steps, 
the alcohol group requires conversion into a good leaving group such as a mesylate group 
in preparation for the subsequent reaction with cyclen.
The first synthetic step involved the protection of the carboxylic acid group with an ethyl 
ester. This was achieved by refiuxing 2.6 in absolute ethanol containing /?-toluenesulfonic 
acid as an acid catalyst (Scheme 2.4).
O
— # - S - O H
O ^
OH
HO.C' Y  'NH, + T
OH 88 %
2.6 2 .7
Scheme 2.4 Estérification of 4-amino-3-hydroxybutyric acid.
The method used was a modification of a procedure described by Bodansky in the 
textbook The Practice o f Peptide Synthesis In the published procedure, 2 eq. 
/ 7-toluenesulfonic acid (pTSA) were employed but it was found here that 1.1 eq. were 
sufficient for the conversion. Since the /?TSA protonates the basic amino nitrogen group as 
well as the carbonyl oxygen atom of 2 .6 , greater than 1 eq. of acid catalyst is necessary 
(see the reaction mechanism in Scheme 2.5). Also, washing with diethyl ether, as outlined 
in the original method, did not remove all the /?-TSA if the stated 2 eq. were used.
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HO OH
2.6
HoN
) OH
OH
HoN
\O
HO
ÔH
HoN
proton
transfer
2 .7
-HoO
OH
OH
Scheme 2.5 Estérification of 2.6 -  the reaction mechanism
The amino group of 2.7 was then protected with the acid-labile, A^-/er^-butyloxycarbonyl 
group which is commonly known as ^-Boc. ^-Boc serves as a protective group in solid 
phase peptide synthesis and it is stable to most bases and nucleophiles Amino acids 
protected with alkoxycarbonylamino PGs such as ^-Boc tend not to undergo racemization, 
which can be described as the conversion of an enantiomer to a mixture of enantiomers. 
The procedure used for the introduction of the ^-Boc group was also described by 
Bodansky (Scheme 2.6). Reaction of 2.7 with di-^er^-butyl dicarbonate (1.1 eq.) and 
TEA (2.2 eq.) produced 2.8 as a colourless oil. A characteristic Boc singlet at ô 1.45 ppm, 
which integrated for 9 protons, was observed in the NMR spectrum of the product.
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EtgN (2.2 eq.)
 ^  °^c
O OH
75%
2 .7  (1 e q .)  1.1 eq . 2 .8
Scheme 2.6 Protection of amino group of 2.7 with ^-butyl (Boc).
The OH group of 2.8 was converted to a mesylate (Scheme 2.7) rather than a halide as 
sulfonic ester groups such as mesylates are regarded as better leaving groups Primary 
and secondary alcohols react with methanesulfonyl chloride in base at room temperature to 
give mesylates, usually in good yield 2 . 8  was reacted with methanesulfonyl chloride and 
triethylamine in DCM to give a high yield (69 %) of the mesylate (2.9). Trituration of the 
mesylate oil with acetone produced a white solid which was subsequently crystallised from 
toluene-hexane.
EtgN (1.1 eq .)
II I
+  0 = S = 0
o = s= o
A X
2 .8  1.1 eq . 2 .9
Scheme 2.7 Transformation of the alcohol group of 2.8 into the mesylate (2.9).
The full synthetic sequence is outlined in Scheme 2.8 oveleaf. The overall yield of 2.9 was 
45 %.
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HOgC 2.6
4-Amino-3- 
hydroxybutyric acid
p-TSA  ^ ^ - S O g H
HO'
8 8 %
2.7
ethyl 4-amino-3- 
hydroxybutanoate
Boo,o X oA ^A X 75%
2.8
ethyl 4-[(Boc)amino]-3- 
hydroxybutanoate
Cl
MsCl o = s = 0 69%
2.9
ethyl 4-[(Boc)amino]-3- 
mesyl butanoate
Scheme 2.8 Synthesis of ethyl-4-[(Boc)amino]-3-mesyl butanoate (2.9).
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2.1.2 Alkylation of cyclen with derivatised 4-amino-3- 
hydroxybutyric acid.
Cyclen (1 eq.) was stirred with 3.1 eq. of ethyl-4-[(Boc)amino]-3-mesyl butanoate (2.9) 
and 3.1 eq. K2CO3 base in dry acetonitrile under argon. Initially, the reaction was carried 
out at room temperature as both SnI and Sn2  reactions are favoured by low temperatures. 
When electrospray mass spectroscopy (ES-MS) detected only mono-W-substituted cyclen 
after 12 hours, the temperature was increased to 60 °C for a further 12 hours. Purification 
of the reaction mixture via silica gel column chromatography yielded the alkene 2.10. This 
revealed that 2.9 underwent mostly elimination as shown in Scheme 2.9. A coupling 
constant between the protons of 15.6 Hz showed the alkene to have a trans configuration.
2.9 (3.2 eq.)
X„x
+  1  eq.
o = s = o
K2 CO3  ( (3.2 eq.) 90%
„Q
O
H H N - ^  \ 
O H
2.10
Scheme 2.9 Alkylation of cyclen with 2.9 to give 2.10.
Primary and secondary substrates normally react by the Sn2 mechanism Sn2 reactions 
can only occur at relatively unhindered sites and are normally only useful with primary 
halides and a few simple secondary halides. In secondary substrates, the Sn2 mechanism
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occurs in competition with the E2 mechanism which explains why most of the product, 
even at room temperature, is an alkene. Also, the mesylate (2.9) can eliminate in either of 
two directions to give either the conjugated alkene (2 .1 0 ) or the non-conjugated alkene 
(2.11) as demonstrated in Scheme 2.10.
HN
0 = S = 0
H HN
2.10 2.11 
Scheme 2.10 Elimination of 2.9 to give the conjugated alkene (2.10).
The FT-IR and NMR spectra of the product confirmed that the more stable conjugated 
alkene (2.10) was produced. In the FT-IR spectrum, the ester C=0 of 2.10 absorbs at 
1728 cm'^ whereas the product absorption was located at 1700 cm"\ Conjugation of C=0 
with an alkene normally lowers the wavenumber of the absorption by 10-20 cm"\ This 
downward shift in the C=0 absorption provided good evidence that the product alkene was 
conjugated.
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The chemical shift values obtained for H’ and H” in both the NMR and NMR (not 
shown) spectra correlate with the 6  values expected for a conjugated alkene, 2 . 1 0  (see 
Figure 2.1)
HN
O O
/
O H'
H' Ô expected = 5.95 ppm, observed = 5.93 ppm 
H" 5 expected = 7.01 ppm, observed = 6.91 ppm
2.10
Figure 2.1 NMR values expected (and observed) for the conjugated alkene (2.10).
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2.2 Alkylation of cyclen with derivatised L-serine methyl ester 
hydrochloride (LSME).
In the previous section, the problem of elimination when a secondary substrate was reacted 
with cyclen was described. Therefore, a primary substrate which should favour the Sn2 
reaction and promote substitution was investigated next. Commercially available L-serine 
methyl ester hydrochloride (LSME; see 2.12 in Scheme 2.11) was employed to investigate 
if the use of a primary substrate would promote the desired substitution over elimination.
COgH
2.1
HOoC
HOoC,
 ^ NHz
O
O'HO
N N.
NH:
2.12 HOgC
2.13
COgH
NHg
Scheme 2.11 Structure of the new target molecule (2.13).
Substituting L-serine methyl ester (2.12) for 4-amino-3-hydroxy-butyric acid (2.6) changes 
the structure of the target molecule from 2.1 to 2.13. The new target ligand (2.13) contains 
three amino acid-bearing pendant arms. Like the ligand (2.1), 2.13 also provides three 
carboxyl groups for coordination to a Gd^^ ion and three amino groups for potential 
conjugation to targeting molecules. However, one area of concern regarding the structure
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of 2.13 is the close proximity of the amino group to the carboxyl group. As the amino 
group is a  to the carboxyl group, this configuration could pose steric crowding issues if 
independent manipulation of either of these functional groups is required.
2.2.1 Derivatisation of L-serine methyi ester hydrochioride
2.12 has its carboxyl group conveniently protected as a methyl ester. For substitution, the 
amino group requires protection and the alcohol once again needs to be transformed into a 
good leaving group. The amine was protected with the Boc (or ^-butyl) group to give a 
yield of 84 % (Scheme 2.12).
O
HO Y  O
NH3+ cr
O O  ^ y HO
Y Xo
2 . 1 2  1 .1  eq. 2.14
Scheme 2.12 N-Boc protection of the amino group of 2.12.
It was decided to replace the sterically-hindered mesylate group with the smaller bromide 
leaving group. However, the standard reagent for brominating alcohols, HBr-acetic acid, 
could not be used as the acidic conditions could hydrolyse the methyl ester. A-Boc-L- 
serine methyl ester (2.14) was brominated using l,2-bis(diphenylphosphino)ethane (DPPE) 
and 1,2-dibromotetrachloroethane (1,2-DB) as shown in Scheme 2.13. These two reagents 
have previously been utilised to brominate alcohols under mild, non-acidic conditions
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HO
HN
2.14
Ph
Ph'
..Ph
Ph
2.15
Cl
Br-
0 1-
- 0 1
-Br 2.16
01
Br
HN
2.17
Ph
2.18 DPPE-O,
Scheme 2.13 Bromination of 2.14 using DPPE (2.15) and 1,2-DB (2.16) 86
DPPE, which is shown in Figure 2.2, was originally investigated as an alternative 
phosphine source to triphenylphosphine (TPP) in the Mitsunobu reaction Unlike 
phosphine oxide, DPPE oxide can be more easily removed at the end of the reaction.
0
O 'T O
2.19 2.15
Figure 2.2 Structures of TPP (2.19) and DPPE (2.15).
Since the structures of TPP and DPPE are similar, it seems reasonable to assume that the 
mechanism of the bromination reaction, as outlined in Scheme 2.13, would be similar to 
the mechanism of the halogénation of alcohols using TPP-CCI4 . A possible pathway for the 
bromination reaction is illustrated in Scheme 2.14 overleaf. The nucleophilicity of trivalent 
phosphorus in compounds such as DPPE should result in the formation o f a phosphonium 
salt 2.20 when they are treated with reactive alkyl halides (TPP combines with most alkyl 
halides to give phosphonium salts). Also, triphenylphosphine has previously been shown to 
induce the 1,2-debromination of 1,2-dibromides and this is thought to proceed via an E2- 
type elimination The electrophilic phosphonium salt (2.20) is then attacked by the OH 
of the alcohol substrate. Displacement of DPPE-O2 by bromide in 2 . 2 2  occurs in an
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irreversible Sn2 step. The formation of the strong P=0 bond provides a thermodynamic 
driving force in favour of halogénation. Evidence to support this mechanism came from 
mass spectral analysis of the reaction mixture before it was chromatographed. Peaks at m/z 
163 and a more prominent one at m/z 182 correspond to [2.21+H'^] and [2.21+NH/], 
respectively.
Ph
+ 2P Cl
Ph
2 .15 2 .16
1,2-debromination 
via E2
Ph
2
Ph
Br*
Ph"
2.20
OH
.Br
+
Ph
Br*
Ph
Ph
H Br*
2.22
.Br
IV
Ph |>
H
V
2H B r
Br
2.21
Ph ;
Br*
2 .23
S m2
Ph Ph
*+* 2 R ^ ^ B r
DPPE-Ü2 (2.18) 2 .17
Scheme 2.14 Bromination of alcohols using 2.15 (DPPE) and 2.16 (1,2 DB):
a possible reaction mechanism.
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The published procedure involves the addition of DPPE (1 eq.) and 
dibromotetrachloroethane (1,2-DB, 1.7 eq.) to the alcohol (1 eq.) in THF and stirring the 
mixture overnight. Work-up consisted of simply filtering the suspension through a plug of 
celite. However, it was found here that the crude product required a more rigorous 
purification by column chromatography as unreacted 2.16 eluted before the product. The 
optimisation of the reaction conditions was aided by the use of a fiuoroscein-hydrogen 
peroxide TLC spray (see Appendix A) The components of this spray react with 
brominated compounds to give intense pink spots on a yellow background. This spray was 
found to be especially useful for analysing reaction mixtures as the pseudo-molecular ions^ 
of brominated compounds are not always observable on electrospray mass spectrometry. 
This is due to displacement of the bromide ion by other ions in the MS Due to the 
requirement for brominated substrates in this project, several reaction conditions were 
investigated in order to optimise yields (see Table 2.1).
Table 2.1 Bromination of A-Boc-L-serine methyl ester (2.14).
AZ-Boc-LSME
(eq.)
DPPE
(eq.)
1,2-DB
(eq.)
Solvent Reaction
conditions
Yield
(%)
0.5 1 1 toluene RT / 24 h 0
1 0.5 1 toluene RT / 72 h < 10 mg
1
0.5 1 DCM RT/24h 9.6
1 0.5 1 THF RT / 24 h 21.2
1 0.6 1.7 THF RT/24h 33.6
1 1 1.7 THF RT/24h 53.8
It was found that using toluene as the reaction solvent resulted in only a trace of product 
and less than 10 mg was isolated. DCM gave good conversion but the solvent also
* [M+H]^ in positive ion mode, [M-H]' in negative ion mode
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dissolved considerable amounts of unwanted DPPE-O2 by-product. The best solvent for the 
reaction was THF as it afforded good yields but did not dissolve excessive oxide by­
product.
These results can be rationalised in terms of what we know about the reaction mechanism. 
Since the reaction is believed to proceed by an Sn2 mechanism, a non-polar solvent like 
toluene' would not be expected to stabilise the phosphorane intermediate This may 
explain the lack of reaction when toluene was used as solvent (see Table 2.1). According to 
the mechanism proposed in Scheme 2.14, 2 eq. of dibromotetrachloroethane react with one 
equivalent of phosphine. Therefore, the use of the recommended 1.7 eq. 1,2-DB appears to 
be sub-optimal. This may account for the rather modest yield of brominated product 
(i.e. 54 %). Since the kinetics of Sn2 reactions are second-order, the rate of the reaction is 
dependent on the concentration of the two reactants.
' On a scale of relative polarity for different solvents where cyclohexane is 0.006 and H2O is 1.000, 
toluene is 0.099, THF is 0.207, DCM is 0.309
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2.2.2 Alkylation of cyclen with derivatised L-serine methyi ester
Scheme 2.15 has two potential advantages over Scheme 2.9 described in Section 2.1.2 
above. In addition to the use of a primary substrate, the protection of one NH group on 
cyclen with a Boc group (2.24) avoids tetra-alkylation. By employing this strategy, the 
potentially troublesome separation of tri- and tetra-substituted products can be 
conveniently avoided. The fully substituted cyclen with one group protected with Boc 
should elute from a column first as it would be less polar than di- and tri-substituted 
compounds. The Boc groups on the cyclen and on the serine side arms can be 
simultaneously deprotected by neat trifluoroacetic acid.
o
+
B r '  Y  O 
HN^  ,0
ro
2 .2 4 2 .1 7 d e p r o te c t
O
HO
NH
OH
HO
Scheme 2.15 Alternative scheme for the synthesis of target ligand.
Mono-A-Boc cyclen (2.24) was prepared according to Scheme 2.16 by reacting cyclen, 
di-^er^-butyl carbonate and EtgN in DCM. Some di-A-Boc cyclen was also produced in the 
reaction but this could be readily separated from the mono-A-Boc cyclen on an alumina
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column. Analysis of mono-A-Boc cyclen by NMR showed that the protons of C2 / C2’ 
adjacent to the ^-butoxycarbonyl (Boc) group are non-equivalent at room temperature 
(Figure 2.3). The presence of two absorptions indicates a restricted rotation of the 
N-C0 2 C(CH3) bond.
1 eq. 
Scheme 2.16
Ow
o o
+
EtaN (1.5 eq.)
59%
o
1 eq. 2.24
Mono-A-protection of cyclen with Boc.
2.24 NHHN
IMSNH
ppm
Figure 2.3 NMR of mono-A^-Boc cyclen (2.24) in CDCI3 (300 MHz).
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Mono-AT-Boc-cyclen was then alkylated with 2.17 (3.2 eq.) in the presence of triethylamine 
(3.2 eq.). The reaction was carried out in dry acetonitrile at 80 °C (Scheme 2.17).
2.24
Ow
/C-O
-N N
O
+ Br
Et,N
O'
2.17 (3.2 eq.)
O
\__ /
O
2.25
Scheme 2.17 Alkylation of 2.24 to give the 1,7-disubstituted regioisomer (2.25).
Purification of the reaction mixture afforded 2.25 in a yield of 60 %. The formation of the 
1,7-disubstituted regioisomer as opposed to the 1,4-disubstituted regioisomer was 
confirmed by NMR spectroscopy. The NMR spectrum showed 5 distinct CH2 
signals which is consistent with the 1,7-isomer. If the product was the 1,4-disubstituted 
regioisomer, extra CH2 resonances would be expected as a result of the 8  non-equivalent 
methylenes in the cyclen ring. The formation of the less-hindered 1,7-diadduct as the major 
product is in good agreement with the greater reactivity of the two trans nitrogen atoms 
deduced from their p^a values The results for this reaction when carried out under 
different experimental conditions are listed in Table 2.2.
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Table 2.2 Alkylation of mono-A-Boc cyclen with 2.17
mono-A-Boc 
cyclen (eq. 2.27)
2.17
(eq.)
Reaction
conditions
LC-MS analysis
1 . 0 3.2 MeCN/RT 
EtsN (3.2 eq.)
di-substituted cyclen (2.25) 
yield = 60 %
1 . 0 4 THF/H2O (30:1) 
Na2COs, RT for 6  days
di-substituted cyclen (2.25) 
yield alcohol (2.14) = 30 %
1 . 0 4 DMF/72h(80 °C) 
EtsN (4 eq.)
di-substituted cyclen (2.25) 
unreacted halide (2.17)
1 . 0 4 MeCN/72h (80 °C) 
K2CO3 (5 eq.)
di-substituted cyclen (2.25) 
unreacted halide (2.17)
cyclen 6 MeCN / 72 h (80 °C) di-substituted cyclen
( 1  eq.) K2CO3 (5 eq.) unreacted halide (2.17)
Several alkylating conditions described in the literature were employed and the reaction 
progress in each case was followed by LC-MS. In all cases, only a peak with an m/z 
corresponding to di-A-substituted cyclen (2.25) was observable ([M+H]^ = 475). No peak 
corresponding to unreacted halide (2.17) was observable when 50 % aqueous THF was 
used as solvent. Purification of the reaction mixture revealed 2.17 was hydrolysed back to 
the alcohol (2.14) by water in the solvent. Although a peak with an m/z corresponding to 
di-A-substituted cyclen (2.25) was observed, none was isolated via column 
chromatography. Significantly, when cyclen was substituted for mono-A-Boc cyclen, a 
peak corresponding to only the di-A-substituted cyclen product ([M+H]’*’ = 575) was 
evident (entry 5 in Table 2.2).
As no tri- or tetra-substitution of cyclen was observed, it was speculated that the bulky Boc 
group may have hindered substitution by locking the cyclen ring into a specific 
conformation, and preventing nucleophilic attack. Support for this view came from the 
work of Griffin et a l who found that when cyclen was protected in the 1,7 positions with
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Boc groups, they produced no tri-A-substituted cyclen. They attributed this result to a 
conformational change which rendered one of the nitrogens inaccessible either before or 
after the first substitution.
To determine if the sterically-hindered Boc group was inhibiting the substitution reaction, 
an alternative group to mono-protect cyclen was required. It was thought that the use of a 
less-hindered protecting group may keep cyclen conformationally mobile and as a 
consequence, nucleophilic. Additionally, it was considered a smaller protecting group on 
the electrophile (i.e. 2.12) would facilitate nucleophilic attack by the macrocycle. The 
effects on substitution of using alternative protecting groups, both on cyclen and 2 .1 2 , are 
investigated in the following sections.
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2.3 Synthesis of mono-Af-acetyl cyclen (2.26): a novel mono-N- 
protected cyclen Intermediate.
In the previous section, it was proposed that the sterically-hindered Boc group on cyclen 
may be hindering substitution by locking the macrocycle into a specific conformation. 
Therefore, an alternative to mono-A-Boc cyclen as a precursor to tri-substituted cyclen was 
required if this hypothesis was to be tested. The acetyl group is one of the smallest 
protecting groups available and would not be expected to restrict conformational 
movement of the macrocycle significantly Since A-acetyl amides require harsh 
deprotection conditions (such as refluxing 12M HCl), the acetyl moiety is unsurprisingly 
rarely used as a protecting group. Mono-A-acetyl cyclen was prepared by the dropwise 
addition of acetyl chloride (1 eq.) in CHCI3 to a solution of cyclen in CHCI3 as outlined in 
Scheme 2.18.
1 eq. I j  + 1  eq.
O CHCN
Cl 6 0 %
H
Scheme 2.18
H
2.26
Synthesis of mono-A-acetyl cyclen (2.26).
Mass spectrometry of the reaction mixture revealed that di-A-acetyl substituted cyclen was 
also formed ([M+H]^ = 256.6). Initial attempts to separate the mono-A-acetyl cyclen from 
the di-A-acetyl cyclen via silica or alumina column chromatography proved futile. 
However, it was found that basification of the product residue prior to column 
chromatography facilitated their separation. Presumably, conversion of the quaternary salts 
into free bases alters their polarities and enables them to be separated by chromatography. 
Mono-A-acetyl cyclen was hygroscopic and stored in a dessicator.
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2.4 Alkylation of cyclen with A^ -acetyl-1 -bromo-L-serlne methyl
ester and Af-Z-1 -bromo-L-serlne methyl ester
2.4.1 Preparation of AZ-acetyl-l-bromo-L-serlne methyl ester  (2.27) and
/V-Z-1 -bromo-L-serine methyl ester  (2.28)
To avoid steric hindrance to the attacking nucleophile (i.e. cyclen) and enable substitution, 
the protecting group on the amino group of 2.12 must be relatively unhindered. The two 
protecting groups chosen were the acetyl and the benzyloxycarbonyl (abbreviated to CBz 
or Z) groups (see Schemes 2.19 and 2.20). Since cyclen was already mono-A-protected 
with an acetyl group, using an acetyl group to protect the amino group on 2 . 1 2  seemed an 
obvious choice. This would permit the simultaneous deprotection of both the acetyl group 
on the side-arm and the acetyl group on the cyclen ring. 2.27 was prepared in two steps 
according to Scheme 2.19.
0  EtsN (2.2 eq.)
HO^ , 9    HO' '  'O 'o  +
NHs^CI- 95%
O 2.29
2.12 1.1 eq.
DPPE (1 eq.) 
1,2-DB (1.7 eq.) u
50%
O
Br" Y  O 
HN.
II
O 2.27
Scheme 2.19 Synthesis of A-acetyl-1 -bromo L-serine methyl ester (2.27).
Acétylation of 2.12 was achieved by the slow addition of acetyl chloride to L-serine 
methyl ester hydrochloride and triethylamine (all 1 eq.) in chloroform. Acétylation of the
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amino group made the product (2.29) water-soluble which precluded a simple organic 
solvent extraction purification procedure. It was found that the addition of acetone 
precipitated the bulk of the triethylammonium chloride by-product which formed in the 
reaction but column chromatography was required to remove final traces. The spectral data 
obtained for 2.27 agreed well with literature values Bromination of 2.29 was then 
achieved by reaction with DPPE (1 eq.) and 1,2 DB (1.7 eq.) in THF to give 2.27 as a 
white solid.
The second protecting group chosen was the benzyloxycarbonyl group which can be 
abbreviated to CbZ or Z. It is an acid-resistant PG commonly used in peptide synthesis and 
usually forms stable, crystalline derivatives It can be easily cleaved by catalytic 
hydrogenation over Pd/C at room temperature and pressure. Whilst the Z protecting group 
is not significantly smaller than the ^-butyl group, it contains a phenyl ring which is a 
planar ring of sp^ hybridized carbons. As a result, it occupies less space in the vicinity of 
the electrophilic carbon than the ^-butoxylcarbonyl group which hinders nucleophile attack 
from all directions. 2.28 was prepared in two steps according to Scheme 2.20.
HO
EtaN (2 .2  eq .)
NH3+CI ■ 88 %
2.12 1.1 eq .
HO
2.30
D P P E  (1 eq .)  
1,2-D B  (1 .7  e q .)  v
6 8 %
Br 2.28
Scheme 2.20 Synthesis of N-Z-1 -bromo L-serine methyl ester (2.28).
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2.28 was synthesised by reacting 2.12 with benzyl chloroformate ( 1  eq.) and triethylamine 
(2.2 eq.) in CHCI3 . After washing the reaction mixture with dilute HCl to remove 
unreacted starting materials, the solvent was evaporated to give an oil. Analysis of this oil 
by NMR revealed the characteristic 5H multiplet of the phenyl group at ô 7.4 ppm 
indicating the amine had been successfully protected. This oil was then brominated without 
further purification to give 2.28 as a white solid.
2.4.2 A lkylation o f cy c len  with A /-acety l-1-brom o-L -serine m ethyl e s te r  
(2.27) and  /V -Z -1-brom o-L -serine m ethyl e s te r  (2.28)
2.27 (3.2 eq.) in acetonitrile was added dropwise to a stirred solution of mono-A-acetyl 
cyclen (2.26, 1 eq.) and triethylamine (4 eq.) (Scheme 2.21).
o
Hx ^  A -
N N
2.26 (1.0 eq.) | |
NH
2.31 (15 %)
Br
+
O'
HN
C
IIO
EtgN (4 eq.)
+
H H N — C
/
O
Scheme 2.21
2.32 (80 %)
Alkylation of mono-A-acetyl cyclen with 2.27.
2.27 (3.2 eq.)
The reaction was then stirred at room temperature for 48 h under argon. Removal of the 
solvent gave an orange oil which was purified on an alumina column to afford the tetra-A-
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substituted cyclen (2.31) in a yield of 15 %. Analysis of the column fractions via LC-MS 
and NMR revealed that a competing reaction was taking place, namely the elimination of 
bromide from 2.27 to give the corresponding alkene, 2.32. The two alkene hydrogens of
2.32 gave peaks at 5.8 and 6.5 ppm in the NMR. In fact, most of the alkyl halide 
underwent elimination rather than substitution (approx. 80 : 15 % respectively). Therefore, 
the substitution reaction was competing with a dominant elimination reaction. Although 
the pendant arms of 2.31 contain 3 asymmetric carbons, their configurations could not be 
determined by NMR as the CH groups absorbed in the same region of the spectrum as 
the methylene groups of the cyclen ring.
A similar pattern of substitution versus elimination was found when unprotected cyclen 
was alkylated with A-Z-1-bromo-L-serine methyl ester (2.28) as shown in Scheme 2.22.
o
+
k' w " ' h
Br
2.28 (6.5 eq.)
HN
HN
O,\
K2CO3
+
H N — C,
2.33 (4.2 %) 2.34 (90 %)
Scheme 2.22 Alkylation of cyclen with 2.28 to give the tri-substituted cyclen (2.33)
and the alkene (2.34).
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The reaction was carried out by stirring cyclen and 3.5 eq. 2.28 in dry acetonitrile under 
argon. After 48 h, LC-MS analysis indicated formation of mono- and di-A-substituted 
cyclen. To promote substitution, another 3 eq. electrophile (2.28) was added and the 
mixture stirred for a further 24 h. LC-MS monitoring indicated formation of 2.33 so the 
reaction was stopped. The organic layer was then evaporated to give a viscous, orange oil 
which was purified on a silica gel column to give the elimination alkene (2.34) as a 
colourless oil (90.8 %) and the tri-substituted cyclen (2.33) as a yellow, semi-solid (4.2 %). 
The tri-A-substituted product (2.33) formed at room temperature but no tetra-A- 
substitution was observed. This result was fortuitous as the tri-A-substituted product (2.33) 
was the desired product. As in the previous reaction (Scheme 2.21), substitution was 
accompanied by elimination of the halide and the alkene (2.34) was the major product 
isolated (90 %). The yield of the tri-A-substituted cyclen (2.33) was low (approx. 4.2 %) 
but purification was relatively straightforward as 2.33 eluted first from a silica column. 
Column chromatography of the non-polar, Z-protected (2.33) proved an easier task than 
the chromatographic purification of the hydrophilic, acetyl-protected (2.31). 2.33 was 
successfully purified on a standard silica gel column whereas 2.31 required 
chromatographic purification on neutral alumina as it adsorbed strongly to silica gel.
These findings support the hypothesis proposed earlier; that is, the size and/or shape of the 
amine protecting group on the L-serine methyl ester influences the substitution pattern on 
the cyclen ring. When Boc was used to protect LSME, only di-A-substitution on the cyclen 
ring was observed whereas the use of an acetyl or Z group resulted in tri-A-substitution. It 
is possible that the alkylation of unprotected cyclen with A-acetyl-protected LSME (2.27) 
may have resulted in tetra-substitution but this reaction was not carried out.
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The yield of substituted cyclen was significantly higher when the amino group of LSME 
was A-acetyl-protected (15 %) rather than A-Z-protected (4.2 %). The A-acetyl-protected 
substrate (2.27) may be able to adopt a less sterically-hindered transition state leading to a 
faster reaction rate. In Sn2 reactions, a planar arrangement of the non-reactive groups in 
the transition state which has a lower energy, is an essential feature (Figure 2.4) If it is 
not possible, the reaction is not observed.
C/,
c^ n:
/
H
%c— Br
Ri
tetrahedral arrangement
— Q— gf
H r , ' h
planar arrangement 2.35
R
H R i "
+ Br
tetrahedral arrangement
C/x,
C ^ N O  O c < 3 C > B r O  
/H Ri
/
r, h /H
Figure 2.4 The planar transition state (2.35) of an Sn2 reaction
In Figure 2.4, a planar planar arrangement of the non-reactive groups in the transition state 
(2.35) is preferred because it permits maximum overlap of the two orbitals, that is the 
HOMO (highest occupied molecular orbital) on the nucleophile and the LUMO (lowest 
occupied molecular orbital) on the alkyl halide. The actual configuration of 2.35 is trigonal 
bipyramidal. Any structural feature which stabilises this trigonal bipyramidal arrangement 
will lower the energy of the transition state and favour the Sn2  reaction.
To determine what effect K2 CO3 had on the reaction, 2.27 was reacted with cyclen in the 
absence of base and elimination was still found to predominate. This result is not so 
surprising when one considers that cyclen is itself quite basic and the pA&s related to two of
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its protonation steps are of the same order of magnitude as triethylamine (pÆa = 10.7). 
Normally, primary substrates tend to undergo substitution but the location of an acidic H’ 
between two electron-withdrawing groups makes it liable to react with base. This gives the 
alkene 2.36 (Scheme 2.23).
PG-HN
E2
elimination
O
H V “ 0
'  H 2.36
NH-PG
Scheme 2.23 Proposed E2 elimination mechanism from serine derivatives.
In fact, a survey of the literature revealed that O-tosylated serine derivatives rapidly 
undergo p-elimination under the action of bases. Photaki found that when 
A^-benzloxycarbonyl-O-tosyl-L-serine methyl ester (2.37) was treated with 0.1 M NaOH at 
room temperature, over 90 % underwent elimination within 15 minutes (Scheme 2.24)
O
O.lMNaOH
TsO ^  O 
NH-Z
RT
2.37
O
H V -O H
'  H
NH-Z
2.38
Scheme 2.24 Elimination from the 0-tosylated serine derivative (2.37)
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2.5 Summary of cyclen alkylation reactions using amino acid 
derivatives (Chapter 2: Part A)
Elimination from both primary and secondary amino acid derivatives was found to be a 
major problem leading to a low yield (15 %) of tetra-substituted cyclen (2.31). These 
findings are schematically summarised in Scheme 2.25.
o==s==o
2.9 2.10
-N HN:
I
2.27
,C— NH
E2
1 5 %
NH
8 0 %  
 ►
O.
) = \  /  2.32
H H N — C
%
Scheme 2.25 Alkylation of cyclen with secondary (2.9) and primary (2.27)
amino acid derivatives.
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It may be possible to promote substitution over elimination by changing the amine and 
carboxyl protecting groups. For example, the carboxyl could be protected with a 
benzyloxycarbonyl group as well. This may provide better protection of any acidic protons 
from base. Dugave and Menez had some success using A-trityl (triphenylmethyl) as a 
protecting group to prevent a-proton abstraction in serine derivatives but only with non- 
nucleophilic bases. Since cyclen is a nucleophilic base, there is always the possibilty of 
elimination. For these reasons, an alternative route to our target ligand is investigated in the 
next chapter.
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Part B Synthesis of a cholic acid-cyclen conjugate
2.6 Introduction
Gadolinium complexes with amphiphilic properties have previously been synthesised and 
evaluated as blood-pool and liver-imaging agents Generally, these are prepared by 
coupling a hydrophilic Gd complex to a lipophilic molecule such as a long-chained fatty 
acid In an aqueous environment, these complexes are able to form supramolecular 
systems such as micelles. The formation of these systems increases the Ti-relaxivity of the 
contrast agent due to an increase in the rotational correlation time ( t r  ) of the Gd complex. 
One example of a lipophilic Gd complex is 2.39 which is shown in Figure 2.5. Lattuada et 
al}^^ conjugated cholesterol to DPTA and after complexation with gadolinium, they 
obtained the agent 2.39 which displayed a high relaxivity (ri = 27.2 mM'^ s"^ ). 2.39 can 
aggregate to form the micelle (2.40) once it’s concentration reaches a certain level, that is, 
it’s critical micelle concentration (CMC).
cholesterol
COQ-■000
COO
2 Na
N
H
000
2.39
self-aggregation
©-
)
2.40 micelle, =  27.2 mM'^  s'*
Figure 2.5 Gd-DPTA-cholesterol (2.39) and a micelle (2.40) formed from 
self-aggregation of 2.39.
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The aim of the present work was to synthesise a cholic acid-cyclen conjugate (2.41), which 
after complexation with gadolinium, could have potential as a blood-pool imaging agent 
(Figure 2.6).
P
HN
0==4
Q
H R 
O
R
NH
OH
where RCO = cholyl =
'OHHO'
R
2.41 2.42
Figure 2.6 Structure of target ligand (2.41) where RCO refers to the cholyl moiety 2.42.
Cholic acid, or 3a,7a,12a-trihydroxy-5p-cholan-24-oic acid, is a major steroidal 
constituent of human bile and is produced in the liver The liver effectively removes 
excess cholesterol from the body by converting it into bile acids via a fifteen step 
enzymatic process. Like other bile acids, cholic acid forms micelles with water-insoluble 
fats allowing their uptake into the bloodstream. The presence of a hydrophobic face on one 
side and a hydrophilic face on the other give cholic acid its unique amphiphilic properties 
(Figure 2.7).
P-face
CH
CH
OH
OH
OH
HO a-face
Figure 2.7 Structure of cholic acid showing the hydrophilic a-face and the 
hydrophobic p-face.
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Cholic acid can form bilayered structures made up of repeating hydrophilic and 
hydrophobic layers, with channels Prior to secretion by the liver, cholic acid is 
conjugated with either the amino acid glycine or taurine (Figure 2.8). Conjugation 
increases the water solubility of cholic acid. As a result, the concentration of bile acids in 
the small intestine can stay high enough to form micelles and solubilize lipids.
o
o
OHOH
2.42
HO O H
OH
2.43
HO 'OH
Figure 2.8 Structures of cholic acid (2.42) and taurocholic acid (2.43).
Based on Lattuada’s work, it was envisonaged that conjugation of amphiphilic cholic acid 
to hydrophilic cyclen may produce a conjugate that has affinity for both aqueous and 
lipophilic media. In effect, it may have properties similar to 2.39 and taurocholic acid
(2.43). After complexation with gadolinium, the resultant amphiphilic complex would be 
expected to form micelles once its concentration reached its CMC.
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2.7 Synthetic strategy
Scheme 2.26 overleaf shows the two routes that were considered for the synthesis of the 
cholic acid-cyclen conjugate (2.41). In both Route A and Route B, 2-bromoethylamine
(2.44) serves as a linker molecule.
Route A involves the formation of an amide bond between cholic acid (2.42) and 
2-bromoethylamine to give the brominated intermediate (2.45). This can be accomplished 
with dicyclohexylcarbodiimide (DCC) which generates amide bonds between carboxyl and 
amine groups. Alkylation of cyclen with 2.45 should then afford the desired ligand 2.41.
Route B is lengthier involving both amine protection and deprotection steps. Once the 
amino group on 2-bromoethylamine is protected with a suitable protecting group such as 
^-Boc, the product (2.46) can be used to alkylate cyclen. Deprotection of the substituted 
cyclen product (2.47) makes the amine groups available for coupling to the carboxyl group 
of cholic acid. As in Route A above, the cholic acid-cyclen conjugate (2.41) is the final 
product.
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Route A
o
A OH
+
2.42
DCC / EtgN
Br"
'Br 2.44
H
R N.
IIO
'Br
2.45
R—
HN \cN N
alkylate
H R
N N
HN-
o A
R
^NH
2.41
Route B
Br> (Boc)20 O
"NHs+'Br ----------
2.44 2.46
R - f  H ,R
™ > o r ^
L  2.41 J
0 <  T
R O ^ R
A
(i) deprotect
(ii) RCOOH / DCC
alkylate
O
0 "^N -\ /  \ / --- '
H A n  n
HN A o X
Scheme 2.26 Synthetic Routes A and B to 2.41
(where RCO and RCOOH refer to the cholyl moiety).
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Synthetic Route A
2.7.1.1 Coupling 2-bromoethylamine to cholic acid using DCC  
(dicyciohexyicarbodiimide)
The first step of Route A was the formation of an amide bond between 2-bromoethylamine
(2.44) and cholic acid (2.42) (Scheme 2.27).
OH
OH2.42
HO 'OHHO
OH
2.45HO t)H
2.44
.Br +  HX
Scheme 2.27 Amide bond formation between cholic acid and 2-bromoethylamine.
DCC was the coupling reagent chosen to effect this transformation (Figure 2.9). Since its 
introduction in 1955, DCC has been one of the most important reagents for activating 
carboxy groups in peptide synthesis
Figure 2.9 Structure of DCC.
A peptide coupling reagent transforms the hydroxyl function into an activated ester which 
is a better leaving group. Nucleophilic attack of this ester by an amine in situ results in the
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formation of an amide bond. For the reaction, 2-bromoethylamine (HBr salt), triethylamine 
and cholic acid (all at 1 eq.) were dissolved in a DCM/DMF (20:2 ml) solution (see 
Scheme 2.28). Triethylamine base was added to convert the hydrobromide salt to the free 
amine. After cooling the mixture on an ice bath, DCC (1 eq.) was added in small portions. 
The reaction was then stirred under argon for 24 hours at ambient temperature.
OH
HO
'Br
OH
OHHO
.Br
2 .4 2 2 .4 4 2 .4 5
DCC/ EtgN 2 6 %
HN
HO' 'OH
2 .4 8
Scheme 2.28 DCC-promoted coupling reaction between cholic acid and 2.44.
After precipitated dicyclohexylurea (DCU) was filtered off and the solvent was evaporated. 
TLC of the reaction residue indicated it consisted of unreacted cholic acid and a less polar 
compound suggestive of an ester or amide. Isolation of this compound by silica gel column 
chromatography yielded 2.48 whose spectral data was consistent with the structure of the 
iV-acylurea derivative of cholic acid (Scheme 2.29). The assignment of individual carbon 
and proton resonances in 2.48 was aided by comparison with reference spectra and by 
cross-referencing with data from a COSY spectrum. No bromoethylamine-cholic
acid conjugate (2.45) was isolated from the reaction mixture.
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< > N = c a H Q
O-Acylurea (2.49)
:o>
R — C — O — C
/
%
HgN— R'
o
-H+
DCC
O
II 1 II H / - A
R— C-------N-----C— N—^  y
A/-Acylurea (2.50)
amide product
/ " A
^ q :
H II H
R— C—NHR' +
dicyclohexylurea (DCU)
Scheme 2.29 The mechanism of amide formation by reaction of a carboxylic acid 
and an amine with DCC
Direct coupling with DCC to form an amide is in theory uncomplicated, involving the 
mixing of the amino and carboxy components in an organic solvent at room temperature 
The formation of 0-acylurea (2.49) results in amide formation via nucleophilic attack with 
the concomitant production of insoluble A^Æ-dicyclohexylurea (DCU). 0-acylurea is very 
reactive and if a good nucleophile is not at hand, intramolecular acyl transfer can occur to
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form the less reactive iV-acylurea (2.50). As 0-acylurea isomerised to A-acylisourea in the 
above reaction, 2-bromoethylamine probably reacted sluggishly with O-acylurea.
2.7.1.2 Coupling 2-bromoethylamine to cholic acid using EDCI
EDCI or EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) has a similar mode of 
action to DCC (Figure 2.10) However, unlike DCC, excess carbodiimide and derived 
urea can be washed out with dilute acid.
Cr +HN^  ^  ^  ^ N = C = N ‘/
Figure 2.10 Structure of EDCI.
Hirayama et al. used EDCI to form amide conjugates between cholic acid and various 
amino-containing substrates (yields > 90 %). When coupling using this established 
procedure failed to produce any conjugate, it was suspected the problem may lie with the 
2-bromoethylamine starting material. 2-bromoethylamine is supplied as a hydrobromide 
salt and for the coupling reaction, it is necessary to add base to free the amine group. 
However, C-2 of 2-bromoethylamine is electron deficient due to bromine substitution and 
could potentially be attacked by the freed amine group of another 2-bromoethylamine 
molecule as depicted in Scheme 2.30.
i t
t
polymer
Scheme 2.30 Potential polymerization of 2-bromoethylamine.
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This self-condensation or polymerisation reaction may have consumed the 
2-bromoethylamine before the carboxyl group was converted to an ester. In an attempt to 
circumvent this potential side-reaction, cholic acid was pre-converted to an active ester 
before the condensation reaction with 2-bromoethylamine. It was anticipated this pre­
activation strategy would maximise the possibility of 2-bromoethylamine reacting with the 
cholate ester and reduce the risk of polymerization taking place. The synthesis of activated 
cholic acid and its subsequent reaction with cyclen are described in the next section.
2.7.1.3 Reaction of 2-bromoethyiamine with the p-nitrophenyi ester of
cholic acid
In peptide bond formation, amidation with an isolated activated ester is often preferred to 
direct coupling With this method, side reactions like racemization are generally less of a 
problem. The isolated /?-nitrophenyl and jV-succinimido esters of cholic acid have 
previously been employed to form amide bonds between cholic acid and the amino group 
of various compounds (Figure 2.11).
. x . x r  .Xîq
Figure 2.11 j9-nitrophenyl ester and A-succinimido ester.
The A>-nitrophenyl ester of cholic acid (2.51) was prepared using DCC to couple the phenol 
to the carboxylic acid group of cholic acid (Scheme 2.31)
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OH
OH
1 eq.
HO 'OH
+  HO- a NO2 1 eq.
{2)-N=C=N-(2} 1 eq.
l.xrNO:
2.51 (46 %)
OH
+
HN
'OHHO
2.48 (23 %)
Scheme 2.31 Synthesis of cholyl /?-nitrophenyl ester (2.51).
The reaction was performed by adding DCC to a cooled solution of cholic acid and 
j9-nitrophenol (all 1 eq.) in an ethyl acetate-DMF solution. After 20 hours, the precipitated 
dicyclohexylurea was filtered off. The organic phase was then washed with a 5 % sodium 
bicarbonate solution and evaporated to dryness in vacuo. TLC of the reaction product 
indicated that two compounds were formed, one that was UV-active (/?f0.36) and one that 
was UV-inactive {R  ^ 0.28). Although both compounds had similar R{ values, they were 
successfully separated on a silica gel column. The crude product yielded 46 % of cholyl p- 
nitrophenyl ester (2.51) and 23 % of what appeared to be the A-acylurea derivative of 
cholic acid (2.48) 2.48 was also a by-product in the coupling reaction involving DCC (see 
Section 2.7.1.1).
It is worth noting here that />-nitrophenol was successfully coupled to cholic acid using 
DCC. Significantly, attempted conjugation of 2-bromoethylamine to cholic acid using a
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similar DCC procedure above failed to give any product. In contrast to j9 -nitrophenol 
which can only react with the activated ester intermediate (2.51), 2-bromoethylamine can 
also undergo polymerisation. This explains the difference in reactivity between both 
substrates.
The next step of Route A involved the condensation reaction between 2-bromoethylamine 
and cholyl /?-nitrophenyl ester (2.51) in the presence of triethylamine (TEA) base. TEA 
(1.7 eq.) in THF was added dropwise to a cooled solution of cholyl p-nitrophenyl ester 
(1 eq.) and 2-bromoethylamine (1.5 eq.) in dry THF according to Scheme 2.32.
2.51 (2 eq.)
NOXTOH
X)HHO
B 3 N (1.7 eq.) 30%
OH
2.45HO 'OH
.Br
+  HO-
1.5 eq.
NO:
Scheme 2.32 Synthesis of 2.45 via cholyl jp-nitrophenyl ester (2.51).
The triethylamine solution was added slowly to ensure the cholyl ^-nitrophenyl ester 
concentration would exceed the concentration of 2-bromoethylamine at the start of the 
reaction. Accordingly, it was anticipated that 2-bromoethylamine would preferentially 
react with 2.51 and amide bond formation would be thus promoted. After stirring the
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reaction for 12 h at RT, the organic layer was washed with 5 % NaH2 C0 3  and then with 
water to remove /?-nitrophenol (yellow colour). After evaporation of the solvent, the 
residue was purified on a silica gel column using 10 % MeOH in CHCI3 to give 2.45 as an 
off-white solid (30 % yield).
An absorbance at 1634 cm'^ in the IR indicated that 2.45 contained an amide group. In 
addition, proton signals arising from the amidic linkage were found to be particularly 
useful for the characterisation of 2.45. Two pairs of triplets resonating at 3.80 and 4.21 
ppm ( V  = 9.52 Hz) were assigned to the methylene protons at C-25 and C-26. A peak at 
m/z 512.4, which may correspond to [M-H]', was observable on LC-MS in negative ion 
mode (Figure 2.12). The presence of bromine was indicated by peaks at m/z 79 and 81 in a 
ratio of 1:1, corresponding to the two different isotopes of bromine. However, the synthesis 
of 2.45 was time-consuming and the yield was poor. Therefore, attention was redirected 
towards the alternative Route B as a means of preparation of the target ligand 2.41 (see 
Scheme 2.26).
patfick_144115 (0.550) Cm (9:19-32:41x1.500}
S.21
81.19
;12.36
30/ . / 3
233.02
50 100 150 200 250 300 350 400 450 500 550 000
Figure 2.12 The ES-MS spectrum of 2.45 (negative ion mode, cone voltage =10 eV)
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2.7.2 Synthetic Route B
The first step of Route B necessitated the protection of the amine group of 
2-bromoethylamine. Reaction of 2-bromoethylamine with di-^er^-butyl dicarbonate and 
triethylamine gave A-Boc-2-bromoethylamine 2.46 as a colourless oil (Scheme 2.33). The 
spectral data for 2.46 agreed well with literature values
^  V y 9 9 V . EtgN (2.2 eq.) O
45 - 70 % H
2.44 (1 eq.) 1.2 eq. 2.46
Scheme 2.33 Synthesis of A-Boc-2-bromoethylamine.
In contrast to the coupling reactions involving 2-bromoethylamine and non-activated 
cholic acid above, the 7V-Boc protection of 2-bromoethylamine was relatively 
straightforward. Since JV-Boc product (2.46) was obtained, the amine group of 
2-bromoethylamine most probably reacts with di-^er^-butyl dicarbonate, which is an an 
anhydride, before polymerisation can take place. Therefore, it can be assumed that this 
protection reaction with the moderately reactive anhydride occurs at a faster rate than the 
unsuccessful DCC coupling reaction described above which proceeds via an ester 
intermediate. Although the reaction was performed several times under similar conditions, 
the yields of 2.46 were highly variable ranging from 45 - 70 %. The inconsistent nature of 
the yields obtained lends further support to the idea that 2-bromoethylamine undergoes 
polymerization.
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The next step of Route B was the alkylation of cyclen with W-Boc-bromoethylamine 
(2.46). Cyclen was refluxed with 2.46 (5 eq.) in acetonitrile in the presence of K2CO3 
(5 eq.) for 12 hours according to Scheme 2.34.
;U
H N
H
+  Br>
+
2.46 ( 5 eq. )
K2 CO3 (5 eq.)
II H N ' ^ O ^
V /  \  / — ^
0 r “w " ^  o
Scheme 2.34 Alkylation of cyclen with iV-Boc-2-bromoethylamine.
Both TLC and ES-MS of the product residue indicated that a mixture of tri-substituted 
cyclen (2.52) and tetra-substituted cyclen (2.47) were formed. Attempted purification of 
the product residue on a silica gel column using a gradient of 0 - 15 % methanol in 
chloroform resulted in poor separation between 2.52 and 2.47. This result ruled out Route 
B as a viable method for the preparation of the cholic acid-cyclen conjugate (2.41).
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2.8 Summary of Chapter 2: Part B
Two synthetic routes (A and B) to 2.41 were attempted and each one was found to be 
problematic. Difficulties with Route A were attributed to the use of 2-bromoethylamine as 
a linker molecule. As discussed above, polymerization of 2-bromoethylamine can occur if 
the amine group of one molecule attacks the electron-deficient C-2 of another molecule. 
This problem was partially solved by pre-converting cholic acid to the ^ -nitrophenyl ester 
before the condensation reaction with 2-bromoethylamine. This modification enabled 
successful amide formation between cholic acid and 2-bromoethylamine to furnish the 
conjugate 2.45. However, a low yield of 2.45 (30 %) coupled with a laborious synthesis 
discouraged further work on this route. Therefore, attention was directed towards the 
alternative Route B proposed in Scheme 2.26.
In Route B, A-Boc-bromoethylamine was prepared and reacted with cyclen. A mixture of 
tri-substituted (2.52) and tetra-substituted cyclen (2.47) was produced which proved to be 
inseparable by silica gel column chromatography. This result highlights the difficulties that 
can arise when cyclen is functionalized with halogenated substrates using conventional 
base-promoted alkylation techniques. These reactions routinely suffer from poor 
regioselectivity due to poly-alkylation A mixture of substituted cyclens is often 
obtained, imposing a difficult and sometimes impossible purification process as was 
discovered above. Consequently, functionalization of cyclen by alkylation has generally 
been addressed indirectly by using various protecting groups in multi-step sequences 
The use of mono-A-Boc cyclen (2.24) and mono-A-acetyl cyclen (2.26) as precursors to 
tri-substituted cyclen derivatives in Part A of this chapter illustrate this protecting group 
methodology. As an alternative to alkylation. Chapter 3 investigates the Michael addition 
of cyclen to conjugated alkenes as a means of the preparation of functionalized cyclen 
ligands.
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3.1 Introduction
Currently, cyclen is primarily functionalized by reaction with alkyl halides 
However, functionalization of cyclen via alkylation tends to be inefficient as the complete 
range of substitution products (i.e. mono-, di-, tri- and tetra-substituted cyclens) is often 
produced. Additionally, substituted cyclens often have similar polarities and cannot always 
be separated by column chromatography To avoid poly-alkylation and the waste of 
expensive cyclen, regioselective functionalization of cyclen generally requires 
pre-protection of the cyclen ring to ensure only the desired amines react. The use of mono- 
A-Boc-cyclen (2.24) and mono-#-acetyl cyclen (2.26) as precursors to tri-substituted 
cyclen derivatives in Chapter 2 illustrate this protecting group methodology.
Additional difficulties encountered with the alkylation approach were described in Part A 
of Chapter 2. These include steric hindrance to the attacking nucleophile (i.e. cyclen) and 
the elimination of the halide substrate. This chapter investigates the Michael addition of 
cyclen to activated alkenes as an alternative route to functionalized macrocycles.
3.2 The aza-Michael reaction
The Michael addition reaction is a valuable synthetic method in which a nucleophile adds 
across the carbon-carbon double bond of an activated alkene The Michael addition 
reaction is a specific example of a conjugate addition where an enolate nucleophile adds to 
a conjugated carbonyl Although nucleophiles do not normally react with simple 
alkenes, they do so if the double bond is conjugated to an electron-withdrawing group and 
resonance stabilizing activating group. Then, the anion formed by addition, and the 
preceding transition state, is stabilized sufficiently by charge delocalization so that addition 
occurs at a reasonable rate.
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Scheme 3.1 shows the addition of dimethylamine to ethyl acrylate. The carbonyl of the 
acrylate stabilizes the resulting anion until proton transfer occurs. The overall driving force 
for the conjugate addition is the enthalpic change that accompanies replacement of a n- 
bond with a a-bond The reaction tends to follow second-order kinetics based on the 
concentration of the alkene acceptor and the amine.
Although the Michael addition reaction originally referred to the addition of enolate 
nucleophiles to activated alkenes, a wide range of functional groups such as amines, thiols, 
and phosphines possess sufficient nucleophilicity to perform as Michael donors. The 
nitrogen-donor version of the Michael addition is often referred to as the aza-Michael 
reaction. Since amines can act as both nucleophiles and bases, no additional base is 
typically needed in these reactions. The ability of the aza-Michael reaction to generate 
p-amino carbonyl compounds has become increasingly important to the natural product 
and pharmaceutical areas The following section looks at some of the Michael-type
reactions that have previously been used to functionalize nitrogen-containing macrocycles.
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C— OEt
HN*.
OEt OEt
transfer
(fast)
H.C,
‘N
I
CH3
OEt
I
o Rate = ki [Amine] [Acrylate]
Scheme 3.1 Aza-Michael addition of dimethylamine to ethyl acrylate 116
3.3 Functionalization of azamacrocycles using the aza-Michael 
reaction
As discussed in Section 1.9.1 of Chapter 1, cyclen has primarily been functionalized by 
alkylation. However, some examples which have used the Michael reaction to 
functionalize cyclen are described in the literature. Notable examples include the synthesis 
of 1,4,710-tetra-(2-carboxyethyl)-1,4,7,10-tetraazacyclododecane by Cocolios et In
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this reaction, cyclen was reacted with a large excess of acrylic acid to give the tetra- 
substituted product 3.1 in a yield of 55 % (Scheme 3.2).
W HOC OH E to n
+ 18 eq.
55%
HO
N N
3.1
N N
OH
OH
Scheme 3.2 Michael addition of cyclen to acrylic acid to give 3.1
The same authors successfully produced the tri-A-substituted macrocycle 3.4 by reacting 
mono-protected, A-benzylcyclam (3.2) with a large excess of acrylic acid. Cleavage of the 
benzylic nitrogen bond in 3.3 was then accomplished by hydrogenation over palladium on 
charcoal to give 1,4,8-tris(carboxyethyl)-l,4,8,11 -tetraazacyclotetradecane, 3.4 (Scheme 
3.3).
c—OH
A/-benzylcyclam  
1 eq.
H H
acrylic acid, 
18 eq.
reflux in EtOH
|—N N—1L  I"-N  N -*
HOgC ^  \ o z H
Hz, Pd/C
HOzC
- N  HN
HOzC CO2H
Scheme 3.3 Synthesis of the tri-substituted cyclam derivative (3.4) via the Michael
addition of A-benzylcyclam to acrylic acid
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Fensterbank et al}^^ carried out the selective mono-ftinctionalization of cyclam using a 
Michael addition (Scheme 3.4). By using one equivalent of a Michael acceptor in 
chloroform in the presence of one equivalent of j^-toluene sulfonic acid (p-TSA), they 
obtained moderate to good yields of mono-alkylated cyclam (3.5). They attributed this 
selectivity to the protonation of the azamacrocycle that occurs in the presence of one 
equivalent of acid. Since two nitrogens on cyclen have very different pXaS from the other 
two, the addition of 1 eq. acid should leave one amine nucleophilic.
CHCI:
X
p N  N—]
3.5
N-l
R
Scheme 3.4 Selective mono-A-alkylation of cyclam via Michael addition
Wainwright prepared the tetra-substituted cyclam product (3.6) by reacting cyclam with an 
excess of acrylonitrile This reaction is an example of cyanoethylation which is often 
used to describe the conjugate addition of nucleophiles to acrylonitrile. Reduction of the 
terminal nitrile residues in 3.6 added functionality to 3.7 as these exocyclic amines could 
bind metal ions (Scheme 3.5).
pN  N—I
+
94%
H H
acrylonitrile (54 eq.)
HoN
HoN
Scheme 3.5 Tetra-alkylation of cyclam via Michael addition
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3.4 Reaction of cyclen with acrylamide
In 1984, the Michael addition of cyclam to acrylamide to give the tetra-substituted product 
(3.8) was described by Freeman et For such a simple synthesis, a high yield of 92 % 
was reported (Scheme 3.6).
\ i  1 /pN N—
— N N—
+
\\
H C— NHz
M
MeOH
92%
H H
HoN
Scheme 3.6 Reaction of cyclam with acrylamide to give 3.8
To ascertain whether this facile, high-yielding, one-step reaction would work similarly for 
cyclen, the experiment was repeated here with cyclen being substituted for cyclam. Cyclen 
has two carbons less in its ring than cyclam. Apart from the fourth amine, both 
macrocycles have similar protonation constants (Table 3.1).
Table 3.1 Protonation constants for cyclen and cyclam 93
Ligand pATa P^a P^ iTa pATa
Cyclen 10.6 9.6 1.5 0.5
Cyclam 11.3 10.2 1.6 1.9
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For the reaction, cyclen (1 eq.) was refluxed with acrylamide (7 eq.) in methanol for 24 
hours (Scheme 3.7). After most of the solvent was removed, diethyl ether was added until a 
white solid formed. The resultant white solid was filtered, washed with ether and dried 
under vacuum. The mass spectrum of the product presented peaks at m/z 385.1 and 457.4 
corresponding to the tri-amide (3.9) and the tetra-amide (3.10) species respectively. The 
peak corresponding to the tri-amide (3.9) was significantly higher than that of 3.10. TLC 
analysis showed that the product consisted of two compounds with similar values (i?f 
3.9, 3.10 = 0.57, 0.62 respectively). In addition, TLC showed that the product contained no 
acrylamide (i?f= 0.78). 0.2 % ninhydrin in ethanol, which stains cyclen ligands purple, was 
used as to detect spots.
1 eq.
\\
H C—NH2
+  7 eq.
H H
O
70%
MeOH
HgN
N
3 .9
NH
reflux/ 24 h
O
H2 N
+  .N N
H2 N
O
8 %
O
NH2
NH:
o
Scheme 3.7 Reaction of cyclen with acrylamide to give 3.9 and 3.10.
Separation of 3.9 from 3.10 was achieved on a silica gel column using 5 % ethanol in 
dichloromethane as eluent. 3.9 was obtained as an hygroscopic, white solid (70 %) whereas 
3.10 was obtained as a colourless, solid in a yield of 8 %. An X-ray crystallographic
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analysis of 3.10 (l,4,7,10-tetrazacyclododecane-4,7,10-tetrapropanamide) is presented in 
the following section.
A high ratio of the triamide (3.9) to the tetramide (3.10) ligand was produced (approx. 8.75 
:1, respectively) even though an excess of Michael acceptor was employed in the reaction. 
Since cyclen has two carbons less in its ring than cyclam, steric crowding close to the 
fourth nitrogen atom may be the key to this regioselectivity. An alternative explanation 
may be an intra-annular H-bond from the unalkylated nitrogen to the nitrogen on the 
opposite side of the ring. In partially-substituted cyclen derivatives, intra-annular hydrogen 
bonding has been observed by various groups When Li and Wong reacted cyclen
(1 eq.) with triethylamine (10 eq.) and /er/-butyl bromoacetate (3.5 eq.) in anhydrous 
chloroform, they obtained the tris A-alkylated product in a 77 % yield (Figure 3.1). 
Significantly, no tetra A-alkylated product was isolated. An intra-annular hydrogen bonding 
effect was invoked to explain this selective alkylation; a hydrogen bond from an 
unalkylated, protonated nitrogen to the nitrogen on the opposite side of the ring (N 1-H—N 3 , 
3.032 Â) was deemed to have caused the lone pairs on the remaining nitrogens to reorient 
towards the cavity. Consequently, these lone pairs would be unavailable for substitution 
reactions. Since the reaction was carried out in a non-polar, aprotic solvent, the authors 
argued that the hydrogen-bonded proton would be tightly held within the macrocycle even 
in the presence of base.
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Figure 3.1
9
Cl 2 I 013 014
Oil
01 Q  02  
-  /
010
09
07
05 Q0#; . O
\ /  06  C22 N 4 |5
o -© o  I
A tris A-alkylated cyclen with an intra-annular H-bond
N3
For 3.9, the number and type of resonances in both the and NMR spectra indicated 
tri-# substitution of the cyclen ring. Individual carbon and proton resonances were 
assigned by data from a COSY experiment and by comparison with the spectra of
structurally-similar ligands The ^^ C NMR spectrum of 3.9 in D2O showed two signals 
at 178.6 ppm (C5) and 179.1 ppm (C6) for the amide carbonyls in an approximate ratio of 
2:1 indicating that the ligand was tri-substituted (Figure 3.2).
«
r—r-1—|—-f—  r |-
175 150 125 100 75
2-3
50
ITpi’ilWi'
■T T
25 ppm!
Figure 3.2 13 C NMR spectrum of the ligand 3.9 (in D2O, 300 MHz).
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A  possible mechanism for the Michael addition of cyclen to acrylamide is shown in 
Scheme 3.8. Addition of cyclen to acrylamide is followed by proton transfer either from 
cyclen (i.e. intramolecular) or from the solvent methanol (i.e. intermolecular). The use of a 
polar, protic solvent like methanol served to stabilise any charged intermediates and 
ensured any anionic intermediates were protonated rapidly. In the absence of acidic or 
basic catalysts, the high electrophile to nucleophile ratio (that is, 7 eq. acrylamide to 1 eq. 
cyclen, respectively) should have promoted addition
H
H - N  HN:
H
\\
: K
CH3OH
H+
0
1
NH:
H
Scheme 3.8 A possible mechanism for the addition of cyclen to acrylamide.
A simple functional group interconversion was next employed to convert the pendant 
amide groups on 3.9 into carboxylic acid acid groups which are known to have stronger
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coordinating ability with Gd^ .^ Hydrolysis of the triamide (3.9) was accomplished by
refluxing with 12 M HCl to give the triacid (3.11) in a 90 % yield (Scheme 3.9) 124
HoN2 '^ HO
^ N ^  12MHCI °
3.9
N N
3.11
N N
9 0%
^2^^^  ^ ^ ^  HOV ^  \ ---- /
O NH2 O OH
+ 3 NH4CI
Scheme 3.9 Hydrolysis of 3.9 with 12 M aqueous HCl to give 3.11
The arms on both the triamide (3.9) and triacid (3.11) were found to be stable to the harsh 
hydrolytic conditions used to hydrolyse the amide bonds. A difference of approximately 
two mass units was observed between the starting material ([M+H]^ = 387.0) and the 
product ([M+H]^ = 388.9). Since ammonium chloride was also formed during this reaction, 
the product required purification. This was achieved by two recrystallizations from aqueous 
methanol.
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3,9 and 3.11, which have one more methylene group in their pendant arms, are analogues 
of the ligands 3.12 and 3.13 respectively (Figure 3.3). 3.12 is known as D03AM 
( 1.4.7.10-tetrazacvclododecane-4.7.10-triacetamide) and 3.13 is known as D03A (1,4,7,10- 
tetrazacyclo^decane-4,7,10-triacetate). Indeed, the system of nomenclature used to name 
D03AM and D03A was employed here to name 3.9 and 3.11 as D03PAM (1,4,7,10- 
tetrazacyclo^decane-4,7,10-tripronanamidel and D03P ( 1,4,7,10-tetrazacyclododecane- 
4,7,10-tripropanoate), respectively.
o
OH
3.12
;n  n
•OH
OH
HoN.
o
3.13
y;n NH:
O ' HgN
Figure 3.3 Structures of the ligands D03AM (3.12) and D03A (3.13).
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3.4.1 X -ray crysta llograp h ic a n a ly s is  o f 1 ,4 ,7 ,1 0 -te tr a z a c y c lo d o d e c a n e -  
4 ,7 ,1 0 -te tra p ro p a n a m id e  (3.10)
Colourless, amorphous crystals of 3.10 were grown by slow diffusion of acetone into a 
saturated, aqueous solution of the compound. Ortep plots showing an overhead and side 
view of 3.10 are given in Figure 3.4.
(a) Overhead view
(b)
F igure 3.4
Side view
Ortep plots o f 3.10
Displacement ellipsoids are shown at a 50 % probability level. Hydrogens are 
omitted for clarity. See Appendix B for bond lengths and bond angles.
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Examination of Figure 3.4 reveals that 3.10 possesses a twofold rotation symmetry, the axis 
of which passes through the centre of the 12-membered ring. Like other cyclen ligands,
3.10 has a [3333] square conformation with carbon atoms occupying comer positions 
The conformation, which is schematically shown in Figure 3.5, is considered important in 
the preorganisation of 1,4,7,10-tetrazacyclododecane and its derivatives prior to 
complexation to metal ions
Figure 3.5
CH2 — CH2'
I
■N
CH2
CH2 — N- 
□
□
-N- CH2
1
CH2
I
N—
■CHo CHs
□  alkyl group 
[U  alkyl group or H
[3333] square conformation of 12-membered cyclen ring
Visualisation of 3.10 from a side perspective (Figure 3.4b) reveals that the methylene 
groups of the cyclen ring have adopted a low-energy, staggered conformation. This 
conformation reduces non-bonded interactions, particularly those of C-H eclipsed bonds 
that would add to the torsional strain of the ring. Torsional strain in a molecule is caused by 
electron repulsion between eclipsed bonds Figure 3.4 also shows that two of the 
propanamide arms extend outside the macrocyclic ring, whereas the other two are folded 
above and below the cavity.
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Figure 3.6 View of two molecules of 3.10
( H-bonds are indicated by dashed lines )
In Figure 3.6, two molecules of 3.10 are shown. A short distance of 2.893 Angstroms^ 
between the amide oxygen of one 3.10 molecule and the amide nitrogen of the adjacent 
molecule indicates the presence of a hydrogen bond No intramolecular hydrogen-bonds 
were found between the tertiary amines of the cyclen ring in 3.10 as they are fully- 
substituted.
3.5 Reaction of cyclen with 1 -cyanoviny(acetate
The Michael addition reaction is ubiquitous in classical polymer chemistry, such as the 
anionic polymerization of alkyl methacrylates and cyanoacrylates Cyanoacrylates like 
ethyl-2-cyanoacrylate (3.14) are initiated with very poor nucleophiles, such as water, due 
to the electron poor alkene and strong resonance contributions of the adjacent cyano and 
ester groups (Figure 3.7).
H CN
Figure 3.7
H
3.14
COgEt
Ethyl-2-cyanoacrylate (3.14).
A distance larger than 2.7 A is considered a weak H-bond, 2.5 - 2.7 Â charcterizes a strong H-bond and 
< 2.5 Â (down to 2.39 A at ambient conditions) defines a very strong H-bond
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Holton originally used 3.14 to construct quaternary carbon centres via the Michael 
reaction More recently, Klemarczyk studied the reactivity of ethyl-2 -cyanoacrylate 
with various amines He found that polymerization was much slower with primary and 
secondary amines than with tertiary amines due to proton transfer after the first addition of 
monomer (Scheme 3.10). In fact, he discovered that polymerisation was not inevitable and 
intramolecular proton transfer could be the preferred reaction to form the neutral, less 
reactive aminocyanopropionate ester (3.15).
\  EGA
Rg— N +  ) = (   ►----------------'---------(  -   ► polym er
Ri
V
COgEt COgEt
+
H CN R—NHo CN R—NH CN
R—NH2 + •H
H COgEt COgEt COgEt
3.14 3.15
Scheme 3.10 Reaction of ethyl-2-cyanoacrylate with secondary and tertiary amines
To establish if an analogous reaction would work with cyclen, 1 -cyanovinylacetate (3.16) 
which has a similar reactivity to ethyl-2 -cyanoacrylate, was added to cyclen in dry 
acetonitrile (Scheme 3.11). After the addition, an off-white solid began to precipitate out of 
solution within minutes. This precipitate was formed irrespective of whether three or five 
equivalents of 1 -cyanovinylacetate was used in the reaction. The analytical data obtained 
for this solid suggests 3.21 as a possible structure which can tautomerize to 3.17 in D2 O 
(Scheme 3.11).
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1 eq.
+
3.16 (3.1 eq.)
OH • • • 0 \
MeCN N N-
‘O • • • HO
enol to keto 
tautomerization in D2O
. 0
Scheme 3.11 Reaction of cyclen with 1-cyanovinylacetate to give 3.17.
High resolution mass spectrometry (m/z = 340.2104) and combustion analysis for 3.17 
showed the molecular formula to be C 16H28N4O4 which is consistent with the two isomeric 
compounds 3.21 and 3.17. Analysis by FT-IR indicates 3.21 exists primarily as an enol in 
the solid state as there is a strong enol (C=C-OH) absorption at 1635 cm'^ (Figure 3.8), The 
C=0 absorption at 1779 cm'^ of the unchelated ester starting material has dissappeared. 
Moreover, an OH band at 3400 cm'^ (and possibly one at 2982 cm" )^ also suggest the 
presence of an enol. Enolization of 3.17 may be stabilised by intra-molecular H-bonding 
between the C=0 groups on the pendant arms. This serves to reduce dipole-dipole 
repulsion between carbonyl groups which can be quite strong in cyclic compounds because 
of their fixed geometry When an ^H NMR of 3.17 was run in D2 O, no evidence of an 
enol was observed. Instead, a resonance at 9.7 ppm indicative of an aldehyde group was 
visible. This suggests that the more polar D2O solvent favours the keto tautomer by 
disrupting the H-bonding of the enol.
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V(OH)
V(C=C-OH)
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1424 .48
1 635 .40
4000 901.64511.1 3000 2000 1500
cm-1
Figure 3.8 FT-IR of 3.21 (KBr disc).
A possible mechanism for the formation of 3.17 is outlined in Scheme 3.12. Addition of 
cyclen to 1-cyanovinylacetate is followed by intramolecular proton transfer. Abstraction of 
the proton on Cl of the pendant arm by another molecule of cyclen results in elimination of 
cyanide to form the ester intermediate (3.20). This ester intermediate spontaneously 
hydrolyses to the enol (3.21). Attack of the C=0 group of 3.20 by the eliminated cyanide 
anion may have been the trigger for this cleavage. The resultant enol (3.21) may then 
rearrange to the keto tautomer (3.17) in D2O.
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HN hn:
3.20
'rN NpT\_y
CN'
ester cleavage
BH
BN n: • ° 7 < ?NC
RN NR
\  /
addition
1,2-
elimination
O
CN
HN
3.18
HN NH
proton transfer
RN
3.19
RN NR
^  ,N N.C  ^ N '___
HO ^
N N
' 0 - - H 0
Scheme 3.12 A possible mechanism to explain the formation of 3.21.
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3.6 Reaction of cyclen with ethyl 3-hydroxy-2-nltropropanoate
Like ethyl-2-cyanoacrylate (3.14) in the preceeding section, ethyl 2-nitroacrylate (3.22) 
offers a route to the bifunctional ligand, 3.23 (Scheme 3.13).
.N N
N N'
+
NO:
COgEt
3 .2 2  (3.5 eq.)
OgN
EtOgC
EtOgC.
N N.
NO:
OoN
'COgEt
HoN.
HO2C
HO2C.
N N
3 .2 3
.NH:
HoN
-CO2 H
Scheme 3.13 A possible route to the bifunctional ligand (3.23).
However, 3.22 is not commercially-available. Babievskii et a l showed that 3.22 could 
be formed in situ from ethyl 3-hydroxy-2-nitropropanoate (3.24). 3.24 was found to 
dehydrate at high temperatures to form 3.22 which then reacted with cyclopentadiene in a 
Diels-Alder cycloaddition reaction (Scheme 3.14).
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NO:
+ HO
-HgO
COgEt 122 °C
COgEt
cyclopentadiene 3.24 3.25
Scheme 3.14 Reaction of cyclopentadiene with 3.24 at high temperature
Ethyl 3 -hydroxy-2-nitropropanoate (3.24) was synthesised by condensing formaldehyde 
with ethyl 2-nitroacetate according to the method described by Babievskii et al. (Scheme 
3.15).
O
II
OoN.. X .
'O'
Ethyl 2-nitroacetate 
(1  eq.)
+ H2C= 0
33 % aq. formaldehyde 
( 1 .8  eq.)
CHsCOONa (1 eq.) HO OgN
16%
COgEt
3.24
Scheme 3.15 Synthesis of ethyl 3-hydroxy-2^nitropropanoate (3.24) 131
The reaction was performed by stirring ethyl 2-nitroacetate (1 eq.) and sodium acetate 
(1 eq.) in 33 % aqueous formaldehyde (1.8 eq.) at -15 °C for 3 hours. Addition of HCl to 
the reaction mixture caused an oil to separate which was extracted with ether. After 
evaporation of the ether, the oil was distilled in a short-path distillation apparatus at 
0.3 mm Hg. TLC analysis of the fraction which distilled between 80-105 °C revealed it 
contained unreacted ethyl 2-nitroacetate, the title compound 3.24 and one other unknown. 
These compounds were successfully separated on a silica gel column using 10 % ethyl 
acetate in DCM as eluent. In contrast, the original method used only distillation to purify
3.24. The reaction mechanism is given in Scheme 3.16.
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EtOgC-
H
-H
NO:
0
O
EtOgC HgC^O
HCl
EtOgC
3.24
Scheme 3.16 Reaction mechanism for the synthesis of 3.24.
The reaction between 3 -hydroxy-2-nitropropanoate (3.24) and cyclen was unsuccessful 
with only a polymeric material being produced (Scheme 3.17).
NO:
+ HO
COgEt
chlorobenzene
110°C
polymer
3.24 (4 eq.)
Scheme 3.17 Reaction of cyclen with ethyl 3-hydroxy-2-nitropropanoate (3.24).
For the reaction, 4 eq. 3.24 and 1 eq. cyclen were heated in dry chlorobenzene (b.p. 131 
°C) at 110 °C. Within minutes, the reaction developed a deep red colour and a precipitate 
formed. After 1 hour, the reaction was stopped and the precipitate which had formed was 
filtered off. All attempts to dissolve the precipitate in a variety of solvents were 
unsuccessful indicating a polymer had been formed. The alkene which is formed during the 
reaction, ethyl 2-nitroacrylate (3.22), is likely to be highly reactive as it has both an ester 
and a nitro electron-withdrawing group. At the high temperatures required to dehydrate
3.24, polymerisation instead of addition was likely to occur.
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3.7 Reaction of cyclen with methyl 2-acetamidoacrylate
In Scheme 3.18, a simple retrosynthetic analysis of the target molecule (3.23) identifies 
methyl-2-acetamidoacrylate (3.25) as the electrophilic reagent. Therefore, reaction of 
cyclen with the commercially-available alkene, methyl-2-acetamidoacrylate (3.25) should 
theoretically furnish the bifunctional ligand (3.23).
NH HN
HOoC
NH HN
N HN
3.23 J = >  +
N n : O.
HOgC -0 ^
/  o
NH; ^   *- /  3 25
o
Scheme 3.18 Retrosynthetic analysis of the bifunctional ligand (3.23).
The reaction was performed by stirring 3.5 eq. methyl-2-acetamidoacrylate (3.25) with 
cyclen (1 eq.) in dry acetonitrile under argon overnight. Analysis by LC-MS indicated that 
only di-substitution (M+H^ = 459) was occuring so an extra 1.5 eq. methyl-2- 
acetamidoacrylate was added to the reaction which was then heated to reflux for a further 
12 hours (Scheme 3.19).
o
A h
\  MeCN
HN
r "  'A  H   o r  ^L J +  ^ I 3.26 J
M  /  \  /  , \ y  I I K I
H N - V   /  A  o
cyclen, 1 eq. 3.25, 5 eq. ^—
O
Scheme 3.19 Reaction of cyclen with 3.25 under forcing conditions.
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Despite these forcing conditions, only di-substituted cyclen (3.26) was formed. A more 
sterically-hindered substrate with less electron-deficient withdrawing groups attached to the 
double bond may explain this lack of reactivity.
Over recent years, catalysts such as iron(III) chloride bismuth nitrate and sodium 
dodecyl sulfate (SDS) have been employed to catalyse the addition of amines to 
Michael acceptors. More recently, Wabnitz and Spencer found that strong Bronsted 
acids like trifluoromethanesulfonic acid could catalyse the hetero-Michael addition of 
weakly basic nucleophiles like carbamates (NHCOOR) to a,p-unsaturated carbonyl 
compounds (Scheme 3.20).
9  0.1 eq . CF3S O 2H O NHCbz
+  1.5eq. H2 NCbz  ►
2  2 7  CH3CN /  RT
Scheme 3.20 Acid-catalysed addition of benzyl carbamate to 3.27
The authors reasoned that activation of Michael acceptors by protonation of the carbonyl 
group (pKa -5 for a, p-unsaturated ketones) was possible with strong acids. One of the 
acids they used to catalyse this reaction was trifluoromethanesulfonic acid. 
Trifluoromethanesulfonic acid (CF3SO3H), which is also known as triflic acid, is one of the 
strongest Bronsted acids, with a pKa of -13.6. It is one of a small group of acids commonly 
known as ‘super acids’, being stronger than 100 % sulfuric acid. Amongst the super acids, 
triflic acid has several important advantages. It is non-oxidizing, has a high thermal 
stability, is resistant to both oxidation and reduction, and does not yield fluoride ions, even 
in the presence of strong nucleophiles.
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In a test reaction, 0.7 eq. triflic acid was carefully added to a solution of cyclen and 
methyl-2-acetamidoacrylate (3.25) in acetonitrile. The reaction was allowed to stir at room 
temperature under argon. LC-MS monitoring of the reaction after 12 hours indicated both 
tri- and tetra-substitution of the cyclen ring had occurred. Since the tri-#-substituted 
product was our desired target, mono-A^-protection of the cyclen ring was required.
3.7.1 Mono-Af-protection of cyclen with a benzyloxycarbonyl 
(Z) group
The cyclen macrocycle was mono-A^-protected with the aromatic benzyloxycarbonyl (Z) 
group as it was considered the hydrophobic character of this group would ease purification. 
Furthermore, compounds containing the Z moiety have another advantage in that they tend 
to crystallize readily Mono-Z-cyclen (3.28) was synthesised using a procedure similar 
to the one that was used to prepare mono-AAacetyl cyclen (see Section 2.3, Chapter 2). The 
synthesis consisted of the dropwise addition of benzylchloroformate in chloroform to a 
solution of cyclen in chloroform (Scheme 3.21).
/O  CHCI3
C J  '  —
N
1 eq. 1.1 eq. 3.28
Scheme 3.21 Synthesis of mono-Z-protected cyclen (3.28)
After the reaction was stirred overnight, it was washed with dilute sodium hydroxide to 
convert the products into free bases. The organic solvent was then separated and 
evaporated to give an oil. This oil was purified by silica gel column chromatography using 
5 % methanol in chloroform containing 0.1 % zPrNH2 . A small amount of di-Z-cyclen
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eluted from the column first. Mono-Z-cyclen (3.28), which eluted from the column as an 
oil, was crystallized by the addition of acetonitrile. The yield of 3.28 was 53 %. Although 
Woods et al. prepared the hydrochloride form of 3.28 in an overall yield of 82 %, their 
synthesis involved three separate steps (Scheme 3.22).
/ —\
HN NH
(  J
HN NH
\  /
i. (Boc) 2 0  
90 %
Boc^ /  \  Boc
f "
HN N
Boc
HN NH
I  J
N NH
Cbz^
iii. HCI/MeOH
94 %
98% ii. BnOCOCI / EtgN
Boc /  \  Bocc:
Boc
Scheme 3.22 Synthesis of mono-Z-protected cyclen by an indirect method 61
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3.7.2 Triflic acid-catalysed addition of mono-Z-cyclen to 
methyl-2-acetamidoacrylate
Scheme 3.23 outlines the triflic acid-catalysed addition of mono-Z-cyclen (3.28) to 
methyl-2-acetamidoacrylate (3.25).
+
HN
3.25 (3.5 eq.)
CF3SO3H  
(0.7 eq.)
70%
3 .2 9
V_7
HN HN
Scheme 3.23 Addition of mono-Z-cyclen to 3.25 catalysed by triflic acid.
Mono-A-Z-cyclen and methyl-2-acetamidoacrylate were suspended in dry acetonitrile. 
Quick but careful addition of the strong acid, triflic acid, caused the suspended reactants to 
become soluble. Triflic acid was added with an automatic pipette to ensure the correct 
amount was added. The reaction was allowed to stir at room temperature under argon 
overnight. After the solvent was removed in vacuo, the residue was partitioned between 
IM ammonia (10 ml) and chloroform (20 ml). The aqueous layer was washed with another 
1 0  ml chloroform and the pooled organic extracts were evaporated to give a pale yellow.
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viscous oil. The resulting oil was dissolved in a small amount of CHCI3  and EtzO was 
added to induce crystallisation. The yield of the fully-substituted Michael adduct (3.29) 
was 70 %.
To avoid complete protonation of the amines and the nitrogens of cyclen becoming non- 
nucleophilic, the concentration of acid in the reaction was kept below the concentration of 
cyclen (i.e. 0.7 eq. acid to 1 eq. cyclen). Despite the use of a strong acid, no evidence of 
ester or amide hydrolysis was observed, presumably because of the non-aqueous 
conditions used. Michael additions often result in poor yields when the acceptor is a di­
substituted trans alkene, presumably because of steric hindrance to the attacking 
nucleophile The protonation of methyl-2-acetamidoacrylate by triflic acid most likely 
enhances its activity as a Michael acceptor (Figure 3.9).
H HN-
o F
O F 
triflic acid
HN
HN
Figure 3.9 Protonation of methyl-2-acetamidoacrylate by CF3SO3H.
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The synthesis of 3.29 demonstates that strong acids can activate poor acceptors to such an 
extent that steric effects are overcome and all four amines of the cyclen ring can react. It is 
possible that triflic acid is having a dual catalytic effect on the reaction. Once the carbonyl 
group of the acceptor alkene is protonated, the triflate anion could engage in hydrogen- 
bonding to the N-H of cyclen and effect a conformational change in its structure (Figure 
3.10). This conformational change may cause the nitrogen lone pair to point away from the 
centre of the ring and become nucleophilic. This switch from an endo to an exo 
conformation would enable cyclen to attack the electron-deficient alkene acceptor.
HN
^ --------------------------------------  CF3SO3-----------
^  X ^ ------------ \
HN NH I
\ -----/  'A/v
Endo lone pair Exo lone pair
Figure 3.10 An acid-catalysed conformational change in cyclen.
Some clues to the effect acid has on the conformation of cyclen in solution can be obtained 
from crystallographic data In its hydrochloride salt form, cyclen adopts a square 
conformation in which its nitrogen atoms and lone pairs point outwards in an exocyclic 
mode. In contrast, the free base form of cyclen has two exocyclic and two endocyclic 
amines. In this conformation, the two endocyclic amines are less available for nucleophilic 
attack as their lone pairs are oriented into the cavity of the macrocycle.
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3 .7 .3  Deprotection of 1 -Benzyloxycarbonyl-4,7,10-tris-(methyl-2- 
acetam idopropanoate)-1,4 ,7 ,10-tetraazacyclododecane (3.29)
Cleavage of the benzylic nitrogen bond in 3.29 was accomplished by hydrogenation over 
10 % palladium on charcoal to give 3.30 (Scheme 3.24) The reaction was performed by 
bubbling a slow stream of H2 through an ethanolic suspension of Pd/C and 3.29 in a fume 
cupboard overnight. After the catalyst was precipitated by centrifugation, the supernatant 
was decolorised with activated charcoal. After filtration through celite and evapoartion 
under reduced presure, the resultant residue was dried under high vacuum to remove traces 
of toluene which is a by-product of the reaction. 3.30 was obtained in a yield of 90 % as a 
viscous, yellow oil. NMR of the product confirmed that the benzyloxycarbonyl group 
had been removed. Furthermore, LC-MS showed that the compound had the expected 
[M+H]'" of 603.
10% Pd/C in 
EtOH / Ho
3.29
90%V_7
HN HN
Scheme 3.24 Deprotection of 3.29 to give 3.30
NH
NH
3.30
w
HN HN
The second deprotection step involved the hydrolysis of the methyl esters and A-acetyl 
amides in 3.30. Simultaneous deprotection of both protecting groups was achieved by 
heating 3.30 in 12M aqueous HCl at 60 °C for 6  hours. The product (3.31) was a 
hygroscopic, white solid and essentially consists of cyclen with three pendant amino acid 
arms. However, analysis of the product by LC-MS indicated cyclen with two amino acid
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arms (3.32) was also present (Scheme 3.25). The peak ratio of 3.32 to 3.31 was found to 
increase in solution after 24 hours.
■oi;:
N NH
HO NH 
C
[ 3 .30 I
12 M HCl (aq.) N NH,   n .......................................
[  3.31 J +  r  3 .32 1
.N NH
H^N
HO
HgN
OH
Scheme 3.25 Hydrolysis of 3.30 with 12M HCl (aq.).
Since hydrolysis using aqueous HCl has previously been used to cleave A^-acetyl amides 
and methyl esters without problems it seems the loss of an arm from N-10 is cyclen- 
related. An acid-catalysed decarboxylation as outlined in Scheme 3.26 is one possibility.
NH OH
NH
NH
3.31
HO
COs
OH
NH
HN
NH
\ _ /
3.32
HO
Scheme 3.26 Acid-catalysed decomposition of 3.31.
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3.8 Reaction of cyclen with ethyl-cis-p-cyanoacryiate
The final Michael acceptor investigated was the di-substituted, cis alkene, ethyl-cw-p- 
cyanoacrylate (3.33) which is commercially-available. The reaction was carried out by 
stirring cyclen with ethyl-cw-p-cyanoacrylate (3.1 eq.) in acetonitrile at room temperature 
(Scheme 3.27). LC-MS monitoring of the reaction mixture after 24 hours indicated that the 
tri-substituted product (3.34) was formed ([M+Na]^ = 569.2). Tetra-substituted product 
was also detected ([M+Na]'*’ = 692.9) but 3.34 was the dominant species. Once the solvent 
was evaporated, the resulting residue was purified on a silica gel column to afford the tri- 
substituted product (3.34) as a viscous, yellow oil. A low yield of product (i.e. 20 %) 
suggests that some decomposition of 3.34 may have occurred on the silica gel during 
column chromatography.
Cl
H 20 %
1 eq. 3.33 (3.1 eq.) 3.34
Scheme 3.27 Reaction of cyclen with ethyl-cw-P-cyanoacrylate.
Analysis of 3.34 by ^^ C NMR revealed that the methine carbon in the pendant arm 
resonated at S  49.41. This indicates that addition of cyclen took place at the carbon 
opposite the nitrile group. Addition opposite the ester group is predicted to give rise to a 
signal with a more upfield chemical shift because of deshielding by the neighbouring 
nitrile group. This regioselectivity was expected as the nitrile moiety has stronger electron- 
withdrawing ability than the ester group. Therfore, the use of two different electron-
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withdrawing groups on the alkene acceptor provides a subtle means of introducing 
regioselectivity into the reaction.
Unlike the previous additions with acrylamide and methyl-2-acetamidoacrylate, addition of 
cyclen to the double bond of 3.33 took place without heating or the use of an acid catalyst. 
Also, the nitrile group offers synthetic versatility as it can potentially be reduced to an 
amine or hydrolysed to a carboxylic acid. For example, reduction of the nitrile groups in
3.34 followed by hydrolysis of the ethyl esters offers a route to the bifunctional ligand,
3.35 (Scheme 3.28).
o  
0
(i) reduction of CN
X  NH (ii) hydrolysis of esters
NH
HO
NH
HO
3 .3 5
NH
OH
Scheme 3.28 A possible transformation of 3.34 into the ligand 3.35.
3.35 has pendant arms which are substituted at Cl with COOH groups (for coordination to 
Gd^^) and substituted at C-3 with primary amino groups. These amino groups can be used 
in coupling reactions to various targeting molecules. As both the amino and carboxyl 
groups in 3.35 are separated by two methylenes, independent manipulation of either group 
should be possible. Additionally, the carboxyl groups in 3.35 are situated closer to the 
cyclen ring than the amino groups and should preferentially coordinate to the Gd^^ ion.
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Summary of Chapter 3
In combination with alkylations and condensations, the Michael reaction has traditionally 
been used to construct a wide variety of complex molecules from relatively simple starting 
materials The Michael reaction benefits from mild reaction conditions, high functional 
group tolerance, a large host of reactive alkenes as well as high conversions and good 
reaction rates. In the reactions investigated, the Michael addition of cyclen to activated 
alkenes proved to be a valuable reaction for fiinctionalizing the cyclen macrocycle.
Reaction of the commonly-available monomer, acrylamide, with cyclen furnished two 
new, potentially-useful, tri-substituted cyclen ligands (Figure 3.11). These were named 
D03PAM (3.9) and D03P (3.11). The syntheses of these two macrocycles were both 
high-yielding and facile. Both ligands were characterised using and NMR 
spectroscopy and high resolution mass spectrometry.
3.9
/
O O
NH:
HO
3.11
HO OH
Figure 3.11 Structures of D03PAM (3.9) and D03P (3.11)
128-
C h a p te rs  The M ichael Reaction
The triflic acid-catalysed addition of mono-Z-cyclen (3.28) to activated alkenes offers a 
new and versatile methodology for the tri-A-substitution of cyclen (Scheme 3.29). Even a 
relatively poor Michael acceptor, like methyl-2-acetamidoacrylate, was found to react with 
cyclen in the presence of the strong Bronsted acid, triflic acid. Since the conditions used to 
remove the benzyloxycarbonyl group are mild, most substituents that are introduced onto 
the macrocycle should remain unaffected during this deprotection step.
o
,N N /  \  N
H' H H R2  /  \  /  V ^R
3.28 3.5 eq.
'R2 Ri
Hz, Pd/C
IMM
R .'R2 R,
Scheme 3.29 General procedure for the tri-A-substitution of cyclen via Michael 
addition.
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Reaction of cyclen with 3.1 eq. ethyl-cw-P-cyanoacrylate gave the tri-A^-substituted ligand 
(3.34) (Scheme 3.30).
A  A
1 . 0  eq.
+
3.1 eq.
3 .3 4
NH
NH
HO.
NH
HO
3 .35
NHH
Scheme 3.30 Reaction of cyclen with ethyl-cw-p-cyanoacrylate to give 3.34.
Interestingly, the addition was regioselective with cyclen attacking the alkene at the side 
opposite to the nitrile group. Once 3.34 is transformed into 3.35, it should have good 
potential as a bifunctional ligand because of the favourable spatial arrangement of its 
carboxyl and amino groups. 3.35 has three carboxyl groups positioned a  to the cyclen ring 
for coordination to Gd^ .^ The terminal amino groups located on C3 of the pendant arms are 
available for coupling to vector molecules. As the amino groups are distant from the 
macrocycle, it is expected they should not coordinate to the central Gd^^ ion.
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The choice of solvent used in the Michael reaction strongly depends on the solubility of the 
catalyst, donor, and acceptor as well as sensitivity to side reactions. Solvents with weakly 
basic functionalities like THF, ether, or acetone could interfere with protonation 
equilibriation and were not used. Reactions involving strong acids or reactive Michael 
acceptors like 1 -cyanovinylacetate could not be carried out in alcoholic solvents as they 
could potentially react with the medium. Non-protic solvents such as acetonitrile, 
chloroform or a combination of both were the solvents of choice for these reactions. In 
these non-protic solvents, the proton transferred to neutralise the carbanionic intermediate 
should have originated from cyclen; in other words, the proton transfer was intramolecular. 
However, the addition of cyclen to acrylamide was performed in methanol. As a result, the 
transferred proton could have originated either from methanol (i.e. intermolecular) or from 
cyclen (i.e. intramolecular).
In common with the alkylation reactions described in Chapter 2, reaction of 1 eq. cyclen 
with 3 eq. Michael acceptor invariably produced unwanted tetra-substituted product in 
addition to the desired tri-substituted cyclen. It was found that mono-protection of cyclen 
with the benzoyloxycarbonyl group conveniently prevented this over-alkylation. 
Additionally, the use of this hydrophobic protecting group facilitated the purification of the 
product via simple extraction with chloroform. In contrast, a difficult column 
chromatography was required to separate the tri- and tetra-substituted products when 
substrate was reacted with unprotected cyclen.
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4.0 Introduction
This chapter is concerned with the preparation, purification and characterisation of 
gadolinium complexes. Complexes were prepared from the ligands synthesised by the 
Michael addition reactions described in Chapter 3. The alkylation reactions described in 
Chapter 2 yielded insufficient products for complexation. Ligands normally require 
purification with ion-exchange chromatography before complexation as extraneous cations 
and anions can interfere with the reaction. Therefore, at least 0.25 g of crude ligand is 
required because of the mechanical losses that occur during the ion-exchange process. 
Cations such as Ca^ "^  and Na"^  compete with the Gd^^ ion for the ligand and a number of 
other anions (e.g. Cf, COs^, OH') compete with the ligand for the Gd^^ ion.
As the donor atoms in macrocyclic ligands are pre-organised for coordination, there is a 
less dramatic ordering effect upon coordination to a metal than their open-chain 
analogues However, the coordination reaction rate of a macrocycle to a metal can be 
slow and often requires heating the ligand and metal salt for many hours. This ensures the 
ligand can attain the higher energy conformations which are often necessary for reaction to 
occur. Conversely, the rate of dissociation of macrocyclic complexes is also slow which 
explains why their use is preferred over acyclic complexes.
Water-soluble gadolinium complexes are usually prepared in water by using either 
gadolinium chloride (GdCl3 .6 H2 0 ) or gadolinium oxide (GdiOs) as the source of the Gd^^ 
ion. When using a salt such as chloride, the addition of base (e.g. NaOH) is then required 
to neutralise the hydrochloric acid produced during the complexation reaction. This means 
that the aqueous solution of the desired complex also contains variable amounts of a NaCl 
by-product. The presence of these inpurity salts can be avoided by using Gd2 0 3  or
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gadolinium acetate (Gd(CH3C0 2 )3) as the source of the Gd^^ ion. The pH can be adjusted 
with volatile ammonium hydroxide base or acetic acid to precipitate any excess Gd^ .^
Following complex prepararation, the chapter then describes the method employed for 
measuring Ti spin-lattice relaxation times of the complexes on a Minispec mq60 NMR 
analyser. The Minispec provides a 1.4 Tesla (or 60 MHz ^H frequency) magnetic field 
which is the same field strength as that used by many MRI instruments. From the measured 
relaxation times, the ri values of the Gd^^ complexes were calculated and compared to 
published values for complexes of a similar nature. For method validation, the relaxivities 
of a clinical preparation of Magnevist (i.e. Gd(DTPA)^’) and Gd(DOTA)' were determined 
and compared to literature values.
4.1 Synthesis of Gd(D03P)
The ligand D03P (3.11), which is shown in Scheme 4.1, was obtained as the hydrochloride 
salt from the hydrolytic reaction described in Chapter 3 (See Section 3.4). For 
complexation, 3.11 required conversion to the free base as chloride anions could compete 
with the ligand for Gd^ .^ This was achieved using anion exchange chromatography.
4.1.1 Deionization of D03P hydrochloride using anion-exchange
chromatography
D03P hydrochloride was converted to the free base by anion exchange chromatography on 
Amberlite IRA-400 (Scheme 4.1). Amberlite IRA-400 is a strongly basic anion exchange 
gel-type resin with a quaternary ammonium functionality. Applications of this resin include 
the deionization of water and the removal of amino acids at high pH
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2.5 HCl
P
OH
Amberlite IRA-400
43%
HO
d
HO
N N
N N
H
p
OH
Scheme 4.1 Deionization of D03P hydrochloride.
3.11 was dissolved in a small amount of water and the pH was adjusted to approximately 10 
using dilute sodium hydroxide. This ensured deprotonation of the carboxyl group and 
enabled adsorption of the negatively-charged ligand onto the positively-charged resin (see 
Figure 4.1). The resin was then washed with deionized H2O to remove unbound Na"^  and Cf 
ions. The presence or absence of C f ions in the eluate was conveniently determined by 
spot-testing with a dilute solution of silver nitrate.
A. ligand application 
at pH 10
B. H2 O wash to 
remove NaCI
Na  ^ OgC ■R. NHc
C. Ligand desorption 
using formic acid
HCOOH
Res N* OH
NH
Res N + -O2  OH
NaOH
+
NaCI
■R.HO2C NH2 O2CH
ligand (formate salt)
Figure 4.1 Deionization of D03P hydrochloride on Amberlite IRA-400.
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Desorption of the ligand from the column was then accomplished by the stepwise addition 
of increasing concentrations of formic acid i.e. 0.1, 0.25, 0.5, 0.75 and 1.0 M. The ligand 
eluted at 0.5 M formic acid. Removal of the formic acid in vacuo at 30 °C gave a waxy 
residue which was the formate salt of the ligand. This formate salt residue was dissolved in 
deionized H2O and the solvent evaporated under reduced pressure at 40 °C. This procedure 
of dissolution in H2 O and evaporation was repeated three times in order to ensure removal 
of the volatile formic acid from the ligand. The free base form of D03P (4.1) was obtained 
as a white, mobile powder.
4.1.2 Complexation of D03P
Scheme 4.2 depicts the complexation of deionized D03P (1,4,7,10-tetrazacyclododecane- 
4,7,10-tripropanoate) with gadolinium oxide to give the complex, Gd(D03P). The method 
used was analogous to that employed by Dischino et a l to synthesise Gd(D03 A)
4.1 (1.0 eq.)
HO
6
HO
C )
o
P
OH
+  Gd2 0 g (1 .2  eq.)
89%
Scheme 4.2
A "A
..........
\
O'
Synthesis of Gd(D03P), 4.2
Gd(D03P) 4.2
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D03P free base (4.1) was refluxed with a slight excess of GdaOs in a small amount of 
deionized H2O for 16 hours. After passing the cooled suspension through a 0.2 micron 
polypropylene filter, the filtrate was freeze-dryed. In addition to confirming Gd(D03P) 
had one Gd^”*” ion, microanalytical data indicated that the complex was monohydrate. The 
high resolution mass spectrum of the product (Figure 4.2) gave the appropriate isotopic 
distribution pattern for the charge-neutral, mono-gadolinium salt (4.2). The NMR of the 
complex showed several broad resonances indicating the presence of paramagnetic Gd^ .^ 
From IR spectroscopy, the carbonyl stretching frequency at 1753 cm"^  in 4.1 was shifted to 
1560 cm '\ an indication that the pendant arms were bound to the metal centre
544.1
542.1
546.1
541.1
547.1
540.1
544.2
542.2
541.1 546.2
547.2
540.1
535 540 545 550
THEORETICAL ISOTOPE MODEL: [M+H]+
m/z
OBSERVED DATA
m/z
Figure 4.2 High resolution mass spectrum of Gd(D03P).
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4.2 Synthesis of Gd(D03PAM)
Gd(D03PAM) was prepared by reacting D03PAM (3.9) with gadolinium chloride 
(Scheme 4.3). The method consisted of heating D03PAM with 1 eq. of GdCls in anhydrous 
MeOH at 60 °C for 16 hours After the solvent was removed, the residue was 
recrystallised from methanol and diethyl ether.
HgN
O
3.9 (1 eq.)
HoN
N
N
,H
P
NHz
MeOH (60 °C)
+  GdClg (1.0 eq.)
70%
Scheme 4.3
NH
O—
NH
Synthesis of Gd(D03PAM), 4.3.
In addition to confirming Gd(D03PAM) had one Gd '^"'ion, elemental analysis data showed 
that the complex was dihydrate and contained three chloride counter-ions. This indicates 
the complex has an overall formal charge of 3+. The HR-MS of the product 
([LGd+2 (NH4 Cl)+HCl]^) is shown in Figure 4.3. It is possible that the NH4CI and HCl 
adduct ions were formed in the ion-source of the mass spectrometer. The Cf anions of the 
complex could have formed clusters with NH4 "^ and which commonly occur with
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electrospray ionisation (ES+) In the HR-MS, the presence of the two expected metal- 
bonded water molecules was not observed.
686.1
Theoretical isotope pattern 
expected for ([LGd+2(NH4Cl)+HCl]t)
684,1
»!
7 «
BOf
««»!
a
a
a
a
688.1
8
683.1
I 682,1
590.1681.1
m/z8B2
686.2
Observed Data
8 683.2
I a 
■i a
681.2
690.2
m/z082
Figure 4.3 High resolution isotope pattern observed for Gd(D03PAM).
From IR spectroscopy, the carbonyl stretching frequency occurring at 1673 cm‘  ^ in 3.9 was 
shifted to 1652 cm '\ an indication that the pendant arms were indeed bound to the metal 
centre.
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4.3 Synthesis of Gd(D03-2AP)
4.3.1 Deionization of D03-2AP hydrochloride using cation-exchange 
chromatography
D03-2AP hydrochloride was converted to its ammonium salt form by cation exchange 
chromatography on Amberlyst IR-120 (Scheme 4.4).
HQ NHi+cr H4NO nh
o V  / — \,N NH Amberlyst IR-120 NH
4 .4
Cl H a N -^ o  NH3+CI- H 2 N -^ 0  H^N
HO H4NO
Scheme 4.4 Deionization of D03-2AP hydrochloride using Amberlyst IR-120.
Amberlyst IR-120 is a strongly acidic cation exchange resin (H^ or Na"^ ) with a sulfonic 
acid functionality D03-2AP hydrochloride was dissolved in a small amount of water 
and its pH was measured (pH = 1.3). At this acidic pH, the amino groups of 3.31 are 
protonated which ensures adsorption onto the negatively-charged resin (see Figure 4.4). 
The resin was then washed with deionized H2O to remove Cl" ions. Desorption of the 
ammonium form of the ligand (4.4) from the resin was then accomplished by the addition 
of aqueous ammonium hydroxide (7.5 %). The yellow residue which remained was 
triturated with ethanol and acetone to give an off-white solid.
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A. ligand application 
at pH 1.3
.R
C|- ■“HgN'" '^COgH
ResSOa'^H
B. H2 O wash to 
remove Cl' ions
Res SO3
HOI
C. Ligand desorption 
using NH 4 OH
NH-
Res SO3 H4 N
^ C 0 2 NH4
ligand (ammonium salt) 
Figure 4.4 Deionization of D03-2AP hydrochloride on Amberlyst IR-120.
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4.3.2 Complexation of D03-2AP
Scheme 4.5 depicts the complexation of D03-2AP with gadolinium oxide to form the 
complex Gd(D03-2AP), 4.5.
NH
NH
4.4
w
+  GdzOa (1 . 2  eq.)
pH 4.5
Scheme 4.5
,NH
Synthesis of Gd(D03-2AP), 4.5,
4.5 m/z = 589
The ammonium salt of 4.4 was reacted with gadolinium oxide at pH 4.5 (the pH was 
adjusted with dilute acetic acid). After 1 hour, the pH had risen to 4.8. The reaction was 
allowed to stir overnight and the pH was readjusted to 7.0 with dilute ammonia. After the 
solvent was removed in vacuo, the residue was resuspended in ethanol and acetone was 
added until a white turbidity appeared. The suspension was then put in the freezer 
overnight and the filtered precipitate dried under a high vacuum for 24 hours. Low 
resolution mass spectrometry revealed that Gd(D03-2AP) had been formed but a peak 
corresponding to the Gd^^ complex of the di-substituted ligand (4.6) was also present (see 
Figure 4.5).
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502.0 
504.0
499.0Xj
506.1 590.1
589.0
588.0XI
595.1
■1..........I ■ I . . I I I I . I
m /z
.NH
HNv_y
4.6 [M+H]^ = 502
Figure 4.5 LR-MS of Gd(D03-2AP) showing the impurity complex 4.6.
In Section 3.7.3 of Chapter 3, deprotection of the tri-substituted ligand (3.31) with acid 
resulted in the loss of a pendant arm to form a ligand with only two arms (3.32). This 
decomposition explains the presence of a peak corresponding to the complex 4.6 in the MS 
spectrum. Since the desired complex (4.5) contained 4.6 as an impurity, a high resolution 
mass spectrum was not obtainable.
4.4 Synthesis of Gd(DOTA)'
DOTA ( 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid) was purchased from 
Sigma-Aldrich and complexed with gadolinium oxide according to Scheme 4.6. The 
complexation technique was analogous to the procedure used to prepare Gd(D03P) in 
Section 4.1.2.
.OH
HO OH
HO
DOTA
Gd2Û3 (1.2 eq.) 
 ►
90%
(Gdj
Gd(DOTA). 4.7
Scheme 4.6 Complexation of DOTA with Gd^^ to give 4.7.
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4.5 Relaxivity measurements of complexes
4.5.1 Theory
As discussed in Section 1.6 of Chapter 1, the presence of a Gd^^ ion increases the 
longitudinal and transverse relaxation rates, 1/Ti and I/T2 , respectively, of water protons. 
The observed solvent relaxation rate, (1/71) is the sum of the diamagnetic (1/Ti)d and 
paramagnetic (1/Ti)p relaxation rates (where i = 1 or 2):
The diamagnetic term l/T^d corresponds to the relaxation rate of the solvent (i.e. water) 
protons in the absence of paramagnetic Gd^ .^ The paramagnetic term 1/T^p gives the 
relaxation rate enhancement caused by the paramagnetic substance, which is linearly 
proportional to the concentration of the paramagnetic species, [Gd^^]:
(1 / Ti U, = (1 / Ti )„ + n [Gd3+] (4.2)
According to Equation (4.2), a plot of the observed relaxation rate versus the gadolinium 
concentration gives a straight line with a slope equal to the relaxivity, n. The unit of 
relaxivity is mM'^ s"\
4.5.2 In vitro relaxivity measurements
Solutions of gadolinium chloride (0.95, 1.90, 2.85, 3.80, 4.75 mM) were prepared by 
dissolving the salt in ultra-pure water. For accuracy, the solutions were made to volume in 
5 ml volumetric flasks. A 5 mm NMR tube was then filled with solution and the tube 
placed in a Minispec mq60 pulsed time-domain analyser (Bruker, Massachusetts, USA). 
The temperature of the sample was maintained at 25 +/- 0.1 °C by an external circulator 
(Haake Phoenix II P1-C35P). Proton solvent longitudinal relaxation times (T’i)obs were
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measured for each sample at 60 MHz and 25 °C by means of the inversion-recovery 
technique. Three measurements were made for each sample and the average was taken to 
represent the Ti relaxation time constant of that sample. A plot of the inverse of this 
average value versus the Gd^^ concentration gives the Ti-relaxivity (n) as the slope of the 
graph (Figure 4.6).
0.06
G d3+
0.05 G d(D 03P )
-•G d (D 03P A M )A
0.04
M agnevist
0.03
0.02
0.01
0.00
0 1 2 3 54
Figure 4.6
Contrast agent (mM) 
Graph of (1/ Ti) against contrast agent (mM).
The coefficient of regression (R^) for each line in Figure 4.6 was found to be greater than 
0.99. The slope of the Magnevist preparation was only linear between 3-5 mmol. As the 
vial of Magnevist was a clinical preparation for intravenous use, its formulation may 
account for this observed behaviour. Since Magnevist, [Gd(DTPA)H2 0 ] '^, is ionic and has 
an overall charge of -2, two counterions of A-methyl-D-glucamine (NMG) are added to the 
complex to neutralise it. NMG is a sugar-amine derivative, which contains multiple 
hydroxy groups that hydrogen-bond effectively with water molecules (Figure 4.7).
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H a  .OH HO
%
HN-
/ HO OH
Figure 4.7 A-methyl-D-glucamine (NMG).
Van Der Elst et al. showed that the addition of NMG to Magnevist increased the rotational 
correlation time of the complex, presumably because of the increase in size of the adduct 
formed Relaxation times were found to be very reproducible and almost identical 
results were obtained for the GdCls solutions when they were re-measured after 7 days.
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4.6 Discussion of results
Relaxivity (ri) describes the effectiveness of the paramagnetic contrast agent in changing 
the rate of water proton relaxation at 1 mM concentration. It represents the reciprocal of 
the longitudinal relaxation time constant per unit concentration (mM) of metal. Table 4.1 
lists the ri relaxivities obtained for the three complexes that were synthesised in this 
project. It also lists the n  of the free Gd^^ ion (prepared from GdCls), Gd(DOTA) and the 
commercial contrast agent, [Gd(DTPA)H2 0 ] ’^, whose trade name is Magnevist.
Table 4.1 Ti-relaxivity ( n )  values of complexes.
Complex r i , mM'' s-% 
(60 MHz, 25 °C)
n ,
Literature values
1 1 . 0 1 2 . 2
(20 MHz, 37 °C)
[Gd(D0TA)(H20)] 3.2 3.5^“
(20 MHz, 25 °C)
[Gd(DPTA)H20]^'
Magnevist
2 . 8 3.1 “
(20 MHz, 25 °C)
[Gd(D03PAM)(H20)2]^'^ 4.6
[Gd(D03P)(H20)2] 4.0
Gd(D03-2AP) 
Impure sample
1.5
Relaxivity values of 11.0, 3.2 and 2.8 mM'^s'^ were determined for free Gd^^, Gd(DOTA) 
and [Gd(DPTA)H2 0 ] '^ (Magnevist) respectively. These values compare well with the 
literature values of 12.2 3.5 and 3.1 mM'^s'\ respectively. The similarity of these
results to the literature values effectively validates the method used to determine the 
relaxivity. However, the ri values of these reference complexes obtained at 60 MHz are
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slightly less than the n  values obtained by other studies at 20 MHz As Ti-relaxivity 
is both field and temperature-dependent, comparison between data taken at different field 
strengths or temperatures must be approached with caution. The Ti-relaxivity of small- 
molecular Gd(III) complexes tends to fall slightly between 20 and 60 MHz (see Figure 
4.8). This explains the slightly reduces relaxivity values obtained in this study.
16
14
12
10
8
6
4
2
0
0.01 0.1 1 10 1 0 0
Frequency ( MHz )
Figure 4.8 n  of [Gd((D0 TA(B0 M ^3)(H2 0 )]‘ versus ‘H frequency
On first inspection, the n  values obtained for Gd(D03P) and Gd(D03PAM) look quite 
promising. They show an estimated 50 % increase in relaxivity over the best-selling 
contrast agent currently on the market, Magnevist, which is shown in Figure 4.9.
Figure 4.9
OoC
(GdCO
Magnevist or [Gd(DTPA)(H2 0 )]'
= 2 . 8  mM'^ s"^
( 60 MHz. 25 °C )
BOM refers to the benzyloxymethylcarbonyl group .
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However, the DTP A ligand of Magnevist occupies eight binding sites at the metal centre 
with the ninth coordination site being occupied by a water molecule, i.e. the complex has a 
q or hydration number of one. Although the hydration numbers of Gd(D03P) and 
Gd(D03PAM) were not determined experimentally, it can be assumed they would 
approximate a hydration number of two. This assumption is based on the fact that each 
ligand has only 7 groups available for coordination to gadolinium leaving 2 available for 
water coordination. Since the hydration number is a strong determinant of relaxivity, a 
comparison with the ri values of other, macrocyclic q = 2 complexes carries more validity 
than a comparison with acyclic, q = 1 Gd(DTPA). Two complexes ideally suited for this 
comparison are the heptadentate complexes Gd(D03A) and Gd(D03AM)^^ which are 
shown in Figure 4.10.
G d (D 0 3 P ) 4.2 = 4 .0
( 60 MHz, 25 °C )
G d(D 03PA M )3+ 4.3
NH
V.LV
Ti = 4 .6
( 60 MHz, 25 °C )
G d (D 0 3 A ) 4.8
( 20 MHz, 25 °C )
/ \  H
/ S
A  ;
G d(D03A M )3+ 4.9 n  = 4.7
(20 MHz, 25 °C)
HoN
Figure 4.10 Comparison of the Ti-relaxivities of Gd(D03P) and Gd(D03PAM)^^ to the 
values of the structurally-similar complexes Gd(D03 A) and Gd(D03 AM)
149-
C h apter 4 Com plexation an d  M easurements
Literature ri values of 4.8 and 4.7 mM'^s'^ (20 MHz, 25 °C) have been reported for 
Gd(D03 A) and Gd(D03 AM)^^, respectively These values compare favourably with the 
n  values determined for the structurally-similar, Gd(D03P) and Gd(D03PAM). The 
relatively high relaxivity of Gd(D03PAM) was unexpected as complexes containing amide 
donors often suffer from slow water exchange in comparison to their acetate analogues. 
For example, the replacement of one carboxylate by an amide group has been found to 
decrease the water exchange rate of a Gd^^ complex by a factor of between 3 and 4 One 
explanation for the relatively high relaxivity of Gd(D03PAM) might be the contribution of 
counterions such as C f in the complex. The nature of the counter-anion has previously 
been shown to affect the water exchange rate for a series of cationic gadolinium complexes 
in aqueous solution, as a consequence of the ordering effect that the anion imposes on the 
structure of the second hydration sphere
In the related triamide complex (Eu(NP-D03AM)(H20)(CF3S02‘)2, hydrogen-bonding 
interactions with triflate anions have been observed (see Figure 4.11) Two triflate 
anions lie above the coordinated water molecule with each triflate positioned such that a 
hydrogen bond from one triflate oxygen to one of the protons of the coordinated water 
molecule is possible. It can also be observed that the oxygen of the water molecule is 
coordinated directly to the Gd^ "*" ion. Since Gd(amide) complexes have been reported to 
possess good selectivity for the Gd^  ^ ion in vivo Gd(D03PAM) merits further 
investigation as a possible contrast agent given its relatively high relaxivity.
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Figure 4.11 Crystal structure of Eu(NP-D0 3 AM)(H2 0 )(CF3 8 0 2 ) 2
where dashed lines indicate the hydrogen-bonding interactions of the 
coordinated water molecule and 2  triflate anions
In Chapter 1, the desirable characteristics of a contrast agent were discussed. Table 4.2 
summarises these properties along with the properties of GdD03P and Gd(D03PAM).
Table 4.2 Desirable properties of a contrast agent.
Properties Gd(D03P) Gd(D03PAM)
Adequate relaxivity y y
Water solubility y y
Amenable synthesis y y
In vitro stability ? ?
In vivo stability ? ?
In the investigations conducted to date, both Gd(D03P) and Gd(D03PAM) have 
properties that are considered desirable in a contrast agent. As well as possessing adequate 
relaxivity, both complexes are highly water-soluble. This allows substantial doses to be
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administered in smaller volumes. Additionally, the synthesis of the corresponding ligands 
was readily accessible. Due to time constraints, no stability or specificity studies were 
conducted on Gd(D03P) or Gd(D03PAM).
Thermodynamic stability ultimately determines the tendency of the Gd^^ ion to dissociate 
from the complex, while the dissociation rate constant ( f^) measures the rate of that process 
(Equation 4.3).
kf
Gd^+ + Gd^+(L) where i^eq= 4 /^ d  (4 .3 )
h
The dissociation rate, which is generally the reverse reaction of Equation (4.4), is only 
measurable in acidic media. Thermodynamic stability data is especially useful in 
formulation work, where aqueous preparations of contrast agents are often stored for long 
periods at room temperature. However, good kinetic stability is a more important property 
of the complex than good thermodynamic stability. The complex only needs to be stable 
whilst in vivo which is for a few hours at most. Table 4.3 shows that the three clinically- 
available complexes have large thermodynamic stability constants (For comparison, iron 
binding by transferrin has log Xeq = 22). As a result of strong chelation, these complexes 
should have long shelf lives.
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Table 4.3 Equilibrium constants, dissociation kinetics and endogenous ion competition 
for selected Gd^^ complexes
Complex Log {KqcJ 
M’ )^
tm-> dissociation 
[H^] = 0 . 0 1
Reaction with 
25 m M Z n(H )/P O /'
Gd(HPD03A) 23.8 1.3 days < 1 %
Gd(DOTA)- 25.8 95 days < 1 %
Gd(DTPA)^- 2 2 . 1 < 2 s 2 1  %
To assess the effect of endogenous ions upon the relaxivity of a complex, a zinc ion stress 
test can be performed. This test measures the free Gd^^ formed in 15 min after mixing the 
Gd chelate with zinc cations in a phosphate medium Table 4.3 shows that the combined 
stress of phosphate and Zn(II) ion was enough to cause significant dechelatation (21 %) of 
Gd(DTPA)^’ in 15 min, but the macrocyclic complexes remained essentially unaffected. 
Additionally, Gd(DTPA)^' was found to be very unstable in the presence of acid and 
dissociated after just 2 sec. Overall, it seems the most important structural feature affecting 
the relative stability and dissociation of a complex is the presence or absence of the 
macrocycle.
As both Gd(D03P) and Gd(D03PAM) are heptadentate, it is important that they undergo 
both stability and specificity studies. Lanthanide complexes with 2 water coordination sites 
are known to bind endogenous anions such as phosphate and bicarbonate. These ions can 
displace inner sphere water molecules leading to a lowering of relaxivity Although 
no heptadentate, q = 2 complexes have yet been approved for clinical use, several q = 2 
have recently been reported with strong safety and relaxivity profiles A recent entry in 
this small group of promising, heptadentate ligands is the triaminotetracarboxylic ligand, 
AAZTA (Figure 4.12)
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Figure 4.12
HOOC COOH
COOH
COOH
Structure of the heptadentate ligand, AAZTA .
The corresponding Gd^  ^ complex of AAZTA was found to have adequate stability. The 2 
coordinated water molecules of Gd(AAZTA) ensure a high relaxivity (7.1 mM~  ^ s"\ 20 MHz, 
25 °C) which was not quenched by bidentate anions such as lactate and phosphate as observed 
in similar heptadentate complexes. Complexes like Gd(AAZTA) demonstrate that not all 
heptadentate complexes are adversely affected by the presence of endogenous ions. Since the 
contrast agents currently available are considered by radiologists as not sensitive enough 
research and interest will continue into ways of boosting their relaxivity and that 
includes looking at complexes with higher hydration numbers.
An important factor in the tolerance of contrast agents is the hyperosmolality^ of their 
aqueous solutions The osmolality of blood and extravascular water is 0.3 0 sm/kg-H2 0 . 
Intravenous injection of a hyperosmolar contrast medium with an osmolality > 0.7 
0 sm/kg-H2 0  can cause pain to the patient.
An osmole (Osm) is the number of moles of a chemical compound that contribute to a solution's osmotic 
pressure Osmolality is a measure of the osmoles of solute per kilogram of solvent. Hyperosmolality is 
the abnormal increase in the osmolality of a solution, especially a body fluid.
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Figure 4.13 Effects from the injection of a hyperosmolar contrast agent
As shown schematically in Figure 4.13, the body responds to an injection of hyperosmolar 
solutions by transferring water from the surrounding areas to the blood. Loss of water from 
the cells in these areas cause them to shrivel. Other effects of raised ion concentrations 
include a reduction in blood pressure and elevation of blood volume which may lead to 
cellular and circulatory damage. To combat these side-effects, Bracco Research developed 
the nonionic contrast agent, ProHance ProHance is Gd(HP-D03A) and has a high 
osmotolerance (Figure 4.14).
•OH
Figure 4.14 Gd(HP-D03 A) or ProHance.
In ProHance, the ligand consists of D03A with an hydroxyalkyl group on the fourth 
amine. The uncharged oxygen on the hydroxyalkyl arm coordinates with Gd^^ to give an
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octadentate, charge-neutral (nonionic) contrast agent. As ProHance is non-ionic and 
octadentate, it is well-tolerated and stable in vivo. Indeed, it is the only example of a 
commercial MRI agent that is both macrocyclic and nonionic. Table 4.4 shows that the 
osmolality of a 0.5 M aqueous solutions of non-ionic, ProHance is 2 to 3 times less than 
that of the ionic complexes, Na[Gd(DOTA)] and NMG: [Gd(DTP A)].
Table 4.4 Osmolality of selected Gd^^ complexes (0.5 M) at 37 °C
Complex Ion type Osmolality
(0sm/kg-H:0)
Gd(HP-D03A) non-ionic 0.63
Na[Gd(DOTA)] ionic 1.35
1 : 1
NMG: [Gd(DTPA)] ionic 2 . 0
2 : 1
blood 0.3
Like D03A, the ligands D03P and D03PAM are conveniently tri-A-substituted. This 
allows their properties to be fine-tuned by adding a functional moiety onto the 
unsubstituted amine group. Using ProHance as an example, D03P could be alkylated with 
l-bromopropan-2-ol and then complexed with gadolinium to give the ProHance analogue
4.10 as outlined in Scheme 4.7. Alternatively, a group which does not coordinate Gd^  ^
could be added at the unsubstituted amine, thus allowing greater relaxivity values.
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HO
O'
HO
O
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/  \
N NH
N N
3.11
Br
OH
O “ \
-OH
P
OH
GCI2 O3
O' '0 ‘
4.10 (a ProHance analogue)
Scheme 4.7 Fine-tuning of D03P to give 4.10: a possible example.
In summary, complexes of the ligands D03P and D03PAM were prepared and 
characterised. Their n  values (mM‘  ^s'^) were found to be in good agreement with literature 
values for complexes of similar structure and hydration number. Gd(D03P) possesses 
three carboxyl groups whereas Gd(D03PAM) has three amide groups for coordination to 
Gd^ .^ In addition, both complexes have a free amine group on the cyclen ring and can be 
further derivatized. For example, a linker group or a targeting biomolecule could be added 
at this location.
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5.1 Summary
Research into targeted contrast agents is currently taking place in all the major imaging 
techniques The first generation of MRI contrast agents, currently in clinical use, are 
small-molecule, extracellular agents such as Gd-DOPA and Gd-DTPA (Figure 5.1).
-o(Gd] 1.1
OoC
CO
1.2
Figure 5.1 Structures of Gd-DOTA (1.1) and Gd-DPTA (1.2).
These CAs distribute non-specifically throughout the plasma and are normally excreted 
within 1.5 hours. Better relaxivity and targeting ability are key requirements for the next 
generation of contrast agents as more innovative MRI applications are envisonaged. With 
this in mind, a major goal of this project (see Section 1.10, Chapter 1) was to develop a 
bifunctional chelating agent (BFCA) with improved targeting ability (Figure 5.2).
HO NH
1.29OH OH
NH
NH
Site of attachment for 
targeting biomolecule 
e.g. biotin, folic acid.
Fi gure 5.2 Structure of the bifunctional chelating ligand (1.29).
Based on the cyclen molecule, the ligand (1.29) is bifunctional as it possesses 3 carboxyl 
groups to co-ordinate with Gd^  ^ as well as three conjugation reactive groups (primary
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amines). Conjugation of a nucleophilic amino moiety to carrier molecules (e.g. antibodies, 
peptides, steroids) is a well-assessed method of obtaining pharmaceuticals that display high 
organ or tissue selectivity For example, conjugation of the amino acid, folic acid,
to a nano-agent enabled uptake of the agent into tumour cells
Initial approaches to the preparation of a bifunctional chelating agent focussed on the 
alkylation of cyclen with mesylated 4-amino-3-hydroxy-butyric acid (2.9). This reaction 
resulted in elimination of the mesylate from the secondary substrate to give the trans 
alkene (2.10) in a high yield (Scheme 5.1).
>  0 = 8 = 0   ^  H
h'' \— /  \  I /
1 eq. 2.9 (3.5 eq.) 2.10
Scheme 5.1 Alkylation of cyclen with the secondary amino acid derivative (2.9).
In an attempt to circumvent elimination, the primary bromide (2.27) was prepared and 
reacted with mono-A-acetyl cyclen (2.26: Scheme 5.2). Although the alkene (2.32) was the 
main reaction product, some tri-substitution (~ 15 %) of mono-A-acetyl-cyclen occurred to 
give the tetra-substituted product (2.31).
NH
V
/  \__ / °  f f  H HN— C/
2.26 (1.0 eq.) 2.27 (3.2 eq.) 2.31 (15 %) 2.32 (80%)
Scheme 5.2 Alkylation of cyclen with the primary amino acid derivative (2.27)
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As the ratio of substitution to elimination in the above alkylation reaction was low, the 
Michael addition of cyclen to activated alkenes was investigated as an alternative route to 
functionalised cyclen derivatives. Although a large body of literature concerning the 
Michael reaction exists for carbon nucleophiles, specific reactions involving 
azamacrocycles are still quite limited. Reaction of cyclen with acrylamide (7 eq.) in 
methanol gave the tri-amide cyclen D03PAM (3.9) in a yield of 70 %. Hydrolysis of 3.9 
was then achieved with 12 M aqueous HCl to give the triacid, D03P (3.11) in a yield of 
90 %.
o
\  H 9 \  HgN- \ ______/---- V H
N H C— NHg MeOH N n'
.  )
H \ ---- /  H------------------------------------------------------------------------------------------- -^--- /  ^ ' ^ w NH2
O O1 eq. 7 eq. acrylamide
12M HCl
O
HO
90%
H
C"“ "3
N n ;
H O ^  ^  \ V ^ O H
o o
Scheme 5.3 Reaction of cyclen with acrylamide to give the tri-substituted cyclen (3.9).
The Michael addition of cyclen to acrylamide was regioselective as the tri-amide 
substituted cyclen (3.9) was the major product. This unexpected result meant that the 
mono-A-protection and deprotection of the cyclen ring after addition were unnecessary. 
Selective methods for the A-substitution of cyclen are central to most syntheses of cyclen- 
based ligands. Both 3.9 and 3.11 possess free amino groups which are available for further
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derivatisation. Encouraged by this result, the addition of cyclen to other Michael acceptors 
was investigated.
The alkene, methyl-2-acetamidoacrylate (3.25), has previously been employed to prepare 
amino acid derivatives via aza-Michael addition Reaction of 3.25 with mono-A^-Z- 
cyclen (3.28) only produced the di-AAsubstituted product. However, it was found that 
addition of a catalytic amount of triflic acid to the reaction mixture resulted in the 
formation of the fully-substituted cyclen compound (3.29: Scheme 5.4). 3.29 was produced 
in a yield of 70 % at room temperature.
CF3SO3H(0.7eq.) °
^  V   ► [ 3.29 ]
H \ /  'H 
3.28
n iv
3.25 (3.5 eq.)
N n i\— ^ 70 % ^
T y = o  hn^Y
Scheme 5.4 Triflic acid-catalysed addition of mono-AAZ-cyclen to methyl-2- 
acetamidoacrylate (3.25).
Deprotection of 3.29 turned out to be problematic. Once the benzyloxycarbonyl group was 
removed via catalytic hydrogenation, the product (3.30) was heated with 12M HCl at 60 °C 
(Scheme 5.5). This hydrolytic reaction produced the desired bifunctional ligand (3.31) as 
well as a significant amount of unwanted di-substituted cyclen (3.32).
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<  12M H C I(aq .) / N  NH NH
^  ^ . 4 ?-^ ■ '■“AHoN
r  T
Scheme 5.5 Deprotection of 3.30 with 12 M aqueous HCl.
Reaction of cyclen with 3.5 eq. ethyl-c/5 -p-cyanoacrylate (3.33) in dry acetonitrile at room 
temperature afforded the tri-#-substituted ligand, 3.34 (Scheme 5.6). The addition was 
regioselective with cyclen attacking the side of the alkene opposite to the nitrile group. 
This regioselectivity can be explained by the stronger electron-withdrawing ability of the 
nitrile group in comparison to the ester moiety.
,_, ^ 6  /N N,/ \ /H —^ p ,_N r
N N /
, + M
 / \  H H 30 % 0 ^ - 0
1 eq. 3.33 (3.1 eq.) 3.34
Scheme 5.6 Regioselective addition of cyclen to ethyl-cw-p-cyanoacrylate (3.33).
Gadolinium complexes of the ligands D03P (3.9) and D03PAM (3.11) were prepared by 
using GdiOs and GdCls as the source of the Gd^’*’ ion, respectively (Figure 5.2). The Ti 
spin-lattice relaxation times of the complexes were measured in H2O using a Minispec 
mq60 NMR analyser. The Ti-relaxivity values (n) of Gd(D03P) and Gd(D03PAM) were 
determined to be 4.0 and 4.6 mM'^ s'^  respectively (Table 4.1, Figure 5.2). These values are 
in good agreement with literature values for complexes of similar structure and hydration 
number.
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4 .2
rj = 4.0
(60 MHz, 25°C)
HgN
4 .3
NHz r i  = 4.6
(60 MHz, 25°C)
HoN
Figure 5.2 Structures of Gd(D03P), 4.2 and Gd(D03PAM), 4.3.
Both Gd(D03P) and Gd(D03PAM) demonstrated properties which are considered 
desirable in a contrast agent. As well as possessing adequate relaxivity and good water- 
solubility, the preparation of both complexes (and their corresponding ligands) were easily 
achieved.
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5.2 Future work
This project has opened up several avenues for further research. More immediate 
objectives relate to the synthetic transformations of the ligands 3.30 and 3.34. As regards 
the ligand 3.30 (Scheme 5.5), a deprotection procedure which prevents the loss of a 
pendant arm is required (see Section 3.7.3, Chapter 3). It is possible that deprotection of 
3.30 with a base such as LiOH may solve this problem. With respect to the ligand 3.34, 
reduction of the nitriles to amines followed by hydrolysis of the ethyl ester groups offers a 
route to the bifunctional ligand, 3.35 (Scheme 5.7).
3 .3 4
NH
(i) reduction of CN
 ►
(ii) hydrolysis of esters
NH
HO.
•NH
HO
3 .3 5
NH
'OH
Scheme 5.7 Preparation of the bifunctional ligand (3.35)
The first step of this subtle transformation requires the use of a chemoselective reducing 
agent; this reagent should be able to reduce nitriles to amines in the presence of ester 
groups. A reagent which may achieve this first step is sodium acetoxyborohydride or 
NaBH3 (OCOCF3). Sodium acetoxyborohydride has previously been used to effect the 
reduction of nitriles to amines whilst leaving ester groups in the same molecule 
unaffected It can be conveniently prepared in situ from NaBH4 and CF3CO2H. Once the 
hydrolysis of 3.30 and the transformation of 3.34 are achieved, two novel bifiinctional 
macrocyclic ligands, namely 3.31 and 3.35, will be produced.
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The ligands 3.9 and 3.11 (Scheme 5.3) are conveniently tri-A-substituted; this allows the 
fourth unsubstituted amine to be further derivatised. A targeting biomolecule or a linker 
moiety can be introduced here (Scheme 5.8). In the design of bifunctional chelates, a linker 
group is often employed to keep the biomolecule distant from the chelate This
strategy minimises any possible chelate interference in the binding of the biomolecule to 
its receptor.
o
N N
H a N ' ^  ^  H  ^  V _ M n  J
N linker group (5 .1 ) f 5.2 J
H a N ^  ^   "  H . N - ^ " - - V N H a
o o
NaBHj
t
P
N N,
C, JN N‘
o o
Scheme 5.8 Introduction of a linker group into the ligand (3.9)
With regards to the gadolinium complexes, both Gd(D03P) and Gd(D03PAM) (Figure 
5.2) need to undergo stability studies. Since the stability of these complexes in solution 
may be compromised by their heptadenticity (see Section 4.6, Chapter 3), preliminary in 
vitro tests should indicate their potential for use as MRI contrast agents.
Macrocyclic ligands based on DOTA are widely employed as radiopharmaceuticals 
because they form complexes that exhibit high thermodynamic stability and kinetic
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inertness The chemistry developed in this project can, in principle, be exploited to
prepare bifunctional chelators for complexing radioactive metal ions for use in other 
imaging techniques. The choice of radiometal depends on whether the radiopharmaceutical 
is to be used for diagnostic or therapeutic purposes. For radiopharmaceuticals, ligands that 
provide higher denticity are preferred as they demonstrate enhanced complex stability. 
Additionally, radiopharmaceuticals do not need to coordinate water molecules which is a 
key requirement for MRI contrast agents Higher denticity can be accomplished by 
incorporating extra donors into the linker arm. Scheme 5.9 shows one possible 
derivatisation of the ligand (3.11) for use as a bifunctional radiochelator.
HOgC^
HO2C
.N NH
HO2C
Br
5.4
^ ^ N C S
CO2H
NCS
\__ / COoH
5.6
/  (i) mAB (ii) Lu177
o
0 -C
NCS-mAB
0 - " —-o
Scheme 5.9 Preparation of the bifunctional chelator (5.6) for the radiolabeling 
of biomolecules.
In summary, the synthetic methods developed in this project have broad applicability and 
can be applied to the preparation of macrocyclic ligands for use as either MRI contrast 
agents or radiopharmaceuticals.
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6.0 General
Chemicals
Cyclen (1,4,7,10-tetraazacyclododecane) was purchased from Strem Chemicals, USA. 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) was purchased from 
Sigma-Aldrich. Dry DMF was purchased from Fluka. Dry acetonitrile was purchased from 
Acros. Potassium carbonate was dried at 105 °C for 1 hour before use. 4A and 3A (for 
alcohols only) molecular sieves were activated in a furnace at 300 °C for 3 hours before 
use. Tetrahydrofuran was distilled from potassium and benzophenone, dioxane was 
distilled from lithium aluminium hydride, chloroform and chlorobenzene were distilled 
from calcium hydride. All solvents were distilled under nitrogen and stored over 4A 
molecular sieves.
Column chromatographv 
Column chromatography was performed on silica unless otherwise stated. Alumina (Type 
507C, neutral) was purchased from Fluka. Thin layer chromatography was carried out on 
Fluka silica or alumina plates with fluorescent indicator. TLC Spots were visualised with 
iodine vapour, UV light or with potassium permanganate spray (KMn0 4 ; water, 0.1 % 
w/v). Compounds containing cholic acid were visualised with phosphomolybdic acid, 
brominated compounds were stained with fluoroscein and ninhydrin was found to be 
particularly useful for detecting cyclen compounds (see Appendix A).
NMR and Ti relaxivitv measurements 
NMR and ^^ C NMR data were obtained using a 300 MHz JEOL instrument. Chemical 
shift values are recorded in parts per million (ppm) from tetramethylsilane (TMS) as the 
internal standard for ^H spectra and from the solvent peaks for ^^ C spectra. Multiplicities 
are given as s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet and br-broad signal.
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Coupling constants are expressed in Hz. The longitudinal water proton relaxation rates of 
the complexes were measured at 59.97 MHz and at 25 °C on a Bruker mq 60 NMR 
analyzer (Bruker Canada, Milton, Ontario, Canada). Gadolinium complexes and GdCls 
were dissolved in ultra-pure water.
Mass spectra
Mass spectra were recorded on a VG Quattro spectrometer, equipped with an electrospray 
ionization source (ESI). The spectrometer was coupled to a Waters HPLC system. 
Electrospray was normally used in the positive ion mode (ES+) and the samples were 
diluted in H2O: MeOH (50:50). Accurate mass spectrometry was kindly carried out by 
EPSRC National Mass spectrometry Service Centre, Department of Chemistry, University 
of Wales Swansea, Swansea, SA2 8 PP.
Other analvses
Melting points were measured using an Electrothermal digital melting point apparatus and 
are uncorrected. Infra-red spectra were recorded as neat films, nujol mulls or KBr discs 
using a Perkin-Elmer 1710 infrared fourier transform spectrometer. Elemental analyses 
were performed by Medac LTD, Brunei Science Centre, Cooper’s Hill Lane, Englefield 
Green, Egham, Surrey TW20 OJZ. X-ray structures were kindly determined by EPSRC 
National Crystallography Service, School of Chemistry, University of Southampton.
New compounds
New compounds are indicated with an asterisk * whereas a new method for preparing a 
known compound is indicated with a double asterisk
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6.1 Estérification of 4-amino-3-hydroxybutyric acid to give 2.7.
+  H O ^  --------- ^  : ^ ^ N H 3 - 03 S ^
HO
OH 8 8  %
2 .6  2 .7
To a suspension of 4-amino-3-hydroxy-butyric acid (2.5 g, 20.9 mmol) in absolute ethanol 
(100 ml), / 7-toluenesulfonic acid (4.79 g, 25.18 mmol) was added with stirring. 2.6 was 
found to dissolve after the addition of />-TSA. The resulting solution was heated under 
reflux for 24 h. After the alcohol was removed under reduced pressure, EtiO (100 ml) was 
added to the resultant oil which induced the formation of a white solid. After the solid was 
stirred with the Et2 0  vigorously for 15 min, the solvent was decanted. This procedure was 
repeated to remove excess /?-TSA which was found to be soluble in Et2Û. The crystals 
were washed on a Buchner funnel with a third aliquot of Et2 0  (100 ml). As the product 
was very hygroscopic, it was dried in a dessiccator over P2O5 for 24 h. 2.7 was obtained as 
a white solid. Yield: 5.9 g ( 8 8  %). m.p. 72-74 °C. 'h  NMR (300 MHz, CDCI3 , 8 ): 1.12 
(3H, t, V  6.96 Hz, CH3,), 2.25 (3H, t, V  7.14 Hz, Atom CH3,), 2.39 - 2.56 (2H, m, CH2),
3.02 - 3.07 (2 H, dd, V2.76 Hz and V  13.02 Hz, CH2), 4.05 (2 H, q, V7.14 Hz, ethyl CH2),
4.11 - 4.20 (IH, m, CH-OH), 7.20-7.23 (2H, d, V8.43 Hz,CH x 2-Arom), 7.55 (2H, d, V  
8.25 Hz, CH X 2-Arom); ‘^ C NMR (75 MHz, CDCI3 , 5); 14.09 (CH3), 21.28 (CH3), 40.22 
(CH2), 44.67 (CH2), 62.89 (ethyl CH2), 65.20 (CH-OH), 126.15 (Arom), 130.25 (Arom), 
140.23 (Arom), 143.28 (Arom), 173.52 (0=0); IR (v„ax / (cm '), KBr): 3076 (broad 
ammonium -NH3*), 1716 (ester 0=0), 1600 (arom), 1569 (NH bend), 1500 (arom), 1231 
(SO3), 1038 (0 0  stretch), 822, 685 (arom), 569 (NH). MS (+ES): 148 [M+H]\ 294 
[2M-I-H]'' (dimer).
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6.2 Synthesis of ethyl 4-[(Boc)amino]-3-hydroxybutanoate (2.8).
'" - O s S - G  H- X o V o X
EtgN (2 .2  eq .)  ^  . Î  \ /
7 5  %
2 .7  (1 e q .) 1.1 eq . 2 .8
2.7 (3.19 g, 10 mmol) and EtgN (2.1 ml, 15 mmol) were stirred in a mixture of dioxane: 
H2O (20:20 ml) in an ice-water bath. Di-^er^-butyldicarbonate (2.4 g, 11 mmol) was added 
in portions over approximately 10 minutes. The ice-water bath was removed and the 
mixture was allowed to stir at RT for 24 hours. As the pH of the solution was adjusted 
from 8.1 to 2.5 using IM HCl, an evolution of bubbles (CO2) was observed. The reaction 
mixture was then extracted with DCM (2 x 50 ml). The extracts were pooled, washed with 
water, dried over MgS0 4  and evaporated under reduced pressure. The residue was dried 
under high vacuum for 3 hours to remove traces of dioxane. 2.8 was obtained as a clear, 
colourless, viscous oil. Yield: 1.87 g (75 %). ^H NMR (300 MHz, CDCI3 , ô): 1.28 (3H, t, 
V  7.14 Hz, CH3), 1.45 (9H, s, Boc), 2.47 (IH, d, CH2-I, /3 .1  Hz), 2.49 (s, IH, CH2 -2 ),
3.07 - 3.17 (IH, m, CH-0), 3.93 (2H, t, CH2 ), 4.17 (2H, q, ’J7 .14  Hz, CH2 ), 5.07 (IH, br 
s, NH); ‘^ C NMR (75 MHz, CDCI3 , S): 14.09 (CH3), 28.31 (Boc CH3), 36.71 (CH2), 45.53 
(CH2), 60.85 (CH2-O), 67.71 (CH-OH), 79.58 (C,) 156.20 (CO), 172.49 (CO); IR (v„ax / 
(cm'') neat, film); 3387 (OH), 2927, 2854, 1723 (C=0), 1530, 1461. MS (+ES): 247 
[M+H]\
Note: DCM could be substituted for dioxane-H2 0  but using this aqueous mixture allowed 
the pH to be adjusted more accurately with a hand-held pH checker. One disadvantage of 
using dioxane is that it can take several hours under high vacuum to remove it because of 
its high boiling point. Dioxane removal was confirmed by the absence of a signal at ô 3.71 
in the ^H NMR spectrum and ô 67.02 in the ^^ C NMR spectrum.
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6.3 Mesylation of 2.8 to give ethyl 4-[(Boc)amino]-3-mesyl butanoate (2.9).
o  ^  a  EI3N (1.1 eq .)
+  0 = S = 0
OH "  I 0 = S = 0
2 .8  1.1 eq . 2 .9
Ethyl 4-[(Boc)amino-3-hydroxybutanoate (1.29 g, 5.2 mmol) and EtgN (0.88 ml, 6.3 
mmol) were dissolved in DCM (10 ml) and cooled on an ice bath. Methanesulfonyl 
chloride (0.66 g, 5.7 mmol) in DCM (10 ml) was added with stirring under N2 over 20 
min. After stirring on the ice bath for 10 min, the mixture was stirred at RT for 3 hours. 
The reaction mixture was washed with H2O (3 x 50 ml) and evaporated to give a pale 
yellow, viscous oil. Crystallisation of the oil was induced by adding acetone and 
evaporating off the solvent. Recrystallisation from toluene-hexane gave white crystals. 
Yield; 1.17 g (68.9%). m.p. 60-63 “C. ‘H NMR (300 MHz, CDCI3 , S); 1.27 (3 H, t, V7.14 
Hz, CH3), 1.45 (9 H, s, Boc), 2.47 - 2.49 (2H, m, CH;-N ), 3.07 (3 H, s, CH3SO3 ), 3.43 - 
3.55 ( 2 H, m, CH2-CO ), 4.17 (2H, q, V= 7.14 Hz, ethyl CH2), 4.98 (IH, br s, NH), 5.05 -
5.12 (IH, m, CH); "C  NMR (75 MHz, CDCI3 , 5); 14.06 (CH3), 28.30 (Boc CH3), 36.99 
(CH2), 38.21 (CH3 SO3), 43.95 (CH2), 61.14 (ethyl CH2), 78.04 (CH), 156.15 (CO),
169.65 (CO); IR (Vmax / (cm‘‘), KBr); 3398, 2982, 1728, 1520, 1337 (mesyl O-SO2-CH3),
1255,1177, (mesyl O-SO2 -CH3), 1029, 918, 870,785, 589, 523, 541,445. MS (+ES); 325 
[M-HH]t
173-
C h a p te rs Experimental
6.4 Alkylation of cyclen with 2.9 to give 2.10
2 .9  ( 3 .2  e q .)
A X
K2C O 3 ( 3 .2  e q .)
+  1 e q .
9 0 %
\
„Q
o
O H
H HN—{  \ 
■ /
2.10
Cyclen (0.16 g, 0.96 mmol), K2CO3 (0.42 g, 3.07 mmol) and MeCN (20 ml) were added to 
a 100 ml round-bottomed flask. 2.9 (1.0 g, 3.1 mmol) was dissolved in MeCN (20 ml) and 
added dropwise to the reaction over 30 min. After the reaction was allowed to stir at RT 
under N2 for 24 hours, the K2 CO3 was filtered off and the organic solvent evaporated to 
give a dark orange oil (0.69 g). This residue was purified on a silica gel column using a 
0-10 % gradient of MeOH in CHCI3 containing 0.2 % /PrNH2 . 2.10 eluted at 6 - 8  % MeOH 
to give a yellow oil which solidified on standing. Yield: 0.3 g (90 %). Rf 0.42 (I2 , 5 % 
MeOH in CHCI3 with 0.2 % iPrNHz). *H NMR (300 MHz, CDCI3 , 8 ): 1.23-1.31 (3H, m, 
CH3 ), 1.45 (9H, s, Boc), 3.00 (2H, t, V =  6.42 Hz, V =  6.96 Hz, C//2-CH3 ), 3.92 (IH, br s, 
NH), 4.09 - 4.23 (2H, m, CH2), 5.94 (IH, dt, V =  15.57, V =  2.0 Hz, HN-/7C=CH ), 6.92 
(IH, dt, V =  16.20 Hz, V =  4.9 Hz, CH-77C=CH); "C  NMR (75 MHz, CDCI3 , 8 ); 14.10 
(ethyl CH3), 28.28 (Bee CH3), 31.71 (CH;), 41.27 (CH2), 121.26 (HC=CH), 144.73 
(HC=CH), 155.56 (CO), 166.07 (CO); IR (v^x / (cm"'), KBr): 3355 (NH), 2980, 1700 
(Conj C=0), 1501,1244,1165,1042, 868,785, 658. MS (4-ES): 229 [M+H]’'.
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6.5 Synthesis of A-Boc(^er^-butoxycarbonyl)-L-Serine methyl ester (2.14).
O
\  /  O  O  . EtgN (2 .2  e g .) ^  -Q
HO' T  'o^  + A oA A A  Rn
NH3+C1- T  ^
o
2.12 1.1 e q . 2.14
L-serine methyl ester hydrochloride (2.0 g, 12.86 mmol) and EtsN (3.25 g, 32.14 mmol) 
were dissolved in a mixture of dioxane and H2O (20 : 20 ml). The solution was cooled on 
an ice-bath and di-fer^-butyldicarbonate (3.1 g, 14.14 mmol) was added in small portions 
over 15 min. The reaction was allowed to stir overnight under N2 . The pH of the reaction 
mixture was adjusted from 8 . 6  to 2.5 with 1 M HCl (20 ml) and extracted with CHCI3 (2 x 
75 ml). The organic extracts were washed with H2O (2 x 50 ml) and dried over MgS0 4 . 
After the CHCI3 was evaporated under reduced pressure, the dioxane was removed under 
high vacuum at 40 °C. The residue was subjected to high-vacuum for several hours to give 
2.14 as a clear, colourless, viscous oil. Yield: 2.37 g (84 %). *H NMR (300 MHz, CDCI3 , 
Ô): 1.46 (s, 9H, Boc), 3.79 (s, 3H, OCH3), 3.94 (dd, J =  3.84 Hz, 2H, CH2), 4.39 (br t, IH, 
CH), 5.48 (br s, IH, NH); "C  NMR (75 MHz, CDCI3 , S): 28.30 (Boc CH3), 52.67 (CH3), 
55.73 (CH), 63.59 (CH2), 157.61 (CO), 171.31 (CO). IR (v„ax / (cm'*), Nujol): 3438, 2982 
(CH), 1709 (C=0), 1505, 1456, 1439, 1394, 1369,1164,1121, 1063 (CO), 1031, 874, 850. 
MS (+ES): 220 [M+H]+.
-175
C h a p te rs  Experimental
6.6 Bromination of 2.14 with DPPE (2.15) and 1,2-DB (2.16).
Ph
.,Ph
Ph" P 2.15
O Ph O
HO   Br 'O " ' P h . y ^  p
+ //
HN._ ,  Cl °  Ph'
Br-
Cl-
-ci
Br 2.16
/ - A
2.14 Cl 2.17 (5 4  %) 2.18 (DPPE-Oj)
W-Boc-L-Serine methyl ester (2.5 g, 11.40 mmol, 1 eq.) and 1 ,2 -dibromotetrachloroethane 
(1,2-DB, 6.31 g, 19.39 mmol, 1.7 eq.) were dissolved in 70 ml THE. DPPE (1,2- 
bis(diphenylphosphino)ethane, 4.54 g, 11.4 mmol, 1 eq.) was added in portions over 10 
minutes. The reaction was allowed to stir at RT for 12h. The suspension was then filtered 
through a 2 cm plug celite on a Buchner funnel. The celite was washed with THE (2 x 1 0  
ml) and the combined filtrates evaporated under reduced pressure to give a yellow oil (9.86 
g). The oil was purified on a silica gel column (150 g) by successively eluting the column 
with DCM (300 ml), DCM with 1 % MeOH (450 ml) and DCM with 2 % MeOH (450 ml).
2.17 eluted at 1 - 2 % MeOH in DCM (Rf = 0.74, fluoroscein spray, 1% MeOH in DCM) 
whereas unreacted 1,2-DB eluted in neat DCM (Rf = 0.43). Fractions containing 2.17 were 
evaporated to give white solid. Yield: 1.73 g (54 %). m.p. 200-210 °C. ^H NMR (300 
MHz, CDCI3 , 8 ): 1.46 (9H, s, Boc), 3.71, 3.84 (2H, dd, V =  3.69, 3.66, Br-C%-CH), 3.81 
(3H, s, OCH3), 4.76 (IH, dt, J  = 3.30 Hz, CH2 -C//-NH), 5.41 (IH, d, V= 8.04 Hz, 
CH-N/7); ‘^ C NMR (75 MHz, CDCI3, 8 ); 28.29 (Boc CH3), 34.10 (CH2), 52.97 (OCH3),
53.92 (CH), 154.98 (CO), 169.70 (CO); IR (v„ax / (cm '), Nujol): 3436, 2983 (CH), 1751
(C=0), 1709, 1440, 1369, 1369, 1309, 1164, 1068 (CO), 1012, 852. MS (+ES): 283 
[M+H)\
176-
C h a p te rs  Experimental
6.7 Synthesis of mono-A-Boc cyclen (2.24)*.
O
w
/ — \  H ^C- 0
/N  N 0 0  EtsNd.Seq.) ^
" X o V o ^  —  L J
H  " H  H  H
1 eq. 1 eq. 2.24
A solution of di-^er/-butyl carbonate (1.9 g, 8.7 mmol) in CHCI3 (20 ml) was added slowly 
over 1 hour to a solution of cyclen (1.5 g, 8.7 mmol) and Et3N (0.97 g, 9.6 mmol) in CHCI3 
(25 ml). After the reaction was stirred for 24 hours at RT, the organic solvent was removed 
under reduced pressure. The remaining residue was purified by alumina (neutral) column 
chromatography using a gradient of 0-15 % MeOH in CHCI3 containing 0.5 % /PrNH2 .The 
title product 2.24 was a colourless, glassy, semi-solid. Yield: 1.4 g (59 %). A small amount 
of di-A-Boc-cyclen eluted first from the column. The mono-A-Boc cyclen eluted with 
5-6 % MeOH in CHCI3 containing 0.5 % /PrNH2 . Rf 2.24 = 0.62 (I2 , 15 % MeOH in CHCI3 
with 0.5 % tPrNHi). ‘H NMR (300 MHz, CDCI3 , 5); 1.48 (s, 9H, C(CH3)3), 2.8 (s, 4H, 
CH2), 3.0 - 3.1 (m, 8 H, CH2), 3.60 (d, V =16.4 Hz, 4H, C2+C2’); ‘^ C NMR (75 MHz, 
CDCI3 , S); 28.50 (Boc CH3), 46.85 (CH2), 48.7 (CH;, C2/C2’), 48.8 (CH2 , C2/C2’), 50.50 
(CH2), 51.00 (CH2), 80.71 ( C q ) ,  155.73 (Boc CO); IR (v„ax / (cm '), KBr): 3522, 2976, 
2818,1691 ( C O b o o ) ,  1464,1418,1366,1272,1250,1171,1100. MS (+ES): 272 [M+Hf.
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6.8 Alkylation of mono-A-Boc cyclen with 2.17 to give 2.25 .
ow
2.24(1.0 eq.) +
Br O'
2.17 (3.2 eq.)
Et,N 55%
H
N N■Q 
\
O \ 'N N
O
W
/ o
2.25
H
O
Mono-A-Boc-Cyclen (0.17 g, 0.61 mmol) and EtgN (0.27 ml, 1.95 mmol) were dissolved 
in MeCN (15 ml) in a 100 ml round-bottomed flask. 2.17 (0.55 g, 1.95 mmol) was 
dissolved in MeCN (10 ml) and added dropwise to the round-bottomed flask over 15 min. 
The reaction was allowed to stir under argon at RT for 30 min. and then the temperature 
was increased to 80 °C. After 24 h, the reaction mixture was evaporated under reduced 
pressure to give a yellow oil. This residue was purified on an alumina column using a 
gradient of 0-10 % MeOH in CHCI3 . 2.25 was obtained as a viscous, yellow oil. Yield 
(0.17 g, 55 %). ‘H NMR (300 MHz, CDCI3. 6 ); 1.48 (s, 18H, C(CH3)3), 2.48 (s, 4H, CHj),
2.65 (m, 4H, CHj), 2.81 (m, 4H, CHj), 2.9 (ra, 2H, CH;), 3.0 (t, 4H, CH;, V =  4.77 Hz), 
3.52 (CH3), 3.0 - 3.1 (m, 8 H, CH;), 3.4-3.6 (m, 4H, CH;); ‘’C NMR (75 MHz, CDCI3 , 5); 
28.50 (Boc CH3), 43.3 (CH;), 43.9 (CH;), 50.9 (CH;), 51.9 (CH;), 54.6 (CH;), 55.1 (CH;), 
56.2 (CH), 80.4 ( C q ) ,  80.7 (C,), 155.7 (Boc CO), 156.0 (Boc CO), 171.6 (CO). MS (+ES):
474.6 [M+H]*.
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6.9 Alkylation of mono-iV-Boc cyclen with 2.17 using THF/ H2O (30:1) as solvent
o o
THF/H2O (30:1)
'n"" \lC  °  NagCOa (4 eq.)
O ,  ^  HN^,P
2.24 2.17 (4 eq.) 2.14
Mono-A-Boc-Cyclen (0.075 g, 0.27 mmol) and Na2 COs.lO H2O (0.85 g, 1.09 mmol) were 
dissolved in THF/H2O (30:1 ml) in a 100 ml round-bottomed flask. 2.17 (0.31 g, 1.1 
mmol) was dissolved in THF (20 ml) and added dropwise to the round-bottomed flask over 
30 min. After stirring overnight, solid material was collected by filtration and the filtrate 
was evaporated in vacuo. This residue was purified on an alumina column using a gradient 
of 0-10 % MeOH in CHCI3 . 2.14 was obtained as a viscous, oil with a yellow tinge. Yield 
(0.072 g, 30 %). ^H NMR (300 MHz, CDCI3 , Ô): 1.46 (s, 9H, Boc), 3.79 (s, 3H, OCH3),
3.94 (dd, J =  3.84 Hz, 2H, CH2), 4.39 (br t, IH, CH), 5.48 (br s, IH, NH); MS (+ES): 220 
[M+H]\
Note: Although a peak corresponding to the disubstituted compound (2.25) was visible on 
LC-MS ([M+H]^ = 475), 2.25 was not isolated from the reaction mixture.
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6.10 Synthesis of mono-Y-acetyl cyclen (2.26)
1 eq. + 1  eq.
>  Cl
H \ ----- /  "h
O CHCU
6 0 %
2.26
N N
H H
A solution of acetyl chloride (0.69 g, 7.4 mmol) in chloroform (25 ml) was added dropwise 
over 90 min. to a cooled solution of cyclen (1.5 g, 7.4 mmol) in chloroform (50 ml). The 
reaction was allowed to reach ambient temperature and stirred for a further 12 hours. The 
organic solvent was removed under reduced pressure and the residue dissolved in H2O. The 
pH of the solution was adjusted to 11.0 with 5 % NaOH and re-extracted with CHCI3 (3 x 
50 ml). After drying over MgS0 4 , the organic extracts were evaporated under reduced 
pressure to give an oil. The oil was purified on a silica gel column with 5 % MeOH in 
CHCI3 containing 0.1 % /PrNH2 . Stirring of the resultant oil with acetone provided 2.26 as 
a white, crystalline, hygroscopic solid. Yield: 1.04 g (60 %). m.p. 187-190 °C, Rf=  0.25 
(Si0 2 , 10 % MeOH in CHCI3 with 0.2 % iPrNHz); ‘H NMR (300 MHz, CDCI3 , 5); 2.14 
(3H, s, CH3), 2.69 - 3.05 (12H, m, CH;), 3.62 (4H, m, CH;); "C  NMR (75 MHz, CDCI3 , 
5); 22.39 (CH3) 44.70 (ring CH;), 46.45 (ring CH;), 46.93 (ring CH;), 48.23 (ring CH;), 
172.15 (C=0); IR (Vm»x / (cm"'), KBr): 3513, 3362 (NH), 3294, 3200, 2934 (CH), 2783, 
2337, 1638 (N-C=0), 1424,1361,1267, 1017, 912, 598,493. HRMS (+ES): found [M+H]+ 
215.1868, C 10H22N4O requires 215.1866.
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6 .1 1  Synthesis of Y-acetyl-L-serine methyl ester to give 2 .2 9  .
HO
O
+
o
O EtgN ( 2 . 2  eq. ) |_|0 '
Cl
O'
NH3+CI
HN^
95% "c-II
O
2.12 1 eq. 2.29
L-serine methyl ester hydrochloride (5.0 g, 31.1 mmol) and triethylamine (7.14 g, 70.6 
mmol) were dissolved in CHCI3 (100 ml). Acetyl chloride (2.78 g, 35.3 mmol) in CHCI3 
(25 ml) was added dropwise over 30 minutes. The reaction was allowed to stir at RT 
overnight. The organic solvent was evaporated under reduced pressure and acetone was 
added to precipitate the bulk of the triethylammonium chloride ( 2 .2 9  was found to be 
soluble in acetone). However, the addition of acetone did not remove all of the 
triethylammonium chloride so the yellow residue was chromatographed on silica. The 
column was eluted with 5 % MeOH in DCM and then with 10 % MeOH in DCM. The 
relevant fractions were collected and evaporated under reduced pressure to give 2 .2 9  as an 
oil with a slight yellow tinge. The oil was dried in vacuo for several hours. Yield: 4.9 g (95 
%). R f = 0.36 (KmN0 4 ; 10 % MeOH in DCM). ‘h  NMR (300 MHz, CD3OD, 5 ):  1.72 (3H, 
s, CH3), 3.45 (3H, s OCH3,), 3.49 (IH, dd, V =  4.23 Hz, 4.20 Hz, HO-C//2-CH), 3.58 (IH, 
dd, V =  4.23 Hz, 4.20 Hz, HO-C//2-CH), 4.22 (IH, t, V =  4.38 Hz, CH), 4.55 (IH, br s, 
NH); ‘^ C NMR (75 MHz, CD3OD, 5); 22.68 (CH3), 49.85 (OCH3), 56.5 (CH), 63.0 (CH;), 
172.59 (CO), 173.63 (CO). IR (v„ax / (cm"'), film): 3277 (OH), 3083 (CH), 1736 (C=0), 
1771, 1545, 1438, 1377, 1226, 1149, 1081 (CO), 983, 756. MS (+ES): 162 [M +Hf, 322.7 
[2M+H] The spectral data agree well with published data for 2 .2 9
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6.12 Bromination of A^-acetyl-L-Serine methyl ester to give 2.27.
o DPPE (1 eq.) + 9
1,2DB(1.7eq.)inTHF
H N ^ O  2.29 H N ^ O  2.27
50%
2.29 (2.0 g, 11.04 mmol, 1 eq.) and 1,2 dibromotetrachloroethane (6.31 g, 19.39 mmol, 1.7 
eq.) were dissolved in 70 ml THF and 4.54 g DPPE (11.40 mmol, 1 eq.) was added in 
portions over 10 minutes. The reaction was allowed to stir at RT for 24 h. The suspension 
was then filtered through a 2.5cm plug of celite on a Buchner funnel. The celite was 
washed with THF (2x10  ml) and the combined filtrates were evaporated at 30 °C to give a 
yellow oil (9.86 g). This oil was purified on a silica gel column with 2 % MeOH in DCM 
containing 0 . 2  % /PrNH2 (zPrNHz was added to the eluent as the product tended to adsorb 
strongly to the silica gel). Fractions containing 2.27 were evaporated under reduced 
pressure to give an off-white solid. Yield: 1.27 g, (50 %). Rf = 0.48 (fluoroscein spray, 2.5 
% MeOH in DCM). m.p. 107-109 °C. ‘H NMR (300 MHz, CD30D, 8 ): 1.92 (3H, s, CH3),
3.67 (3H, s, OCH3), 3.72 (IH, d, J =  4.2 Hz, CH2), 3.35 (IH, t, 7  = 4.02 Hz, CH), 3.72 (IH, 
dd, V =  1.47 Hz, V =  3.84 Hz, CH2); ‘^ C NMR (75 MHz, CD3OD, 5); 22.23 (CH3), 32.56 
(CH2), 53.19 (OCH3), 54.89 (CH), 170.79 (CO), 173.27. Anal. Calcd (found) for 
CeHioBrNOs: C, 32.16 (33.51); H, 4.50 (4.84); N, 6.25 (5.99). IR (v^ax / (cm '), KBr): 
3436, 1749 (0-C=0), 1635 (N-C=0), 1521, 1442, 1376, 1242, 1046 (CO), 975, 778, 603. 
HRMS (+ES): found [M+H]'"222.9836 C6HioN0 3 Br requires 222.9839.
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6.13 Synthesis of A^-Z-L-Serine methyl ester (2.30).
O
^  A  ^  Î (2.2 eq.)
“ ■ '^ r ° * 0 ^ °  “ — - hnV
NH3 * -Cl ^  8 8  %
O
2.12 (1 eq.) 1.1 eq. 2.30
L-serine methyl ester hydrochloride (3.0 g, 19.28 mmol) and EtsN (4.29 g, 42.42 mmol) 
were dissolved in CHCI3 (50 ml). Benzylchloroformate (3.62 g, 2 1 . 2 1  mmol) in CHCI3 (25 
ml) was added dropwise over 20 minutes. The reaction was allowed to stir at RT for 3 h. 
The organic solvent was evaporated under reduced pressure at 40 °C (to remove the bulk of 
the Et3N). The residue was redissolved in CHCI3 (50 ml) and washed with 50 ml IM HCl 
(to remove traces Et3N and LSME starting material) and then with H2O (50 ml). After 
drying the extracts over MgS0 4 , the organic solvent was evaporated under reduced 
pressure. The colourless, viscous oil was dried for 6  h in vacuo. Attempted crystallisation of 
this oil from ethyl acetate-hexane, DCM-hexane and Et0 H-H2 0  solvent pairs proved 
unsuccessful. Yield: 4.39 g (87.9 %). R{=0.21 (UV, 2.5 % MeOH in DCM). ‘h  NMR (300 
MHz, CDCI3 , 8 ): 3.77 (3 H, s, OCH3), 4.15 (2 H, dd, V= 4.23 Hz, CH;), 4.59 (IH, t, V =
4.38 Hz, CH), 5.12 (2H, s, CHj-Arom), 5.74 (IH, br s, NH), 7.35 (5H, s, Arom CH); ‘^ C 
NMR (75 MHz, CDCI3 , S); 52.77 (CH3), 56.04 (CH), 63.29 (CH;), 67.24 (CH;), 128.28 
(CH Arom), 157.10 (CO), 170.98 (CO). IR (v„ax / (em'‘), film): 3374 ( OH), 2949 (CH), 
1716 (C=0), 1529, 1454, 1343, 1216, 1059 (CO), 981, 912, 743 (arom), 701 (arom), 457. 
MS (+ES): 254 [M+H]\
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6.14 Synthesis of 1-bromo-A^-Z-L-Serine methyl ester (2.28).
P DPPE (1 eq.) +
HO Y "  O 1,2 DB (1.7 eq.) in THF
2.30
O— 68 %
Br
HN-^
O 2.28
2.30 (6.0 g, 23.7 mmol) and 1,2 DB (15.43 g, 47.4 mmol) were dissolved in 75 ml THF in 
a 250 ml conical flask. The mixture was cooled on an ice-bath and DPPE (9.4 g, 23.7 
mmol) was added in portions over 10 minutes. The reaction was allowed to stir at RT 
overnight under argon and then filtered through a 2.5 cm plug of celite on a Buchner 
funnel. After washing the celite with THF (2 x 10 ml), the combined filtrates were 
evaporated under reduced pressure at 30 °C to give a yellow oil (19.9 g). The oil was 
purified on a silica gel column with DCM containing 1 % MeOH to give 2.28 as a white 
solid. Yield: 5.1 g, (67.8 %). Rf = 0.54 (fluoroscein spray, 1 % MeOH in DCM). ^H NMR 
(300 MHz, CDCb, 8 ): 3.74, 3.84 (2H, dd, V =  3.48 Hz, Br-C%-CH), 3.80 (3H, s OCH3 ,), 
4.82 (IH, dt, V= 3.3 Hz, CHz-CTf-NH ), 5.13 (2H, s, Cft-Arom), 5.63 (IH, d, V =  7.14 
Hz, NH), 7.37 (5H, s, CeHs); '^C NMR (75 MHz, CDCI3 , 5); 33.69 (CHa-Br), 53.09 
(OCH3), 54.31 (CH), 67.33 (CHa-Arom), 129.32 (benzyl CH), 155.54 (CO), 169.32 (CO). 
MS (+BS): 316.57 [M+H]\ 338.57 [M+Na]t
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6.15 Alkylation of mono-A-acetyl cyclen with 2.27 to give 2.31 and 2.32.
o
N N.
O
2.26(1.0 eq.)
N N
Br
+
O' 2.27 (3.2 eq.)
HN
H
C-
//O
o
o
EtgN (4 eq.)
V " C
oV
+
H H N — C
/
O
2.31 (15 %) 2.32 (80 %)
Mono-A-acetyl cyclen (168 mg, 0.78 mmol) and EtsN (0.30 g, 4 eq.) were dissolved in 
acetonitrile (20 ml) in a twin-necked round-bottomed flask (100 ml). 2.27 (0.7 g, 3.14 
mmol) in acetonitrile was added dropwise and the reaction allowed to stir at room 
temperature overnight under argon. The reaction was then heated at 60 °C for a further 
12 hours. Acetonitrile was removed under reduced pressure to give a viscous, orange oil 
(0.62 g). Purification of the oil was carried out on an alumina column with 5 % MeOH in 
CHCI3 . 232 (white solid); ‘H NMR (300 MHz, CDCI3 , 8 ): 2.14 (s, 3H, CH3), 3.85 (s, 3H, 
CH3), 3.85 (s, R=CH, CH2), 5.89 (s, IH, R=CH), 6.60 (s. IH, R=CH). MS: 255.1 [M+H]*. 
The title product (2.31) eluted as a viscous, yellow oil. Crystallisation of the oil was 
achieved by dissolving it in CHCI3 and adding EtzO dropwise until turbidity. Yield: 0.10 g 
(15 %) Rf 2.31 =  0.78 (5 % MeOH in CHCI3 ; KMn0 4 ). ‘H NMR (300 MHz, CDCI3 , 5): 
1.96 (s, 9H, NHCOC7 T3), 2.03 (s, 3H, CH3), 2 . 2  - 3.75 (m, 29 H, CH2 + CH), 3.33 (s, 3H, 
CH), 3.68 (s, 9H, CO2CH3), 4.61 (br s, 3H, NH); "C  NMR (75 MHz, CDCI3 , 8 ): 21.76
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(CHj), 23.03 (CH3), 48.35 (CH2), 50.90 (CH2), 51.27 (CH), 52.49 (CH3), 171.20 (CO),
172.65 (CO). HRMS (+ES): found [M+H]'" 644.3624 C28H49N7O 10 requires 644.3614.
6.16 Alkylation of cyclen with 2.28 to give 2.33 and 2.34
H H
N N
2.33 (4.2 %)
+
N N
_HN
N N
K2CO3
O
Br
HN'C'O
+
HN—C
/
/
%
2.28 (6.5 eq.)
2.34 (90 %)
To a suspension of cyclen (0.39 g, 2.3 mmol) and K2 CO3 (1.09 g, 3.5 eq.) in MeCN (25 
mL) was added 2.28 (2.5 g, 7.9 mmol, 3.5 eq.) in MeCN (25 mL) dropwise. The reaction 
mixture was stirred for 24 h at RT. LC-MS analysis indicated formation of mono- and di­
substituted cyclens. To promote substitution, an extra 3 eq. 2.28 (2.14 g, 6 . 8  mmol) was 
added and the mixture stirred for a fiirther 48 h. LC-MS indicated 2.33 had formed so the 
reaction was stopped. The K2CO3 was filtered off and the organic layer evaporated to give 
a yellow oil (3.32 g). Partitoning of this oil between water (50 ml) and CHCI3 (50 ml) 
successfully separated the mono-substituted cyclen (aqueous layer) from the di- and tri­
substituted cyclen products (organic layer). The organic layer was then dried over
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magnesium sulfate, filtered and evaporated to give a viscous, orange oil (2.74 g). The 
resulting oil was purified by chromatography using 5 % MeOH in DCM to give 2.34 as a 
colourless oil. Yield: 1.69 g (90.8 %). Rf = 0.84 (UV, CHzCk-MeOH, 9 : 1). ‘H NMR (300 
MHz, CDCI3): 3.75 (s, 3H, CH3), 5.09 (s, 2H, CH2), 5.65 (s, R=CH, CH2), 6.17 (s, IH, 
CH=R), 7.29 (m, IH, CH=R). MS (+ES): 257.5 [M+Na]^. 2.33 was obtained as a yellow, 
semi-solid. ( R f  = 0.56, CH2Cl2-MeOH, 9 : 1 ) .  Yield: 0.29 g (4.2 %). *H NMR (300 MHz, 
CDCI3): 2.63-2.86 (16H, m, cyclen CH2), 3.62 (9H, s, 3 x CH3), 5.03 (6 H, s, O-CH2-PI1), 
7.19-7.29 (15H, m, 3 x phenyl), 9.67 (3H, br s, 3 x NH); ‘^ C NMR (75 MHz, CDCI3 , 5):
52.67 (CH2), 66.85 (OCH2), 128.0 (Ph), 136.17 (Ph), 156 (NH-CO), 171.63 (C=0-0). 
HRMS (+ES): found [M+H]^ 878.4294 C4 4H59N7O 12 requires 878.4302.
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6.17 DCC-mediated coupling of 2-bromoethylamine to cholic acid.
Experimental
OH
HO
2 .4 2
DCC/ EtgN
2 .4 4
OH
Br
OHHO
2 .4 5
.Br
2 6 %
HN
'OHHO
2 .4 8
2 -bromoethylamine hydrobromide (0 . 2  g, 1 mmol), EtsN (0.16 ml, 1 . 1  mmol) and cholic 
acid (0.41 g, 1 mmol) were dissolved in DCM (20 ml). DCC (0.23 g, 1.1 mmol) was added 
in small portions over 10 min. As cholic acid was not fully-soluble, 2 ml DMF (dry) was 
added to the reaction mixture. The reaction was allowed to stir at RT overnight. The white 
dicyclohexylurea precipitate which developed was filtered off. The filtrate was washed 
with H2O (25 ml) and evaporated under reduced pressure. TLC of the residue on silica gel 
using 10 % MeOH in DCM showed up two spots, one with an Rf identical to cholic acid 
(0.16) and the second spot had an Rf =0.26. The residue was applied on to a silica column 
and chromatographed with 0 - 12 % MeOH in DCM. 2.48 eluted at 9 % MeOH in DCM. 
Evaporation of the solvent gave a white solid. Yield: 1.1 g (26.3 % based on 10 mmol 
cholic acid).
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A^-acylurea derivative of cholic acid (2.48)*.
HO ,„•«
2.48
m.p. 130-137 °C, R/ = 0.24 (PMA, UV active; 10 % MeOH in CHCI3); ‘h  NMR (300 
MHz, CDCI3 , 5): 0.68 (3H, s, I 8 -CH3), 0.89 (3H, s, 1 9 -CH3), 0.99 (3H, d, J =  6.1 Hz, 21- 
CH3), 1.08 - 2.52 (44H, m, aliph), 2.76 (IH, br s, NH), 3.45 (IH, m, CH), 3.68 (IH, m, 
CH), 3.85 (IH, d, / =  2.55 Hz, 7p-H), 3.97 (IH, s, 12P-H): 12.48 (CH3- I 8 ), 17.53 (21- 
CH3), 22.46 (I 9 -CH3), 24.72 (CH2), 25.32 (CH2), 25.47 (CH2), 26.30 (CH), 26.46 (CH2), 
30.90 (CH2), 31.45 (CH2), 32.69 (CH2), 34.58 (CH2), 34.72 (CH2), 35.42 (CH;), 39.54 
(CH2), 41.44 (CH), 41.74 (CH), 46.51 (CH), 46.83 (CH), 49.81 (CH), 68.45 (C^H-OH), 
71.94 (C’H-OH), 72.99 (C'^H-OH), 77.43 (CH), 154.17 (CO), 172.3 (C^‘‘0): IR (v„ax / 
(cm'*), KBr): 3347 (OH), 2932 (CH stretch), 1689 (amide I), 1610 (amide II, CO), 1527, 
1451, 1380, 1078 (CO stretch), 612. HRMS (+ES): found [M-t-H]'"615.4730. C 17H36N7O3 
requires 615.4731.
Note: The assignment of individual carbon and proton resonances was aided by comparison 
with reference spectra and by cross-referencing with data from a COSY
spectrum.
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6 .1 8  Estérification of cholic acid with jp-nitrophenol to give 2 .5 1  and 2 .4 8 .
1 eq.
OH
OH
'OH
2.51 (46%)
+  HO
+
NO2 1 eq.
OH
HN
OH
2.48 (23 %)
To a solution of cholic acid (4.1 g, 10 mmol) in 80 ml ethyl acetate and DMF (15 ml), 
^-nitrophenol (1.39 g, 10 mmol) was added. The reaction mixture was cooled on an ice 
bath and dicyclohexylcarbodiimide (DCC, 2.1 g, 10 mmol) was added with stirring. After 
20 h stirring at RT, the dicyclohexylurea (DCU) which precipitated was filtered off. The 
organic phase was washed with a 5 % sodium carbonate solution (100 ml), 4 x 50 ml water 
(to remove the yellow colour of ^ -nitrophenol). Evaporation of the solvent gave an orange, 
crystalline material. TLC of the product on silica using 10 % MeOH in CHCI3 showed two 
spots, Rf 2 .5 1  = 0.36 (uv-active,/?-np ester), Rf 2 .4 8  = 0.28 ( R f  cholic acid = 0.14). Both 
spots were detected with phosphomolybdic acid spray reagent. Although the R f  values of 
both compounds were similar, 1.7 g crude product was successfully purified on a silica gel 
column (52 g) using a gradient of 0 -11 % MeOH in chloroform.
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j!7-nitrophenyl ester of cholic acid (2.51).
NO2OH
2.51HO OH
Off-white crystals. Yield: 1.9 g (43.5 % based on 10 mmol cholic acid). R/=  0.31 (PMA, 
UV active; 10 % MeOH in CHCI3). m.p. 122-125 °C (Lit. 123-125 °C). *H NMR (300 
MHz, CDCI3): S 0.71 (3H, s, CH3. I 8 -CH3), 0.89 (3H, s, CH3 , I 9 -CH3), 1.06 (3 H, d, J  =
6.1 Hz, 2 I-CH3), 1.28 - 2.72 (27H, m, aliph H), 3.50 (IH, m, 3p-H), 3.86 (IH, d ,J =  2.58, 
7P-H), 3.99 (IH, s, 12P-H), 7.27 (2H, d, J=  10.8 Hz, arom CH), 8.27 (2H, d, J =  10.8 Hz, 
arom CH); ‘^ C NMR (75 MHz, CDCI3): 8  12.55 (CH3- I 8 ), 17.36 (CH3-2 I), 22.49 (CH3- 
19), 23.21 CH2), 26.52 (CH), 27.55 (CH;), 28.33 (CH;), 30.46 (CH2), 30.68 (CH;), 31.30 
(CH2), 34.68 (CH;), 34.74 (CH), 35.19 (CH;), 39.52 (CH;), 41.42 (CH), 41.83 (CH), 46.50 
(CH), 46.96 (C), 68.47 (C^H-OH), 71.94 (C^H-GH), 73.04 (C'^H-OH), 122.43 (arom CH), 
125.21 (arom CH), 145.2 (arom-NO;), 155.53 (0-C-arom), 171.79 (C^‘*=0); IR (Vmax 
KBr/cm '): 3392 (OH), 2928 (CH stretch), 2862, 2108, 1764 (C=0), 1692, 1641, 1517 
(conjugated NO2), 1448, 1343 (conjugated NO2), 1204, 1074, 1038, 984, 918, 858, 610. 
MS (+ES) 530 (MH+), 547 (MNH4 '^.
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6.19 Synthesis of 2.45* via cholyl j9 -nitrophenyl ester (2.51).
Experimental
OH
2.51 (1.0 eq.)
'OHHO
+ .NHgBr 1.5 eq.
OH
HO OH
30%
25
M '
H 26
,Br
2.45
To a cooled solution of cholyl /?-nitrophenyl ester (0.33 g, 0.64 mmol) and 2- 
bromoethylamine (0.198 g, 0.964 mmol, 1.5 eq.) in THF (60 ml, dry), EtgN (0.16 ml, 1.1 
mmol, 1.7 eq.) in THF (20 mL) was added dropwise over 30 min. After stirring the 
reaction for 12 h at RT, the organic layer was washed with 5 % NaH2C0 3  and then with 
water to remove free />-nitrophenol (yellow colour). After evaporation of the solvent, the 
residue was purified on a silica gel column using 10 % MeOH in CHCI3 to give 2.45 as an 
off-white solid. Yield: 0.15 g (30 %). R/=  0.35 (fluoroscein-peroxide; 10 % MeOH in 
CHCI3); m.p. 6 6  - 70 °C. 'h  NMR (300 MHz, CDCI3): 8  0.67 (3H, s, CH3 , I 8 -CH3), 0.88 
(3H, s, CH3 , I 9 -CH3), 1.01 (3H, d, y  =5.49 Hz, 2 I-CH3), 1.23 - 1.98 (19H, m, aliph H),
2.2 (3H, s, OH), 2.96 (2H, s, CH2), 3.45 (2H, m, CH), 3.79 (2H, t, 7 =  9.54 Hz, C^^Hz),
3.95 (IH, s, CH), 4.22 (2H, t , J =  9.51 Hz, C^% ), 8.02 (IH, hr s, NH); "C  NMR (75 
MHz, CDCI3): ): 8  12.48 (CH3 -I 8 ). 17.45 (CH3-2 I), 22.52 (CH3-I 9 ), 24.98 CH2), 25.32 
(CH2), 26.52 (CH), 27.62 (CHz), 28.33 (CH2), 30.46 (CHz), 30.68 (CHz), 31.01 (CHz),
34.68 (CHz), 35.30 (CH), 35.73 (CH), 36.49 (CH2), 68.31 (C’H-OH), 71.84 (C’H-OH),
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72.93 (C‘^ H-OH), 169.59 (C=0-N); IR (Vmax KBr/cm''): 3328 (OH), 2933 (C-H sir), 1660 
(amide I, CO), 1643 (amide 11, CO), 1533, 1451, 1369, 1078 (C-0 str), 981, 914, 690. MS 
(+ES): 434 [M-Br+H]^. MS (-ES): 512.4 [M-H]'.
6 .2 0  Synthesis of A-Boc-2-bromoethylamine ( 2 .4 6 ) .
Bf +H2 N -  0  0  pt.M /OO^n\  Q
2.44 1 eq.
" - " " " y
45-70 % ^
1.2 eq. 2.46
2-bromoethylamine hydrobromide (0.41 g, 2 mmol) and EtgN (4.4 mmol, 0.48 g) were 
added to a 1:1 mixture of dioxane and H2O (40 ml) on an ice bath. Di-^gr^-butyldicarbonate 
(0.148 g, 2.2 mmol) was added in portions over approximately 10 min. The ice bath was 
removed and the mixture was allowed to stir at RT for 24 hours. As the pH of the solution 
was adjusted to 2.5 with IM HCl, an evolution of C O 2  bubbles was observed. The reaction 
mixture was then extracted with DCM (2 x 50 ml). The extracts were pooled, washed with 
water, dried over MgS0 4  and evaporated in vacuo. The product was a clear, colourless, 
viscous oil. TLC on silica gave a single spot with an Rf = 0.48 (KMn0 4 ; hexane-Et2 0 , 
80/20). ‘H NMR (300 MHz, C D C I 3 ,  5) :  1.45 (s, 9H, Hoc), 3.38 - 3.55 (m, 4H, 2 x C H ; ) ,  
4.99 (br s, IH, NH); '^C NMR (75 MHz, C D C I 3 ,  5): 28.31 (Hoc C H 3 ) ,  32.78 ( C H z ) ,  42.32 
( C H 2 ) ,  79.75 ( C q ) ,  156.20 ( C O ) ;  IR (Vmax / (cm '), film): 3347 (NH), 2924, 2854, 2361, 
2342, 1725 ( C = 0 ) ,  1709, 1503, 1462. MS (+ES): 224 (M+H'). Note: yields for this 
reaction varied from 45 - 70 %.
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6.21 Alkylation of cyclen with A-Boc-2-bromoethylamine.
H N
H
:N N
■ i x
K2 CO3 (5 eq.)
2.46 ( 5 eq. )
HN
L , . J
A o X
Cyclen (78.4 mg, 1 eq.) and K2CO3 (0.32 g, 5 eq.) were refluxed with 2.46 (0.51 g, 5 eq.) 
in acetonitrile for 12 hours. LC-MS (+BS) of the product residue indicated that a mixture 
of tri-A-substituted cyclen ([M+H]^= 460) and tetra-A-substituted cyclen ([M+H]'^= 603) 
were formed. Attempted purification of the product residue on a silica gel column using a 
gradient of 0 - 15 % methanol in chloroform resulted in poor separation between 2.52 and 
2.47.
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6.22 Syntheses of l,4,7,10-tetrazacyclododecane-4,7,10-tripropanamide (3.9) and 
1,4,7,10-tetrazacyclododecane-1,4,7,10-tetrapropanamide (3.10)*.
1  eq.
)
NJ M
3.9 ( 70 % )
+
MeOH
+
HoN
O
H C— NHz
7 eq.
H H
0^ N H 2
HoN
3.10 ( 8 %)
■?
NHz
Acrylamide (2.5 g, 35 mmol) and cyclen (0.86 g, 5 mmol) were dissolved in 75 ml 
methanol. The solution was heated under reflux for 24 h. After most of the methanol was 
removed under reduced pressure, diethyl ether was added until a white solid formed. The 
resultant white solid was filtered, washed with ether ( 2  x 2 0  ml) and dried under vacuum. 
Separation of 3.9 from 3.10 was achieved on a silica gel column using 5 % ethanol in 
dichloromethane as eluent. 3.10 was obtained as a colourless, solid. Yield: 0.18 g 
hygroscopic, white solid ( 8  %). m.p. 174-177 °C. Rf = 0.62 (Ninhydrin; CHCI3 , MeOH, 33 
% aq. NH3 , 1:1:0.5 by volume respectively. ^H NMR (300 MHz, D2 O, 5): 2.27 (8 H, t, 
NCH2 , V= 6 . 8  Hz), 2.53 (16H, s, ring CH2), 2.60 (8 H, t, CH2CONH2 , 6 . 8  Hz). HRMS 
(+ES): found [M+H]"  ^457.3235. C19H45N4O8 requires 457.3232.
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H^ N '
V - N - X  \ „ ,
3
HgN
Yield 3.9: 1.35 g hygroscopic, white solid (70 %). m.p. 170-172 °C. Rf = 0.57 (Ninhydrin; 
CHCI3 , MeOH, 33 % aq. NH3 , 1:1:0.5 by volume respectively). ^H NMR (300 MHz, D2O, 
Ô): 2.29 (6 H, t, V =  6.7 Hz, NCH2CH2CONH2, 4), 2.42 (4H, br s, ring CH2 , 1), 2.55 (12H, 
br s, ring CH2 , 2+6), 2.62 (6 H, t, 6 . 8  Hz, N % C H 2C0 NH2 , 3); NMR (75 MHz, 
D2O, Ô); 32.36 (ÇH2CONH2 , 4), 45.15 (CH2 , 1), 50.01 (CH2 , 2 ), 50.42 (CH2 , 2 ), 50.59 
(CH2 , 2), 51.16 (CH2 , 3), 51.33 (CH2 , 3), 178.62 (C=0, 5), 179.11 (C=0, 6 ). Anal. Calcd 
(found) for C 17H35N7O3 • 1.0 H2O • 0.37 CH3 OH: C, 50.23 (50.41); H, 9.34 (9.12); N, 
23.60 (23.46). IR (v^ax / (cm"^), KBr): 3349 (NH), 3154 (NH), 2969 (CH), 2837, 1673 
(C=0), 1424. HRMS (+ES): found [M+H]^386.2878. C17H36N7O3 requires 386.2874.
Note: Individual carbon and proton resonances were assigned by data from a ^H - ^^ C 
COSY experiment and by comparison with the spectra of structurally-similar ligands
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6.23 Hydrolysis of 3.9 to give 1,4,7-tris-(2-carboxylethyl)-l ,4,7,10-tetrazacyclododecane 
(3.11)*.
HgN
O
HoN
3.9
N N
\  / P
NHg
12M HCl
 ►-
9 0 %
HO
d
HO
O
3.11 J
N N
\  / P
OH
+ 3NH4CI
3.9 (0.3 g, 0.78 mM) was dissolved in 10 ml HCl (12 M) and refluxed vigorously for 2 h. The 
reaction was switched off and allowed to cool overnight. The white solid which developed 
was filtered off and re-dissolved in H2O. After the H2O was removed by lyophilisation, the 
white solid was recrystallised twice from aqueous methanol. The product was then dried in a 
vacuum oven at 50 °C for 12 h to give 3.11 as a white solid. Yield: 0.27 g (90.1 %). m.p. 
180-183 °C. ‘h  NMR (300 MHz, D2O, S): 2.63 (6 H, t, V =  6 . 6  Hz, CH2CH2COOH), 3.01 
(22 H, br s, ring CH2 + arm NCH2CH2); ‘^ C NMR (75 MHz, D2O, 5); 28.83 (CH2), 49.07 
(CH2), 176.13 (C=0). Anal. Calcd (found) for C 17H32N4O6 • 1.0 H2O • 1.0 HCl: C, 46.1 
(45.9); H, 7.9 (7.7); N, 12.7 (12.5). IR (v„ax / (cm '), KBr): 3076 (OH), 1753 (C=0), 1411, 
798, 653. HRMS (+ES): found [M+H]'" 389.2395. C 17H33N4 O6 requires 389.2395.
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6.24 Reaction of cyclen with 1-cyanovinylacetate to give 3.17 (3.21)*.
H H
1  eq.
+
3.16 (3.1 eq.)
MeCN
40%
O - HO
DoO
N N
O
C ,
Cyclen (0.3 g, 1.74 mmol) was dissolved in dry acetonitrile (15 ml) under an argon 
atmosphere. Cyanovinylacetate (0.59 g, 3.1 eq.) was added in dropwise over 10 min. An 
off-white, solid began to precipitate out of solution after approx. 10 min. After 
centrifugation of the reaction mixture, the white precipitate was collected and purified by 
recrystallisation from aqueous acetonitrile. Yield: 0.24 g (40 %). m.p. 175 °C (with 
decomposition). NMR (300 MHz, D2O): 2.01 (br s, 16H, CH2), 3.52 (d, 8H, J=  6.3 Hz, 
CH2), 9 . 7 3  (t, IH, J  = 6.3 Hz, CHO); "C  NMR (75 MHz, D2O, 5); 50.42 (CH;). 65.42 
(CH;), 199.25 (CHO); Anal. Calcd (found) for C 16H28N4O4 : C, 56.45 (56.56); H, 8.29 
(8.07); N, 16.45 (16.56). IR (v„ax / (cm '), KBr); 3431 (OH), 2987, 2837, 1652 (enol, 
C=C-OH). HRMS (+ES); found [M+H]+341.2183. C 16H28N4O4  requires 341.2183.
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6.25 Synthesis of ethyl 3-hydroxy-2-nitropropanoate (3.24).
? CHgCOONa (1 eq.) HO OgN
OgN ,C +  H2C=0
COgEt
Ethyl 2-nitroacetate 3 3  % aq. formaldehyde ® %
(leq.) (1 .8  eq.) 3.24
An ice bath at -15 °C was prepared from ice, IMS and salt. Ethyl 2-nitroacetate (8.5 g, 
0.064 moles) and 33 % aqueous formaldehyde (10 ml, 0.12 moles) were added to a small 
conical flask and cooled on the bath. Sodium acetate (0.16 g in 1 ml H2O) was added with 
intensive mixing and the reaction was stirred for 3 h. The reaction was quenched by 
pouring the mixture onto 50 g crushed ice containing 1 ml conc. HCl. The oil that separated 
was extracted with Et2 0 . The Et2 0  extract was then dried over Na2 S0 4 . After evaporation 
of the Et2 0 , the oil was distilled in a short-path distillation apparatus under vacuum (0.3 
mm Hg). Three fractions were collected: Fraction A; b.p. 40 °C (1.23 g); Fraction B; b.p. 
44 °C (0.9 g); Fraction C; b.p. 80 - 105 °C (1.42 g). Fraction C was purified on a silica gel 
column (60 g) using 10 % ethyl acetate in DCM as eluent to give a colourless oil with a 
slight yellow tinge. Yield: 0.96 g (15.7 %). Rf = 0.39 (KMn0 4 , UV active; 10 % ethyl 
acetate in CH2CI2); 'H NMR (300 MHz, CDCI3 , 5): 1.33 (3H, t, V =  7.14 Hz, CH3 ), 4.28 -
4.38 (4H, m, CHCH2 CH2OH), 5.30 (IH, dd, 3.84, 4.02 Hz, CHNO2 ); ‘^ C NMR (75 
MHz, CDCI3 , 5); 13.73 (CH3), 60.82 (CH2), 63.45 (CH2), 88.36 (CHNO2), 162.86 (C=0); 
IR (Vmax / (cm-'), film): 3535 (OH), 1756 (CO), 1572 (NO2), 1375 (NO2). MS (+ES):
326.18 [2M+H]''. The spectral data above agree well with published data for 3.24
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6.26 Reaction of cyclen with ethyl 3-hydroxy-2-nitropropanoate (3.24).
Hs /H
/ N  N. NO 110 °C
+  I  ^  polymer
1 eq. 3.24 (4 eq.)
Chlorobenzene (b.p. 131 °C) was distilled from CaH2 at 150 °C. Cyclen (75.4 mg, 1 eq.) 
was dissolved in freshly-distilled chlorobenzene (15 ml) in a 50 ml twin-necked flask. The 
solution was heated to 110 °C under argon. Ethyl 3-hydroxy-2-nitropropanoate (0.36 g, 
1.75 mmol) was added through the side-arm. Addition of 3.24 caused the colourless 
reaction mixture to turn yellow and then to a deep red colour within 10 minutes. After 1 h, 
the reaction was stopped and the brown precipitate which had formed was filtered off. 
Attempts to dissolve the precipitate in methanol, chloroform and acetone were unsuccessful 
indicating a polymer had been formed. As the compound was insoluble in common 
solvents, an NMR could not be run.
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6.27 Synthesis of 1 -Benzyloxycarbonyl-1,4,7,10-tetraazacyclododecane (3,28)**.
\
O
N N r CHCI3
N N
+
1.1 eq
53%
1 eq. . 3.28
A solution of benzylchloroformate (2.7 g, 15.9 mmol) in CHCI3 (20 ml, dry) was added 
slowly over 1.5 hour to a cooled solution of cyclen (2.5 g, 14.5 mmol) in chloroform (50 
ml). The reaction was allowed to reach ambient temperature and then stirred for 12 hours. 
Some of the organic solvent was removed under reduced pressure and the reaction stirred 
vigorously after the addition of 5 % NaOH (75 ml). The organic layer was separated and 
the aqueous layer re-extracted with CHCI3 (2 x 25 ml). The organic extracts were pooled, 
dried over MgS0 4  and evaporated in vacuo. The resultant oil was purified on a silica gel 
column with 1% MeOH in CHCI3 containing 0.1 % /PrNH2 to yield an oil which after 
trituration with acetonitrile provided 3.28 as a white, crystalline solid (2.6 g, 53 %). A 
small amount of di-Z-cyclen eluted from the column first. mono-Z-cyclen = 0.51 (SiOz, 
5  % MeOH in CHCI3 . m.p. 146-152 °C; ‘h  NMR (300 MHz, CD3OD, 8 ); 3.13 (16H, m, 
ring CH2), 5.15 (2H, s, OCH2), 7.36 (5H, m, Ph); "C  NMR (75 MHz, CD3OD, 8 ); 47.87 
(ring CH2), 48.44 (ring CHz), 49.58 (ring CH2), 50.51 (ring CH2), 68.56 (OCH2PI1), 128.89 
(3-Ph), 128.93 (4-Ph), 129.08 (2-Ph), 129.37 (1-Ph), 157.52 (C=0): IR (Vm.x / (cm '), KBr): 
3391 (NH), 3183 (NH), 2959 (CH), 2837,2352, 1673 (C=0), 1455,1012, 776, 728 (arom), 
558, 456. MS (+ES); 307 [M+H]^. The spectral data above agree well with published data 
for the hydrochloride salt of 3.28
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6.28 Synthesis of 1 -Benzyloxycarbonyl-4,7,10-tris-(methyl-2-
acetamidopropanoate)-1,4,7,10-tetraazacyclododecane (3.29)*.
o
H ° V o ^  CF3SO3H(0.7eq.) °  N ^ N H
(  '1 V  + \= /  ► I 3.29 J
°  j ‘' r °3.28 3.25 (3.5 eq.) o' J
3.28 (0.25 g, 0.82 mmol) was dissolved in a 3:1 mixture of CH3CI and CH3CN (20 ml). 
Methyl 2-acetamidoacrylate (0.37 g, 2.61 mmol) was then added. Triflic acid (50 pi, 0.7 
eq.) was promptly added with an automatic pipette. This resulted in a clear solution which 
was then stirred under argon for 24 h. After the solvent was removed in vacuo, the residue 
was partitioned between 1 M ammonia solution (10 ml) and chloroform (20 ml). After the 
aqueous layer was washed with another 1 0  ml chloroform, the organic extracts were 
pooled and evaporated to yield a viscous, pale yellow oil. The resulting oil was dissolved 
in a small amount of CHCI3 and EtiO was added to induce crystallisation. A colourless, 
crystalline solid was obtained. Yield: 0.42 g (70.4 %). R f  2.29 = 0.62 (SiOz, 3 % zPrNH2 in 
CH2 CI2). m.p. 209 °C (with decomposition); 'H NMR (300 MHz, CDCI3 , 5); 1.98 (6 H, s, 
CH3), 2.06 (3H, s, CH3), 2.72 - 3.25 (20H, m, ring CH2), 3.69 (9H, s, CH3), 4.55 (m, 3H, 
CH), 5.80 (2H, s, OC/ZjPh), 7.24 (5H, m, Ph), 7.68 (br s, 3H, NH); NMR (75 MHz, 
CDCI3 , 5); 22.86 (CH;), 23.24 (CH;), 47.71 (CH2), 48.65 (CH), 52.49 (CH;), 68.56 
(0 CH2Ph), 127.98 (Ph), 128.69 (Ph), 130.95 (Ph), 170.19 (C=0), 172.19 (C=0). Anal. 
Calcd (found) for C;4H5;N7 0 n: C, 55.50 (55.10); H, 7.26 (7.61); N, 13.32 (13.06). HRMS 
(+ES): found [M+H^ 736.3871. C;4H5;N7 0 n requires 736.3876.
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6.29
Experimental
Deprotection of 3.29 to give 3.30 .
NH
3.29
v _ y
HN HN
10% Pd/C in 
EtOH / Hg
90%
NH
NH
3.30
HN HN
3.29 (0.40 g, 0.54 mM) was stirred in a suspension of 10 % palladium on carbon (50 mg) in 
ethanol (20 ml). A slow flowrate of H2 was bubbled through the suspension in a fume 
cupboard. After 12 h, the reaction mixture was centrifuged to remove the catalyst. The 
supernatant was treated with activated charcoal and filtered through a bed of celite. After 
the solvent was removed under reduced pressure, a viscous oil was obtained. Yield 3.30: 
0.29 g (90 %). ‘h  NMR (300 MHz, CDCI3 , 8 ): 1.99 (6 H, s, CH3), 2.05 (3H, s, CH3), 2.70 - 
3.20 (20H, m, ring CH2), 3.69 (9H, s, CH3), 4.55 (m, 3H, CH), 7.68 (br s, 3H, NH). MS 
(+ES): 603 [M+H]+.
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6.30 Hydrolysis of 3.30 with 12M HCl (aq.)
" K "
<  1 2 M H C I ( a q . )  NH
\  O HO
'Q NH
3.30 (0.28 g, 0.465 mM) was then heated with 12 M HCl (20 ml) at 60 °C for 3 h. After the 
acid was removed under reduced pressure, the residue was disssolve in EtOH (20 ml) and 
treated with activated carbon (0.25 g). The suspension was filtered through a bed of celite 
on a Buchner funnel and the filtrate was evaporated under reduced pressure. The resulting 
residue was recrystallised from aqueous EtOH to give 3.31 as an hygroscopic, white solid. 
Yield; 0.206 g (70 %). ‘h  NMR (300 MHz, D2O, 5): 1.84 (4H, s, 2 x  CH2 ), 2.57 - 3.10 
(18H, m,ring CH2), 4.60 - 4.70 (9H, br s, 3 x NHj'^; '^C NMR (75 MHz, D2 O, 5); 47.2,
48.6 (CH2), 176.61 (C=0). MS (ES*): 434 [M+H]*.
Note: A peak corresponding to the disubstituted compound (3.32) was also observable on 
LC-MS ([M+H]^= 347.2). The size of this peak relative to the peak corresponding to 3.31 
([M+H]"  ^= 434) increased in aqueous solution after 24 h.
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6.31 Synthesis of l,4,7-tris-(ethyl 2-cyanomethyl-ethanoate)-l,4,7,10- 
tetraazacyclododecane (3.34)*.
/  \  / H    ^ ,N  /
N N W  //
H H 20 %
1 eq. 3.33 (3.1 eq.) 3.34
Cyclen (0.20 g, 1.16 mmol) was dissolved in MeCN (15 ml) in a twin-necked, round- 
bottomed flask (25 ml). 3.33 (0.43 ml, 0.45 g, 3.59 mmol, 3.1 eq.) was added with an 
automatic pipette through the side-arm and the solution was stirred under argon for 1 2  h. 
The solvent was removed in vacuo to give an orange, viscous oil. The oil was purified by 
silica gel column chromatography using 2 0  % ethyl acetate in hexane to give a pale, yellow 
oil. Yield: 0.13 g (20 %), 3.34 = 0.74 (SiOi, 20 % ethyl acetate in hexane). NMR
(300 MHz, CDCI3 - CD3OD, 7 : 1 , 0 )  1.22 (6 H, t, 7.14 Hz), 1.29 (3H, t , J =  7.14 Hz), 
2.28 - 2.88 (21H, m, CH2+CH), 2.97; 2.91 (6 H, dd, J =  7.5 Hz, 7.5 Hz), 4.16 (4H, q, J  = 
7.14 Hz), 4.22 (2H, q, J =  7.14 Hz); ^^ C NMR (75 MHz, CDCI3 - CD3 OD, 7:1, Ô); 13.72 
(CH3), 13.83 (CH3), 35.80 (CH2), 36.36 (CH2), 43.39 (CH2), 45.24 (CH2), 47.67 (CH2), 
49.41 (CH), 61.16 (ethyl CH2), 61.83 (ethyl CH2), 114.11 (CN), 116.83 (CN), 168.77 
(C=0), 169.33 (C=0). IR (Vmax / (cm'^) neat, film): 3435 (broad NH), 2963, 2852, 2362, 
1747, 1655, 1542, 1438, 1376, 1262, 1218, 1095, 1032, 801.6. HRMS (+ES): found 
[M+H^ 548.3191, C17H36N7O3 requires 548.3195.
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6.32 Deionization of 3.11*HC1 using anion exchange chromatography to give 4.1 .
HO HO
O V  _H O V  /  \  H
N . Amberlite IRA-400
r J  - 2.5 HCl  ► r  4 . 1  ]
o  O H  O  O H
Amberlite IRA-400 (Aldrich, chloride form, 40 g) was stirred with 10 % NaOH (200 ml) 
in a IL beaker for 10 minutes. The colour of the resin changed from a light to a dark brown 
colour. Using a batch process, the resin was stirred vigorously with deionized H2O (250 
ml) on a magnetic stirrer. After a few minutes stirring, the stirrer was switched off and the 
resin allowed to settle. After careftil décantation of H2O, this procedure of washing- 
decantation was repeated with a ftarther 8  volumes (250 ml) of H2O. The pH of the resin 
was 9.4. Three further washings of H2O (3 x 500 ml) were required to bring the pH of the 
resin to 7.0. The resin was then packed into a squat glass column (3.5 x 15 cm) which was 
plugged with glass wool just above the on/off tap. Meanwhile, 3.11 (1.0 g) was dissolved 
in H2O (50 ml) and the pH was adjusted from 1.9 to 9.5 with 3.5 % aq. NH3 (~ 15 ml). The 
solution was applied to the ion-exchange column and successively eluted with water (spot- 
testing of the H2O eluate with AgN0 3  solution revealed eluted fractions were positive for 
chloride ions) and then with formic acid of increasing concentrations; 0.1, 0.25, 0.5, 
0.75 M. 4.1, which eluted from the column as a colourless oil with 0.5 M formic acid, was 
crystallized from EtOH and acetone. Yield: 0.39 g white, mobile powder (42.7 %). 
‘h  NMR (300 MHz, D2O, 5): 2.63 (6 H, t, V =  6 . 6  Hz, CHzC^COOH), 3.00 - 3.03 (22 H, 
br s, ring CH; + arm NC%CH;). MS (+ES): 386.9 [M+H]*.
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6.33 Synthesis of Gd(D03P) (4.2)
HO
d
HO
O
4 .1
N N
P
OH
reflux in HgO
+  G dgO g (1 .2  eq .)
89%
-O'
Q A " \
N ! N'
\
G d (D 0 3 P ) 4 .2
O ' O'
4.1 (0.28 g, 0.72 mmol) and GdzOs (0.126 g, 0.45 mmol) were refluxed in 8  ml water 
overnight. After 1 h, some white precipitate was observed in the flask. After the reaction 
was stopped, the suspension was filtered through a 0 . 2 0  micron polypropylene filter 
(Minisart RC 15, Sartorius) and lyophilised to give a white solid. Yield 4.2: 0.35 g (89.4 
%). m.p. > 250 °C. IR (Vmax / (cm'‘), KBr): 3435 (broad NH), 2843, 1560, 1440, 1316, 
755.9. Anal. Calcd (found) for CnHzgGdNiOg'HzO: C, 37.63 (36.42); H, 5.57 (5.39); N, 
9.99 (10.32); Gd, 28.05 (28.98). HRMS (+ES): found [M+H]* 544.1407. C34H53N7O 11 
requires 544.1401.
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6.34
Experimental
Synthesis of Gd(D03PAM), 4.3 .
HgN
O
HoN
/  \
N N.
3.9
N N
O
+ GdCIs (1.0eq.)
P
NHz
MeOH (60 °C) 70%
NH
O—
NH
4.3
3.9 (0.15 g, 0.39 mmol) was suspended in anhydrous methanol under an inert atmosphere. 
Addition of GdCla (anhydrous) to the ligand caused it to become fully-soluble. The 
solution was heated at 60 °C overnight under argon. After the reaction was stopped, most 
of the MeOH was removed at 40 °C under reduced pressure. EtiO was added dropwise 
until turbidity just began. After cooling in the freezer overnight, the white, dense 
precipitate (4.3) which developed was collected by centriftigation. Yield: 0.19 g (70 %). 
m.p. > 250 °C. One spot on TLC with Rf = 0.4 (Silica plate, acetonitrile-water-^BuOH, 
2:9:2 v/v). IR (Vmax / (cm '), KBr): 3371 (broad), 2860, 1652, 1457, 1094, 968, 728. Anal. 
Calcd (found) forC i7H35GdN7 0 3 -(H2 0 )2 -(Cr)3*(CH3 0 H): 0,32.15 (32.65); H, 6.61 (6.81); 
N, 13.12 (13.27); Gd, 21.04 (21.82). HRMS (+ES): found [M+2 (NH4CI)+C1+H]* 
681.1776. [M+2 (NH4C1)+C1+H]'"requires 681.1775.
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6.35 Deionization of 3.31 using cation exchange chromatography to give 4.4 .
HQ NHs+cr H4 NO nh
o V /  \  o
:n NH Amberlyst IR-120 NH
3 .31 4 .4
N 9  70 0/. .N  N 9
r  \70%OH 7      ^  'O N H 4
c r H s N - y o  NH3+CI- H z N - ^ o  H^ N
HO H4 NO
Amberlite IR-120 (Fluka, form, 16-45 mesh, 70 g) was stirred with 5 % HCl (250 ml) 
in a 1 L beaker for 10 minutes. The orange supernatant was decanted. Using a batch 
process, the resin was stirred vigorously with deionized H2O (250 ml) on a magnetic 
stirrer. After a few minutes stirring, the stirrer was switched off and the resin allowed to 
settle. After the H2O was carefully decanted, this procedure of washing-decantation was 
repeated with a further 6  volumes of H2O (250 ml). The pH of the resin was measured (~ 
5.4). Meanwhile, 3.31 (0.2 g) was dissolved in 15 ml H2O (pH ~ 1.3). The solution was 
applied to the ion-exchange column and successively eluted with water ( 1 0 0  ml fractions) 
and then with 0.5 M N H 4 O H .  Spot-testing of the H 2 O  eluate with AgNO] solution revealed 
specific fractions were +ve for chloride. As the product did not elute with 0.5 M N H 4 O H ,  
the column was eluted with 7.5 % N H 4 O H  (43 ml 33 % aq. N H 3  in 150 ml H 2 O ) .  4.4 
eluted as a viscous, yellow oil which afforded an off-white solid upon trituration with 
EtOH and acetone. Yield: 0.13 g (70 %). *H NMR (300 MHz, D2O, 5): 1.84 (4H, s, 2x  
CH2), 2.57 - 3.10 (18H, m,ring CH2), 4.65 (9H, br s, 3 x NHs'"). MS (+ES): 473.7 [M+K]*.
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6.36 Synthesis of Gd(D03-2AP), 4.6 .
Experimental
H4NO nh
oH N NH
HgN
H4NO
4 .4
ONH,
GCI2O3 (1 .2  eq.) pH 4.5
HgN
NH
4 .5
[M+Hl = 589 -O
V/L7
+
.NH
O'
w
502
The ammonium salt ( 6 8  mg) of the ligand 4.4 was reacted with gadolinium oxide at pH 4.5 
(pH was adjusted with dilute acetic acid). After 1 hour, the pH was checked and it had 
risen to pH 4.8. The reaction was allowed to stir overnight and then the pH was readjusted 
to 7.0 using dilute ammonia. After the solvent was removed in vacuo, the residue was 
resuspended in ethanol and acetone was added until a white turbidity appeared. The 
suspension was then put in the freezer overnight and the filtered precipitate dried under 
high vacuum for 24 hours. Yield: 56 mg (30 %). m.p. > 250 °C. 2 spots on TLC with Rf = 
0.45, 0.57 (Silica plate, acetonitrile-water-rBuOH, 2:9:2, v/v). LC-MS (+ES) of the product 
gave 2 peaks one with an [M+H]^ = 589 (which corresponds to the title product, 4.5) and 
the other peak had an [M+H]’*’= 502 (which corresponds to the disubstituted complex, 4.6).
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6.37 Synthesis of Gd(DOTA), 4.7.
Experimental
.OH
HO OH
HO
DOTA
Gd2 0 3  (1.2 eq.) 
 ►
90%
Gd(DOTA). 4.7
DOTA (0.10 g, 0.247 mmol) and Gd2 0 3  (55.5 mg, 0.15 mmol, 0.625 eq.) were dissolved in 
water ( 8  ml) and refluxed under argon overnight. After the reaction was stopped, the 
suspension was filtered through a 0 . 2 2  micron polypropylene filter and lyophilised to give 
4.7 as a white solid. Yield: 0.135 g (90.4 %). m.p. > 250 °C. IR (Vmax / ( c m '\  KBr): 3400, 
2916, 2361, 1579, 1448. Anal. Calcd (found) for Ci6H2 4GdN4 0 g • 2.5 H2 O: C, 31.89 
(31.10); H, 4.85 (4.65); Gd, 26.09 (26.54); N, 9.30 (10.01). MS (+ES): 559.2 [M+H]+.
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Appendix A  - TLC spray reagents 90
Fluoroscein-peroxide spray (specific for brominated compounds)
Preparation:
Procedure:
Results:
Solution A. 2 M NaOH.
Solution B. Half saturated fluoroscein in glacial acetic acid.
Solution C. 30 % H2O2 .
Solution D.0.5 % copper acetate.
The chromatogram is sprayed with Solution A, heated under a heat gun 
for 1-2 minutes. It is then sprayed with a mixture of equal volumes of B 
and C containing a drop of D and reheated as before (the B-C-D reagent is 
stable in the fridge for 1 - 2  days).
Brominated compounds appear as intense pink spots on a bright 
yellow background.
Phosphomolybdic acid sprav (useful for steroids such as cholic acid)
Preparation: Phosphomolybdic acid (4.8 g) is dissolved in ethanol (100 ml). It is stable
indefinitely.
Procedure: Chromatograms are sprayed with the reagent and heated with a heat gun
until spots develop ( 1 - 2  min).
Results: Compounds containing cholic acid appear as blue spots on a pale yellow
background.
Ninhydrin (0.2 %) in ethanol (useful for amines such as cyclen and amino acids)
Preparation: Ninhydrin (0.2 g) is dissolved in ethanol (100 ml). The spray is freshly
prepared.
Procedure: Chromatograms are sprayed with the reagent and heated at 125 °C for 10
min.
Results: Amines appear as blue-purple spots.
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A ppendix  B - crystallographic data for the ligand 3.10
Table 1. Crystal data and structure refinement.
Identification code 
Empirical formula 
Formula weight 
Temperature 
Wavelength 
Crystal system 
Space group 
Unit cell dimensions
Volume
Z
Density (calculated) 
Absorption coefficient 
F(OOO)
Crystal 
Crystal size
Grange for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Completeness to 0= 27.50° 
Absorption correction 
Max. and min. transmission 
Refinement method 
Data / restraints / parameters 
Goodness-of-fit on 
Final R indices [i^ >
R indices (all data)
Largest diff. peak and hole
a  =90°
y^= 116.3670(10)' 
Y = 90°
2006src0632 (PO C l)
C 2 0 H 4 2 N 8 O 5  
474.62 
120(2) K 
0.71073 Â 
Monoclinic 
C2/c
a = 16.1654(5) A 
6 =10.1413(2) A 
c=  17.0495(5) A 
2504.29(12) A^
4
1.259 Mg/m^
0.092 mm~^
1032
Block; colourless 
0.25 X 0.20 X 0.20 mm^
4.06 -  27.50°
-2 0 < h < 2 0 ,- \2 < k <  1 3 , - 2 2 < / <  18 
15776
2864 [R/„, = 0.0384]
99.5%
Semi-empirical from equivalents 
0.9818 and 0.9774 
Full-matrix least-squares on F^ 
2864 / 0 / 170  
1.024
R1 = 0.0399, wR2 = 0.0880 
R1 = 0.0602, wR2 = 0.0980 
0.247 and-0.235 eA"^
Diffractometer: Nonius KappaCCD area detector (^ scans and co scans to fill asymmetric 
unit sphere). Cell determination: DirAx (Duisenberg, A.J.M.(1992). J. Appl. Cryst. 25, 
92-96.) Data collection: Collect (Collect: Data collection software, R. Hooft, Nonius B.V., 
1998). Data reduction and cell refinement: Denzo (Z. Otwinowski & W. Minor, Methods 
in Enzymology (1997) Vol. 276: Macromolecular Crystallography, part A, pp. 307-326; 
C. W. Carter, Jr. & R. M. Sweet, Eds., Academic Press). Absorption correction: SORTA V 
(R. H. Blessing, Acta Cryst. A51 (1995) 33-37; R. H. Blessing, J. Appl. Cryst. 30 (1997) 
421-426). Structure solution: SHELXS97 (G. M. Sheldrick, Acta Cryst. (1990) A46 467- 
473). Structure refinement: SHELXL97 (G. M. Sheldrick (1997), University of 
Gottingen, Germany). Graphics: Cameron - A Molecular Graphics Package. (D. M. 
Watkin, L. Pearce and C. K. Prout, Chemical Crystallography Laboratory, University of 
Oxford, 1993).
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Table 2. Bond lengths [A].
C l-N l 1.4753(16)
C l-C 4‘ 1.5219(17)
C2-N1 1.4732(16)
C2-C3 1.5237(17)
C3-N2 1.4775(16)
C4-N2 1.4822(16)
C4-CV 1.5219(17)
C5-N1 1.4649(17)
C5-C6 1.5282(19)
C6-C7 1.512(2)
C7-01 1.2428(16)
C7-N3 1.3323(19)
C8-N2 1.4802(16)
C8-C9 1.5382(18)
C9-C10 1.5175(18)
ClO-02 1.2429(16)
C10-N4 1.3249(18)
Table 3. Bond angles [°].
N1-C1-C4* 110.70(10)
N1-C2-C3 115.77(10)
N2-C3-C2 113.90(10)
N2-C4-C1* 111.79(10)
N1-C5-C6 112.80(10)
C7-C6-C5 1 1 1 .2 1 (1 1 )
01-C7-N 3 122.84(14)
01-C 7-C 6 120.61(13)
N3-C7-C6 116.54(12)
N2-C8-C9 111.56(10)
C10-C9-C8 110.78(11)
O2-C10-N4 123.03(12)
O2-C10-C9 119.87(12)
N4-C10-C9 117.09(12)
C5-N1-C2 109.84(10)
C5-N1-C1 112.33(10)
C2-N1-C1 109.81(10)
C3-N2-C8 108.57(9)
C3-N2-C4 110.41(10)
C8-N2-C4 109.64(10)
Symmetry transformations used to generate equivalent atoms: (i) -x -l/2 ,-y+ 3/2 ,-z
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